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Abstract
Although Lyme disease is the most frequently reported vector-borne illness in the United
States, recent evidence from the CDC suggests that Lyme disease incidence in the United
States may be much higher than reported. Lyme disease symptoms can be mistaken for a
wide variety of diseases, which can complicate the diagnosis. To date, no diagnostic
criteria analysis has been conducted examining the association between
sociodemographic variables (sex and age) and seasonality of infection with the severity
and symptomology found in Lyme disease cases. Using the CDC’s outbreak investigation
model, a primary case/control study was conducted using the ROSS Scale to collect data.
Comparisons were made between a Lyme disease-diagnosed group (n = 203) and a
convenience sample of non-Lyme disease patients (n = 388). Novel symptom patterns
were found to significantly predict a diagnosis of Lyme disease. Odds ratio results
revealed a positive association between musculoskeletal (OR = 11; 95% CI), neurological
(OR = 12; 95% CI), cognitive (OR = 10; 95% CI), and cutaneous (OR = 144; 95% CI)
symptoms frequency and severity and the diagnosis of Lyme disease. In addition, overall
symptom frequency and severity scores displayed significant differences between cases
and controls, between males and females, and among certain age groups. No correlation
was found between symptom frequency and severity with the seasonality of infection.
Current diagnostic tools search for antibodies to the Borrelia bacteria, but antibody
production takes a few weeks. The results of this study help identify at-risk patients based
on the presentation and severity of Lyme disease symptoms when antibodies are not
present in measureable quantities in the blood stream, allowing for earlier diagnosis.
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Chapter 1: Introduction to the Study
Problem Statement
Lyme disease is a tick-borne illness caused by the spirochete Borrelia burgdorferi
(Borchers, Keen, Huntley, & Gershwin, 2015; Deluca, Eisendle, & Zelger, 2013; Henry
et al., 2011; Mead, 2015). Currently, Lyme disease is reported more frequently than any
other tick-borne illness (Binder, Telschow, & Meyer-Hermann, 2012; Mead, 2015).
According to the most recent surveillance data provided by the Centers for Disease
Control and Prevention (CDC), there were 33,461 cases of Lyme disease reported in the
United States in 2014 (CDC, 2015). These cases represent a 38% increase over the
previous year’s total. In addition, reported and confirmed Lyme disease cases show a
bimodal distribution with children between the ages 5-9 years and adults between 40-50
years showing the highest incidence rates. Males account for 54% of reported cases and,
except in the 70-plus age groups, consistently have a higher incidence of confirmed Lyme
disease (CDC, 2007). Based on preliminary data reported from three ongoing CDC
research studies, Lyme disease may be underreported across all ages by a factor as high
as 12-to-1 resulting in 300,000 actual cases yearly (Aucott & Seifter, 2011; Borchers et
al., 2015; CDC, 2015; Johnson, Aylward, & Stricker, 2011; Mead, 2015). The cause of
this underreporting remains unclear.
Sex differences in symptom presentation could be a possible reason why Lyme
disease is underreported. In a study conducted in Slovenia (2013), sex differences existed
with the presentation and appearance of the erythema migrans (EM) rash (Strle et al.,
2013). The Slovenia study (2013) examined three specific symptoms commonly found in
Lyme disease patients—EM rash, Lyme arthritis, and Lyme neuroborreliosis—for sex
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differences. The results of the Slovenia study showed that of the 10,539 patients who
displayed the EM rash, 58% were women, while males (42%) tended to present with
other noncutaneous symptoms (Strle et al., 2013). In addition, the women who presented
with the EM rash were 15 years younger than those women who presented with other
cutaneous symptoms (Strle et al., 2013). In the same study, men were more likely to
display Lyme arthritis and Lyme neuroborreliosis (later stage symptoms) than women
(Strle et al., 2013).These results may be related to the specific type of Borrelia species
found in Europe, which differs from the Borrelia species found in the United States.
Because of these species variations, further study in the United States is warranted.
According to the Institute of Medicine’s (IOM) report (2001), sex differences are
based on factors related to being male or female. These differences result from biological
differences at the genetic level, cellular level, and/or via hormonal variations between
males and females (Wizeman & Pardue, 2001). Prior to puberty and the production of the
sex hormones (estrogen, progesterone, and testosterone), male to female sex differences
are related only to the anatomical differences present. This study will focus on adult male
and female subjects.
Sex differences in symptom presentation have been reported in many chronic and
autoimmune diseases. For example, coronary heart disease (CHD), stroke, Parkinson’s
disease, rheumatoid arthritis (RA), multiple sclerosis (MS), and fibromyalgia show
distinct male to female differences in disease presentation (Casimir et al., 2010; Caracta,
2003; Hassan, Gordon, & Einstein, 2016; Hirsch, Jette, Frolkis, Steeves, & Pringsheim,
2016; Kure et al., 2016; Maselli et al., 2016; Ngo, Steyn, & McCombeet, 2014; Quintero,
Amador-Patarroyo, Montoya-Ortiz, Rojas-Villarraga, & Anaya, 2012). Although Lyme
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disease is caused by a bacterium, long term infection mimics a few autoimmune disorders
such as RA, MS, and systemic lupus erythematosus (SLE) (Savely, 2010).
Sex differences may also be found in recreational or occupational exposure to
ticks. Studies have been conducted examining both recreational and occupational risk of
contracting Lyme disease, but none have examined this risk based on sex (Borchers et al.,
2015; Finch et al., 2014; Piacentino & Schwartz, 2002). In addition, seasonality of
infection may be important because exposure to ticks and risk for contraction of Lyme
disease may increase based on outdoor exposure to the Ixodes tick during peak tick
growth seasons (CDC, 2015; Borchers et al., 2015; Finch et al., 2014; Mead, 2015).
Age variations in Lyme disease presentation have also been reported. According
to CDC data for the years 2000-2010, males in the age group 5-9 years contain the most
reported confirmed cases of Lyme disease (Borchers et al., 2015; CDC, 2015). A second
spike in the number of cases during the same time frame occurs in both males and
females age 40-50 years old (Borchers et al., 2015; CDC, 2015). This bimodal
distribution is also seen in Europe and was supported by a study in Germany (Borchers et
al., 2015; Dehnert et al., 2012). Why do these age variations exist? Are these variations
related to sex differences in symptom presentation?
Gender differences, although the term is often used interchangeably with sex
differences, are related to an individual’s interactions with and expectations from their
social environment (Sieck, 2015; Wizeman & Pardue, 2001).According to the World
Health Organization’s report on sex and gender differences in epidemic-prone infectious
diseases (2007), gender roles can determine exposure possibilities and treatment seeking
behaviors. The potential for exposure to infectious agents such as the Ixodes tick can be
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increased based on occupational and recreational exposures (Borchers et al., 2015; Finch
et al., 2014; McKenna, Faustini, Nowakowski, & Wormser, 2004). Gender differences
can be seen in many occupational and recreational choices. While occupational and
recreational choices as part of the risk of exposure to the Ixodes tick were considered, the
focus of this study remained on differences in symptom presentation based on biological
sex and not on gender roles.
In addition, Lyme disease shows seasonality in incidence rates. According to the
CDC (2015), the highest number of reported cases for Lyme disease occur between the
months of May and August. This time frame corresponds directly with the life cycle of
the Ixodes scapularis tick (Aucott & Seifter, 2011; Borchers et al., 2015; CDC, 2015;
Mead, 2015). Although incidence data is collected and reported by the CDC, an analysis
based on sociodemographic and clinical factors, including sex, age, time since exposure
to the Ixodes tick, month of case confirmation, symptomology, and severity of symptoms,
has not been performed. Factors associated with seasonality of infection, sex, and age
could provide insight into the risk of exposure to Lyme disease and whether these factors
play a role in the underreporting of Lyme disease.
Lastly, severity of reported symptoms must be considered. While the severity of
the EM rash or Bell’s palsy may not prevent someone from performing daily tasks, the
changes in appearance may prevent a person from going to work, school, or out in public
(Fu, Bundy, & Sadiq, 2011). In addition, some of the other symptoms of Lyme disease
may significantly impact day-to-day activities.
Arthritic pain in the major joints can prevent sufferers from performing normal
everyday tasks and is one of the most frequently (up to 60% of untreated cases) described
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symptoms of Lyme disease in the United States (Borchers et al., 2015; Feder, Abeles,
Bernstein, Whitaker-Worth, & Grant-Kels, 2006; Mead, 2015; Nadelman, & Schwartz,
2012; Wormser et al., 2006). According to the Arthritis Foundation (2014), arthritis is the
leading cause of disability in the United States. Severity of arthritis pain in the joints due
to B. burgdorferi infection is no different than that caused by RA or osteoarthritis and can
lead to similar levels of disability (Borchers et al., 2015; Nadelman, & Schwartz, 2012;
Wormser et al., 2006).
Symptom severity may lead to additional negative outcomes. These negative
outcomes may include, but are not limited to, inability to work, loss of job, and loss of
insurance coverage (Chandra, Keilp, & Fallon, 2013; Johnson et al., 2011). The more
severe the symptom experienced, the more functional impact Lyme disease can have on
the individual.
Significance
Lyme disease has been classified into three phases of infection: early localized
Lyme disease, early disseminated Lyme disease, and late Lyme disease (Binder et al.,
2012; Borchers et al., 2015; Donta, 2012; Girschick, Morbach, & Tappe, 2009; Wormser
et al., 2006). In addition to the three accepted phases of Lyme disease, posttreatment
Lyme disease syndrome and chronic Lyme disease have also been reported (Aucott,
Rebman, Crowder, & Kortte, 2012; Cairns & Goodwin, 2005; Cameron, 2010). In early
or localized Lyme disease, symptoms include mild flu-like symptoms, malaise, fatigue,
headache and the erythema migrans (EM) rash that begins around the site of the tick bite
and slowly increases in size to a typical diameter of at least 5 cm (Binder et al., 2012;
Borchers et al., 2015; Donta, 2012; Girschick et al., 2009; Wormser et al., 2006). The EM
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rash occurs more frequently with B. burgdorferi sensu stricto, which is the bacterial
species found in the United States, than in Lyme disease cases in Europe caused by other
species of the bacterium (Borchers et al., 2015; Mead, 2015; Girschick et al., 2009).
In 50 – 80% of all cases of Lyme disease, the erythema migrans (EM) rash is
present and can be used as a primary method for diagnosis (Aucott, Crowder, Yedlin, &
Kortte, 2012; CDC, 2015; Miraflor et al., 2016). The EM rash can serve as a strong
clinical marker for diagnosis according to the case definition of the National Notifiable
Diseases Surveillance System (CDC, 2008). Correct identification of this rash is vital to
the diagnosis of early Lyme disease because current diagnostic tools result in negative
tests 60% of the time in patients who show up for treatment during the earliest stage of
infection (Aucott et al., 2009). Inaccurate identification of this rash can lead to delayed
treatment or treatment with antibiotics that would have no effect on the organism leading
to long term, serious effects on the patient (Aucott et al., 2009).
Early disseminated Lyme disease signals the spread of the bacteria from the initial
site of infection. The hallmark of this stage of infection is nervous system symptoms such
as meningitis and cranial nerve palsies (Binder et al., 2012; Borchers et al., 2015; Donta,
2012; Girschick et al., 2009; Wormser et al., 2006). In some cases, secondary EM lesions
may appear at sites not near the initial tick bite (Binder et al., 2012; Borchers et al., 2015;
Donta, 2012; Girschick et al., 2009; Wormser et al., 2006). Secondary EM lesions have
been seen in approximately 40% of children who show up for treatment but are less
common in adults (Girschick et al., 2009). In addition, mild musculoskeletal system
symptoms have been reported during this phase, especially in the United States (Borchers
et al., 2015; Girschick et al., 2009).
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Late Lyme disease may occur many months after the initial tick bite and results
from systemic spread of the bacteria (Binder et al., 2012; Borchers et al., 2015; Donta,
2012; Girschick et al., 2009; Wormser et al., 2006). Typical manifestations of this stage
include arthritis, especially in the large joints of the arms and legs, polyneuropathy,
cranial neuropathy, cardiac complications, and encephalomyelitis (Binder et al., 2012;
Borchers et al., 2015; Donta, 2012; Girschick et al., 2009; Wormser et al., 2006).
If left untreated or inadequately treated, early Lyme disease can progress quickly
to late phase infection and the serious complications that come with this phase of the
disease. Most research suggests that earlier treatment provides the patient’s best chance
for a full recovery (Cameron, 2007; Donta, 2012; Johnson & Stricker, 2004; Miraflor et
al., 2016). Once treatment is initiated, 80-90% of patients significantly improve (CDC,
2015). Delaying treatment can be costly, both in patient health costs and in reduced
quality of life (Johnson et al., 2011). Zhang et al. (2006) determined that the annual
health care costs associated with late Lyme disease treatment ($16,199 per person) can be
12 times higher than those costs associated with early Lyme disease treatment ($1,310
per person).
During the early stage of infection, treatment with beta-lactam antibiotics is
highly successful at killing the bacteria and stopping the progression of the infection
(Binder et al., 2012; Borchers et al., 2015; Cameron, 2007; Donta, 2012; Girschick et al.,
2009; Wormser et al., 2006). Late phase infections may require longer term or
intravenous treatments with antibiotics (Binder et al., 2012; Cameron, 2007; Donta, 2012;
Girschick et al., 2009; Wormser et al., 2006). Unfortunately, antibiotic treatment for late
phase infections does not always result in a complete recovery with no symptoms (Aucott
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et al., 2013; Johnson et al., 2011). It is in these instances that post-treatment Lyme
disease syndrome and/or chronic Lyme disease may be the diagnosis.
Because late phase manifestations can be incapacitating, adults could be burdened
with “functional impacts” of Lyme disease (Aucott et al., 2013, p 2). Functional impacts
occur when patients experience symptoms and/or increased severity of symptoms that
prevent them from completing daily activities (Aucott et al., 2013). These functional
impacts may include loss of job, loss of productivity, lapse of insurance coverage, and
disability (Johnson et al., 2011). In fact, loss of productivity makes up more than half the
costs of late Lyme disease infection (Johnson et al., 2011). Early, accurate diagnosis of
Lyme disease can prevent all of these impacts by stopping the spread of the infection
before the serious complications of late Lyme disease occur (Miraflor et al., 2016).
In cases of misdiagnosis in children and adults, the burden of Lyme disease may
be measured in more than just the financial burden. In a study conducted by Tager et al.
(2001), children diagnosed with Lyme disease showed many cognitive difficulties even
after the completion of treatment. These cognitive difficulties included attention and
organizational deficits, as well as memory and IQ issues (Tager et al., 2001). Similar
cognitive difficulties have also been reported for adult patients with late Lyme disease
(Borchers et al., 2015; Cairns & Godwin, 2005). Early, accurate diagnosis is vital to
prevent these long term cognitive changes (Tager et al., 2001).
Identification of the comorbidities that alter the symptom presentation of Lyme
disease would be helpful in ensuring the accurate diagnosis and appropriate treatment at
the earliest stage of infection of Lyme disease. In chronic diseases such as cardiovascular
disease and Parkinson’s disease, sex and age differences in symptom presentation have
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been identified (Fairweather, Petri, Coronado & Cooper, 2012; Hassan et al., 2016;
Hirsch et al., 2016; Kure et al., 2016; Maselli et al., 2016; Ngo et al., 2014; Quintero et
al., 2012). In autoimmune diseases such as RA and SLE, females are more likely to be
affected than males based on the specific mechanisms of the female immune system
(Fairweather et al., 2012; Ngo et al., 2014; Quintero et al., 2012). According to Dey et al.
(2009), women with acute coronary syndromes were more likely to have a milder form of
the disease and to report atypical symptoms, such as jaw pain and nausea, when seeking
treatment. The study by Dey et al. supported the findings of a previous study on sex
differences in symptom presentation for cardiovascular disease (Polk & Naqvi, 2005).
In Parkinson’s disease, both age and sex differences play a role in the progression
of the disease (Hirsch et al., 2016; Haaxma et al., 2007). Women develop symptoms 2.2
years later than men (Hirsch et al., 2016; Haaxma et al., 2007). After disease onset,
women displayed different symptoms than men at initial diagnosis; women seemed to
display the “tremor dominant form” of the disease (Haaxma et al., 2007, p. 822).
Understanding of these differences has led to targeted prevention and education
programs for both patients and physicians, and timely administration of treatment for
women who present with nonclassical symptoms of disease. These advances can be
realized for Lyme disease as well if potential differences in symptom presentation can be
identified.
Background
Lyme disease is caused by the spirochete Borrelia burgdorferi sensu lato
(Borchers et al., 2015; Deluca et al., 2013; Mead., 2015; Miraflor et al., 2016). This
classification of bacteria has been further delineated into more than 20 distinct
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genospecies based on the bacterial genome, geographical location, tick vector, reservoir
animal, and Lyme disease symptoms produced (Borchers et al., 2015; Deluca et al., 2013;
Mead et al., 2015; Pritt et al., 2016). The five most commonly found pathogenic
genospecies include B. burgdorferi sensu stricto found in North America and Europe; B.
garinii and B. afzelii found in Europe; B. japonica found in Japan; and B. andersonii
found in North America (Borchers et al., 2015; Mead, 2015; Pritt et al., 2016). A new
genospecies of Borrelia was recently discovered in the Midwestern United States,
specifically Minnesota, North Dakota, and Wisconsin (CDC, 2015; Pritt et al., 2016).
This new genospecies, proposed name Borrelia mayonii, has similar symptoms to
Borrelia burgdorferi (Pritt et al., 2016). Signs and symptoms of infection vary based on
the Borrelia species causing the infection (Borchers et al., 2015; Deluca et al., 2013;
Mead, 2015).
Lyme disease is transmitted through the bite of the Ixodes tick (Arsnoe, Hickling,
Ginsburg, McElreath, & Tsao, 2015; Borchers et al., 2015; Deluca et al., 2013; Mead,
2015; Miraflor et al., 2016). The tick vector varies based on the geographic area where
the tick is found. In the United States, the primary vectors of Lyme disease are Ixodes
scapularis in the Eastern states and Ixodes pacificus on the West coast (Arsnoe et al.,
2015; Borchers et al., 2015; Deluca et al., 2013; Mead, 2015). In order for Lyme disease
to be transmitted to a human host, the tick must first be infected with B. burgdorferi
while feeding from an infected animal host (Arsnoe et al., 2015; Deluca et al., 2013).
Typical animal reservoirs for B. burgdorferi include small rodents like the white-footed
mouse, hares, small birds, and white-tailed deer (CDC, 2015; Deluca et al., 2013).
Infection of the tick is for life (Deluca et al., 2013). In addition, the tick must feed on the
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human host for 24-48 hours to pass on the infection (Borchers et al., 2015; CDC, 2015;
Hynote, Mervine, & Stricker, 2012).
Clinical manifestations of Lyme disease occur in three phases (Binder et al., 2012;
Borchers et al., 2015; Deluca et al., 2013; Girschick et al., 2009; Johnson & Feder Jr.,
2010). These phases include early or localized Lyme disease, early disseminated Lyme
disease, and late Lyme disease (Binder et al., 2012; Borchers et al., 2015; Deluca et al.,
2013; Girschick et al., 2009; Johnson & Feder Jr., 2010). In addition, posttreatment Lyme
disease syndrome and chronic Lyme disease have been discussed in the literature. Each
phase has typical signs and symptoms associated with movement of the bacteria from the
initial tick bite to a systemic infection (Binder et al., 2012; Borchers et al., 2015; Deluca
et al., 2013; Girschick et al., 2009; Johnson & Feder Jr., 2010).
Signs and symptoms include, but are not limited to, flu-like symptoms such as
malaise, fatigue, fever, arthralgia, myalgia; arthritis; neuropathy including Bell’s Palsy;
meningitis and encephalitis; cardiac symptoms including atrial block; and erythema
migrans (EM) rash (Binder et al., 2012; Borchers et al., 2015; Deluca et al., 2013;
Girschick et al., 2009; Johnson & Feder Jr., 2010; Miraflor et al., 2016).
The classic bull’s eye EM rash is the most widely known symptom associated
with Lyme disease (Aucott et al., 2012a; Borchers et al., 2015; Miraflor et al., 2016). Key
features of the EM rash include a shape that is round to oval; a red to bluish-red color; a
clearly defined edge; occurs at the location of the tick bite; and increases in size over time
from 5 cm to 16 cm (Moore, 2015; Muellegger, 2004). Typical locations for the EM rash
appear to coincide with common tick bite locations. In adults, EM usually occurs on the
calf, back of the knee, thigh, groin, buttocks, armpit, shoulder, waist, and occasionally,
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the scalp/hairline (Muellegger, 2004). With the new genospecies Borrelia mayonii, the
rash is more diffuse and distributed and does not take on the typical bulls-eye appearance
(Pritt et al., 2016). In children, head and neck lesions are more common than in adults
(Muellegger, 2004). Unfortunately, some of these sites are not conducive to finding the
tick or viewing the EM rash, so patients may not seek treatment during the early phase of
infection.
Because some form of the EM rash is present in 50 – 80% of reported cases, the
EM rash alone can be used to definitely diagnose Lyme disease without any additional
testing (Johnson & Stricker, 2004; Miraflor et al., 2016; Moore, 2015). The EM rash
provides the best clinical marker for Lyme borreliosis (Moore, 2015; Muellegger, 2004).
According to the National Notifiable Disease Surveillance System (NNDSS) case
definition, a diagnosis can be made based on the presence of the EM rash or positive twotiered serology testing with ELISA and Western blot (CDC, 2008). Unfortunately, the
classic appearance of the bull’s eye EM rash (concentric rings with a central clear area) is
present only 20% of the time with Borrelia burgdorferi infections and not at all with
Borrelia mayonii infections (Aucott et al., 2012a; Pritt et al., 2016).
Other manifestations of this rash can be present and can significantly confuse the
accurate diagnosis of Lyme disease in the early stages. These manifestations include
homogenous red lesions with no central clearing; secondary lesions; vesiculopustular
lesions; lesions with bruising, which typically occur on the calves; and a “diffuse macular
rash” occurring all over the body including the palms of the hands and soles of the feet
(Aucott et al., 2012a ; Pritt et al., 2016, pg. 7;). In addition, other skin lesions may be
confused with the EM rash lesion. This group of lesions includes small insect bites
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(spider or mosquito); immediate allergic inflammatory responses to the initial tick bite
which decreases in size over time; poison ivy rash; shingles rash; cellulitis; hand-footmouth disease; and S. aureus infection (Aucott et al., 2012a; Tibbles & Edlow, 2007).
Lipsker, Lieber-Mbomeyo, and Hedelin (2004) found that almost 72% of physicians in
Lyme endemic areas could not correctly diagnose the EM rash (Aucott et al., 2012a;
Brett, Hickley, Zielinski-Gutierrez, & Mead, 2014). Early diagnosis is necessary to
ensure full recovery from infection (Brett et al., 2014).
Lyme disease can be successfully treated with a 21 day course of oral antibiotics
as long as neurological or cardiac symptoms are not present (Borchers et al., 2015;
Gerstenblith & Stern, 2014; Johnson & Feder Jr., 2010). Neurological or cardiac
symptoms may require up to 28 days of IV antibiotics (Borchers et al., 2015; Johnson &
Feder Jr., 2010). The earlier this treatment begins, the more likely a full recovery will
occur (Borchers et al., 2015; Brett et al., 2014; Johnson & Stricker, 2004; Mead, 2015).
Delayed treatment may lead to more chronic symptoms and may require longer courses
of antibiotics (Cameron, 2007; Johnson & Stricker, 2004). In addition, the direct and
indirect medical costs may pose problems for patients over the long term. Zhang et al.
(2006) found that the economic impact of Lyme disease nationwide was more than $200
million in direct and indirect medical costs, as well as nonmedical costs like loss of
productivity. This cost can be avoided with accurate diagnosis in the early stages of
infection so that appropriate treatment can be implemented.
Tager et al. (2001) discuss the cognitive deficits found in children with late phase
Lyme disease. These deficits can lessen quality of life and increase the burden assumed
by families where these cognitive deficits are present. Common issues found include

14
memory and IQ deficiencies, attention and concentration disorders, and withdrawal from
social situations (Tager et al., 2001). Similar cognitive defects have also been found in
adults in the later stages of the infection (Cairns & Godwin, 2005).
Posttreatment Lyme disease (PTLD) syndrome occurs when patients have been
diagnosed with Lyme disease via the traditional methods of EM rash identification or
enzyme immunosorbent assay (EIA) and Western blot, treated with a 21-day course of
antibiotics, and still display symptoms like fatigue, arthralgia, myalgia, and memory and
concentration issues (Lantos, 2011; Nichols & Windemuth, 2013). While rare, PTLD
syndrome does occur more frequently in patients who are diagnosed in the later stages of
infection or had severe symptoms at diagnosis (Lantos, 2011; Nichols & Windemuth,
2013).
Lastly, the controversy surrounding chronic Lyme disease must be presented. The
controversy is centered on the existence of chronic Lyme disease. On one side of the
controversy are the physicians and researchers who believe that chronic Lyme disease
does not exist; that Lyme disease is rarely found in the general population, is not easily
acquired, and is simple to cure with the standard course of antibiotics (Johnson et al.,
2011; Stricker & Johnson, 2007). On the other side of the controversy are the physicians
and researchers who believe that chronic Lyme disease exists and is extremely difficult to
treat and cure (Johnson et al., 2011; Stricker & Johnson, 2007).
An important component of this controversy stems from the fact that the
Infectious Diseases Society of America (IDSA) is influential in determining treatment
regimens for Lyme and other infectious diseases in the United States (Johnson et al.,
2011). The IDSA does not believe that chronic Lyme disease exists, so the
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recommendations set forth do not cover treatment for long term infection, providing
barriers to health care access and increased disease burden for those diagnosed with
chronic Lyme disease (Johnson et al., 2011).
The International Lyme and Associated Diseases Society (ILADS) is on the
opposite side of this controversy. ILADS was formed by a group of physicians and
researchers to advance the options available for chronic Lyme disease sufferers (ILADS,
2009). This group has also offered a case definition of chronic Lyme disease with
diagnostic criteria and treatment recommendations. The ILADS case definition is broader
and covers many more presentations of symptoms (ILADS, 2009; Lantos, 2011). In
addition, diagnostic criteria take into consideration the expertise of the physician and do
not rely exclusively on the EM rash, EIA, and/or Western blot tests (ILADS, 2009;
Lantos, 2011). Lastly, treatment options are expanded to allow for extended antibiotic
treatment as needed (ILADS, 2009; Lantos, 2011). Although the existence of chronic
Lyme disease remains controversial, identification of sex differences in symptom
presentation may help inform this issue more fully.
Sex differences in symptom presentation have been seen in many other diseases.
In coronary heart disease (CHD), women often do not present with chest pain as their
primary symptom (Dey et al., 2008; Fairweather et al., 2012; Kure et al., 2016; Polk &
Naqvi, 2005; Wizeman & Pardue, 2001). However, males experiencing CHD most often
report chest pain as a primary symptom (Dey et al., 2008; Fairweather et al., 2012; Polk
& Naqvi, 2005; Wizeman & Pardue, 2001). According to the American Heart
Association (2015), a woman is likely to experience shortness of breath and/or pain and
discomfort in the jaw or back instead of the classic chest pain symptom. The lack of chest
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pain may prevent a woman from seeking help, since it is an accepted convention that
heart attacks present with chest pain.
Parkinson’s disease is another example where women and men present with
different symptoms. Parkinson’s disease is more common in men than women, where
women tend to present with symptoms at an older age (Haaxma et al., 2006; Hirsch et al.,
2016). In addition, women are more likely to present with the classic tremors associated
with Parkinson’s disease while men tend to present with rigidity and bradykinesia, which
is slow, limited movement (Haaxma et al, 2006; Hirsch et al., 2016).
Observed advantages for women in both CHD and Parkinson’s disease may be
related to estrogen levels circulating in the bloodstream. Differences in symptoms of both
CHD and Parkinson’s disease between males and females seem to equal out after
menopause (Haaxma et al., 2006; Hirsch et al., 2016; Kure et al., 2016; Wizeman &
Pardue, 2001). While age of onset and estrogen levels may affect symptom presentation
for CHD and Parkinson’s disease, autoimmune diseases are another example where
symptom presentation differs between males and females and estrogen levels may not be
the cause. For many autoimmune diseases, the prevalence in women is 60 – 75% higher
than it is in men (Maselli et al., 2016; Ngo et al., 2014; Quintero et al., 2012; Whitacre,
2001).
Late Lyme disease mimics a few autoimmune diseases and is often misdiagnosed
as MS, SLE, and RA (Hassan et al., 2016; Ngo et al., 2014; Quintero et al., 2012; Savely,
2010). Some symptom similarities between MS and Lyme disease include confusion,
weakness, peripheral nerve numbness, dizziness, and malaise (Savely, 2010). Joint and
muscle pain is not found in MS, so patients presenting with musculoskeletal issues should
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not receive a diagnosis of MS (Savely, 2010). Unfortunately, in SLE and RA, joint and
muscle pain and malaise are primary symptoms (Hassan et al., 2016; Savely, 2010).
Lastly, autoimmune diseases tend to present later in life, so misdiagnosis with
autoimmune diseases versus Lyme disease may occur more frequently in older patients
than in children (Savely, 2010; Whitacre, 2001).
Because Lyme disease displays a bimodal distribution when considering age as a
variable, it becomes important to identify why this distribution occurs (Dehnert et al.,
2012; Esposito, Bosis, Sabatini, Tagliaferri, & Principi, 2013). Are these variations due to
sex differences in recreational behaviors and occupational exposures? While studies have
been conducted on outdoor worker exposure and tick counts/types in recreational areas,
no studies have looked at Lyme disease, occupational and/or recreational exposure, and
sex (Belongia et al., 1999; Finch et al., 2014; Piacentino & Schwartz, 2002; Schwartz &
Goldstein, 1990; Smith, Benach, White, Stroup, & Morse, 1988). Most of these studies
collected sex (male/female) information, but none of the studies analyzed sex as a
variable for study. This study will include a sex comparison in the collection and analysis
of data.
In addition, none of the described studies examined seasonality of infection in
relation to either sex or age. Seasonality of infection could be directly related to outdoor
activities because exposure to the Ixodes scapularis tick occurs outdoors during certain
stages of the tick’s life cycle. Month of diagnosis and potential month of tick exposure
will be collected from the medical records and ROSS scale surveys in order to make
comparisons with sex and age.
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Theoretical Framework
An appropriate theoretical framework for this study is the CDC’s outbreak
investigation model (Rohrer, 2013). Although Lyme disease is not considered a typical
outbreak type of disease (like Salmonella or E. coli), the outbreak investigation model
can still apply. This model allows for examining the relationship between a variable
under consideration and a disease like Lyme disease (Reingold, 1998). This model also
allows for the expansion of the variables studied as more information becomes available
(Roher, 2013). In addition, the outbreak investigation model fits well with the casecontrol study design. Independent variables to be studied include socio-demographic
characteristics like age and sex; seasonality of infection characteristics like month of
infection and month of diagnosis; and time since tick exposure; dependent variables to be
studied include symptoms present at diagnosis and severity of symptoms as reported by
the patient (Table 1).
Table 1
Study Variables
Independent variables
Sociodemographic
Seasonality of
infection
Age
Month of tick
exposure
Sex
Month of diagnosis

Dependent variables
Symptoms*
Symptom
severity
Musculoskeletal
Not affected
Neurological

Cognitive
State of Residence**

*See Appendix A for a complete list of symptoms.
**State of residence will be collected only for case/control matching.

General
Cardiac
Cutaneous

Slight/
barely
noticeable
Minor but
noticeable
Moderate
Major
disabling

Symptom
frequency
Never
1-2 days

3-4 days
5-6 days
7 days
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The CDC outbreak investigation model has 10 components, but only seven were
applied to this study (Reingold, 1998). The three components that were not applicable to
the current study included environmental sampling and testing, controlling the spread of
infection, and dissemination of information via the press to the public (Reingold, 1998).
Dissemination of information on the finding of this study will occur in public forums at
the completion of the study. The steps of the model that were applied include the
following:
First, a case definition was established to ensure that all cases met specific,
consistent criteria for inclusion in the study. Cases (n = 203) were defined as adult
subjects (≥ 18 years of age) that met one of the following diagnostic criteria: (a) patient
presented with a physician confirmed EM rash; (b) patient had a positive EIA and/or
Western Blot laboratory result for IgG and IgM antibodies to B. burgdorferi surface
proteins; or (c) patient had a score of 5 or higher on the Burrascano Diagnostic Criteria
for Lyme Disease scale (Burrascano, 2005).
Controls (n = 388) were selected from adult subjects (≥ 18 years of age) from the
primary care clinic who did not suffer from Lyme disease, family members of Lyme
disease patients at the primary care clinic, and employees and students at a small, liberal
arts college. Subjects who suffered from illnesses other than Lyme disease were not
excluded from the study. All controls were Lyme disease free at the time of selections as
determined by: (a) never having had a tick bite; (b) having no evidence of EM rash; or (c)
no prior laboratory testing for or diagnosis of Lyme disease by a physician. Controls were
selected at an approximate 1:2 case/control ratio to address the sampling bias introduced
by non-random selection of participants.
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Removal of participants who did not meet the established case criteria was
performed. Cases were removed based on age (participant must be over 18 years old),
missing data for date of birth, and state of residence. Because state of residence was used
to match cases and controls, participants were required to live in a Lyme endemic state
for this study to equalize the risk of exposure to the Ixodes tick vector. Additional
information on case inclusion and exclusion criteria can be found in chapters 3 and 4.
Next, case confirmation was performed by a qualified physician who specialized
in the treatment of Lyme disease. Completed forms were reviewed with the primary care
physician to verify inclusion as a case or control for this study from a clinical standpoint.
Because controls must NOT be Lyme disease positive, any indicators from the symptom
checklist for a potential undiagnosed Lyme disease patient were reviewed carefully for
appropriate case/control placement or exclusion from the study. No undiagnosed Lyme
diseases cases were identified through this review.
Incidence rates for Lyme disease were established for all states of residence used
in the study. This data was collected from the CDC, which reports data received via the
National Notifiable Disease Surveillance System. Lyme disease is a vector-borne disease
that, if caught early, can be cured with a 21-28 day course of antibiotics (Gerstenblith &
Stern, 2014). Lyme disease is therefore reported in incidence rates because each case
reported to the National Notifiable Disease Surveillance System (NNDSS) represents a
newly diagnosed infection.
Cases and controls were enrolled from two sites – a primary care clinic that
specializes in the treatment of Lyme disease and a small, liberal arts college campus. At
both sites, cases and controls had to meet the inclusion criteria established for the study.
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Because sex and age were two variables of interest in this study, matching between cases
and controls based on sex or age could not occur. Matching based on state of residence
was done to insure that exposure to the Ixodes scapularis tick was the same between
cases and controls. In addition, both cases and controls had to be available from a
particular state to be considered for inclusion in the study.
Descriptive data was collected and analyzed. Data collected included, but was not
limited to: sex, date of birth, state of residence, education level, date of tick bite, and date
of diagnosis. These demographic characteristics allowed for the establishment of person,
place, and time variables. Cases consisted of both females (n = 130) and males (n = 73)
ranging in age from 18 years to 75+ years. Controls consisted of both females (n = 268)
and males (n = 120) also ranging in age from 18 years to 75+ years. States of residence
for both cases and controls included Connecticut, Massachusetts, New Hampshire, New
Jersey, New York, Pennsylvania, and Vermont. All of these states are considered Lymeendemic states by the CDC (2015).
Overall, 51% of the study population had at least a high school diploma and 44%
of the population had completed at least a baccalaureate degree. Cases occurred in all
twelve months; the majority of cases occurred in May (n = 34) and June (n = 29) and the
fewest number of cases occurred in March (n = 3). Twenty one cases did not list a month
of tick exposure or month of diagnosis, so they were excluded from the analysis for
seasonality of infection only.
Research Questions
Five research questions were formulated, each with a null and alternate hypothesis
for testing. The following research questions were generated following an extensive
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review of the published literature. These research questions were an important guide for
the inquiry into specific factors that ultimately affect the diagnosis of Lyme disease.
Symptom presentation and severity were compared to defined sociodemographic
variables, seasonality of infection variables, and time since tick exposure to identify areas
to expand health providers’ knowledge and awareness of Lyme disease which can lead to
earlier diagnosis and treatment, reduced treatment costs and improved health outcomes
for Lyme disease patients.
RQ1: Is the presentation of symptoms in Lyme disease-positive patients
associated with the sociodemographic variables age and sex as assessed by patient
medical record and ROSS Scale survey review?
H01: Lyme disease symptom presentation is not associated with the
sociodemographic variables age and sex as assessed by patient reported
symptoms recorded in patient medical records or on the ROSS Scale survey.
Ha1: Lyme disease symptom presentation is associated with the
sociodemographic variables age and sex as assessed by patient reported
symptoms recorded in patient medical records or on the ROSS Scale survey.
RQ2: Is the severity of symptoms in Lyme disease positive patients associated
with the sociodemographic variables age and sex as assessed by patient medical
record and ROSS Scale survey review?
H02: Lyme disease symptom severity is not associated with the
sociodemographic variables age and sex as assessed by patient reported
symptoms recorded in patient medical records or on the ROSS Scale survey.
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Ha2: Lyme disease symptom severity is associated with the sociodemographic
variables age and sex as assessed by patient reported symptoms recorded in
patient medical records or on the ROSS Scale survey.
RQ3: Is the presentation of symptoms associated with the diagnosis of Lyme
disease as assessed by patient medical record and ROSS Scale survey review?
H03: Lyme disease symptom presentation is not associated with the diagnosis
of Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
Ha3: Lyme disease symptom presentation is associated with the diagnosis of
Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
RQ4: Is the severity of symptoms associated with the diagnosis of Lyme disease
as assessed by patient medical record and ROSS Scale survey review?
H04: Lyme disease symptom severity is not associated with the diagnosis of
Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
Ha4: Lyme disease symptom severity is associated with the diagnosis of Lyme
disease as assessed by patient reported symptoms recorded in patient medical
records or on the ROSS Scale survey.
RQ5: Is Lyme disease symptom presentation and severity associated with
seasonality of infection variables as assessed by medical record and the ROSS
Scale survey review?
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H05: Lyme disease symptom presentation and severity are not associated with
the seasonality of infection variables as assessed by patient medical record
and the ROSS Scale survey review.
Ha5: Lyme disease symptom presentation and severity are associated with the
seasonality of infection variables as assessed by patient medical record and
the ROSS Scale survey review.
Nature of the Study
In this study, I followed a quantitative approach to data collection. Patient records
and ROSS scales were examined for symptoms present at time of doctor’s appointment
for Lyme disease; severity of symptoms present as described by the patient; sex of
patient; age at diagnosis; time elapsed between tick exposure and diagnosis; and month of
possible tick exposure and month of initial diagnosis. Because sex is a nominal variable,
age, month of exposure and month of diagnosis can be measured using an interval scale,
and symptom severity is an ordinal variable, quantitative analysis of the data will be
performed using SPSS (version 21).
Statistical tests performed include the Chi-square test (if the data are normally
distributed) or the Kruskal-Wallis test (if the data are not normally distributed), which
allowed for comparisons between the control group and the study population. The Chisquare test and the Kruskal-Wallis test can be performed because the sample size is well
over 60 participants and there was more than five participants in each age category.
Analysis of Variance (ANOVA) was performed on normally distributed data samples,
both with and without the Tukey Post-hoc analysis as needed, to compare the various age
groups. In addition, an odds ratio was calculated for each of the symptom categories
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included in the study. Lastly, a receiver operating characteristic (ROC) curve was
generated to analyze the usefulness of the symptom index score as a diagnostic tool.
In addition to the described univariate and bivariate statistical analyses, multiple
linear regression analysis was conducted on sex and age variables in comparison to the
symptom index score. The independent variables of age and sex were included in the
analysis regardless of their association with the dependent variables after bivariate
analysis based on evidence from previous literature (Katz, 2006).
Since the goal of this research was to identify additional potential factors to use
for the earliest possible diagnosis of Lyme disease, an analysis based on the use of the
information from this study for diagnosis was performed. Once associations between
symptoms and/or symptom severity and the independent variables were determined, the
sensitivity, specificity, positive predictive value, and the negative predictive values were
calculated for the groups of symptoms. These values describe the ability of the test to
identify correctly those individuals who have a disease. A ROC plot was also generated
determine the diagnostic value of the symptom index score for Lyme disease.
Possible Types and Sources of Information or Data
1. ROSS Scale surveys from patient records from a primary care medical
practice.
2. ROSS Scale surveys distributed and collected at a small, rural liberal-arts
college.
Definition of Terms
The following section provides working definitions of the terms used in this
research.
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Age: A numerical value distinguishing the number of years an individual has been
alive, beginning at birth and ending with death (Free Dictionary, 2013).
Chronic Lyme disease: Persistent symptoms of Lyme disease despite 30 days of
treatment or a recurrence or relapse of symptoms without evidence of a new tick bite or
incidence of EM rash (Cameron et al., 2004).
Early disseminated Lyme disease: The stage of Lyme disease infection associated
with the spread of the B. burgdorferi bacteria from the initial site of infection as
associated with neurological symptoms, like cranial nerve palsies and meningitis, and
initial musculoskeletal complaints (Binder et al., 2012; Donta, 2012; Franz & Krause,
2003; Girschick et al., 2009; Wormser et al., 2006).
Early localized Lyme disease: The stage of Lyme disease infection signaled by
symptoms that include mild flu-like symptoms, malaise, fatigue, headache and the
erythema migrans (EM) rash that begins around the site of the tick bite and slowly
increases in size to a typical diameter of at least 5 cm (Binder et al., 2012; Donta, 2012;
Franz & Krause, 2003; Girschick et al., 2009; Wormser et al., 2006). Neurological
symptoms, including Bell’s palsy, may be present as well (Binder et al., 2012; Donta,
2012; Franz & Krause, 2003; Girschick et al., 2009; Wormser et al., 2006;).
Erythema migrans (EM) rash: A characteristic rash of early localized Lyme
disease with the key features that include a shape that is round to oval; a red to bluish-red
color; a clearly defined edge; occurs at the location of the tick bite; and increases in size
over time from 5 cm to 16 cm (Muellegger, 2004).
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Sex: For the purposes of this research, the term sex will be used to describe male
or female biological sex, as well as the individual’s interactions with and expectations
from their social environment (Wizeman & Pardue, 2001).
Late Lyme disease: The stage of Lyme disease infection characterized by
musculoskeletal complaints including arthritis, especially in the large joints of the arms
and legs, polyneuropathy, cranial neuropathy, cardiac complications, and
encephalomyelitis (Binder et al., 2012; Donta, 2012; Franz & Krause, 2003; Girschick et
al., 2009; Wormser et al., 2006).
Posttreatment Lyme disease syndrome: The stage of Lyme disease characterized
by the continuation or return of symptoms after a standard course of treatment for the
disease (Aucott, Crowder, & Kortte, 2013).
Symptom presentation: The subjective signs of Lyme disease as reported by the
patient (Free Dictionary, 2013).
Symptom severity: The intensity of the subjective signs of Lyme disease as
reported by the patient (Free Dictionary, 2013).
Limitations
One of the main limitations for this study is related to sampling bias. The patient
records examined all came from one clinic in New York. The patient records do not
represent a random sampling of individuals because this study focuses on those
individuals who have already been diagnosed with Lyme disease. In addition, all of these
patients have access to health care and have health insurance, so results may not be
typical of those individuals who do not have access to either.
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Controls were selected by convenience sampling, which can lead to a reduction of
external validity (Mann, 2003; McDermott, 2011; Pannucci & Wilkins, 2010). The
convenience sample was chosen despite this reduction because the medical clinic treats
patients from a broad sampling of states within the Lyme endemic region of the United
States and the college also has students and staff from these same Lyme endemic regions.
According to the CDC surveillance data, 97% of all reported Lyme disease cases come
from only 14 states (CDC, 2015). These states include: Connecticut, Delaware, Maine,
Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York,
Pennsylvania, Rhode Island, Vermont, Virginia, and Wisconsin (CDC, 2015). The
medical clinic is centrally located and within driving distance from Connecticut, New
York, Pennsylvania, and New Jersey. The college is located two hours west from the
medical clinic. This central location provided the opportunity for both Lyme disease and
non-Lyme disease participants to be chosen as both cases and controls. In addition, the
age distribution of controls from the college was well matched to the age distribution of
the medical clinic.
To address this non-random sampling bias, a ratio of 1:2 cases to controls was
used. Frequency matching was used to insure that cases and controls had a similar
percentage of participants that fell into the male/female and the selected age categories.
Because age and sex are variables under investigation in this study, matching could not
occur on these variables, but to make meaningful comparisons on these variables, there
must be similar numbers of cases and controls for each sex and age category
(McDermott, 2011; Pannucci & Wilkins, 2010; Zondervan, Cardon, & Kennedy, 2002).
In addition, matching was performed between cases and controls on the basis of state of
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residence. Because Lyme disease is endemic to only 14 states in the United States,
matching of cases and controls on their state of residence insures that potential exposure
to the Ixodes tick is equal in both groups.
Recall bias is a potential problem with case-control study designs (Mann, 2003;
McDermot, 2011; Pannucci & Wilkins, 2010; Schulz & Grimes, 2002). Because this
study collected data through medical record review and via the ROSS Scale survey, recall
bias was minimized. Cases reported signs and symptoms experienced at the time of their
medical office visit. Controls reported symptoms experienced within the previous week
from the date the ROSS scale was filled out. The ROSS Scale survey collects data on
symptoms for the week prior to filling out the survey. Recalling information from the
past seven days helped to minimize recall bias considerably.
Lastly, confounding must be addressed. Because matching of cases with controls
and stratification were difficult due to age and sex being variables under study, potential
confounders were dealt with in the analysis portion of the study through multivariate
regression analysis (McDermott, 2011; Schlesselman, 1982; Schulz & Grimes, 2002).
Statement of Positive Social Change Implications
The implications of this research for positive social change include increased
knowledge of the sex differences found in Lyme disease; prevention of delays in
diagnosis and treatment for patients with Lyme disease; decreased expenses associated
with late Lyme disease due to increased diagnosis in the early stage of infection; and
early access to needed health care services.
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Summary
This chapter outlined the key components of this research project. Research
questions and hypotheses were identified. Key definitions were provided. Significant
background for and descriptions of Lyme disease were provided to show the importance
of studying factors that could increase the accurate diagnosis and early treatment of Lyme
disease. Further evidence to support the importance of studying Lyme disease is provided
in chapter two via a thorough examination of the literature on Lyme disease to date.
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Chapter 2: Literature Review
Introduction
This chapter provides a review of the literature in support of an examination of
the factors that affect the presentation of Lyme disease. First, I provide a description of
Borrelia burgdorferi, the causative agent of Lyme disease. Because Lyme disease is a
tick-borne disease, Ixodes scapularis and Ixodes pacificus, the tick vectors found in the
United States, must be described as well. In addition, I review the complex lifecycle of
both Borrelia burgdorferi and Ixodes scapularis.
Next, I establish evidence for sex differences in other chronic and infectious
diseases. These established differences, although not well studied in Lyme disease in the
United States, can be utilized as support for identifying the same differences in Lyme
disease. In addition, I review comparisons between the male and female immune
response. I also discuss age differences in the incidence of Lyme disease. Lyme disease
symptoms are clearly defined to provide the necessary basis for study measurements.
Finally, I discuss the theoretical framework for the study.
I identified pertinent literature using Google and Google Scholar search engines,
as well as Science Direct, PubMED, and ProQuest databases. Search terms included
Lyme disease, symptoms of Lyme disease, sex differences + Lyme disease, gender
differences + Lyme disease, age + Lyme disease, sex differences + immune response,
gender differences + immune response, sex differences + chronic disease, gender
differences + chronic disease, sex differences + cardiovascular disease, gender
differences + cardiovascular disease, sex differences + autoimmune disease, gender
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differences + autoimmune disease, sex differences + infectious disease, gender
differences + infectious disease, Lyme disease + children, behavior risk factors + Lyme
disease, occupational exposure + Lyme disease, recreational activity + Lyme disease,
symptom severity + Lyme disease, and environmental risk factors + Lyme disease. Both
sex differences and gender differences were searched separately because these terms are
often used interchangeably.
The Causative Agent
The causative agent for Lyme disease, as it is known in the United States, or
Lyme borreliosis, as it is known in Europe and Asia, was discovered in 1981 by Dr.
Willy Burgdorfer, an entomologist who studied ticks and the organisms who lived inside
them (Sternbach & Dibble, 1996). This bacterium, Borrelia burgdorferi sensu lato, has
been separated into more than 20 distinct species to date, not all of which cause disease in
humans (Borchers et al., 2015; Caimano, Hu, Radolf, & Stevenson, 2012; Mead, 2015).
The primary disease causing agents for Lyme disease are Borrelia burgdorferi sensu
stricto, found in the United States and Europe, Borrelia garinii, and Borrelia afzelii,
found in Europe and Asia, and the recently discovered Borrelia mayonii, found only in
the Midwestern United States (Borchers et al., 2015; Caimano et al., 2012; Mead et al.,
2015; Pritt et al., 2016). Because the patient sample for this research will be in the eastern
United States, the focus of this literature review will be on Borrelia burgdorferi sensu
stricto.
Borrelia burgdorferi sensu stricto is a Gram negative, microaerophilic member of
the family Spirochaetaceae (Johnson, Schmid, Hyde, Steigerwalt, & Brenner, 1984;
Neelakanta et al., 2007; Rosa, Tilly, & Stewart, 2005). This organism displays the typical
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flexible spiral shape of other members of the Spirochaetaceae family with both inner and
outer protective membranes that enclose the periplasmic flagella which allow the
organism to be motile by either rotational or translational movement (Johnson et al.,
1984; Rosa et al., 2005). The cell wall of B. burgdorferi is missing lipopolysaccharides, a
unique characteristic for a Gram negative organism, since most Gram negative cell walls
contain a high concentration of lipopolysaccharides (Rosa et al., 2005). In addition, the
peptidoglycan layer of the cell wall contains a high concentration of ornithine (Johnson et
al., 1984). Peptidoglycan composition is important since peptidoglycan is a typical
antimicrobial target for treatments.
The cell wall encloses a unique genome. First, the genome contains both a
segmented linear chromosome and between 13 and 21 linear and circular plasmids
(Brisson et al., 2012; Caimano et al., 2011; Rosa et al., 2005; Schutzer et al., 2011).
While the linear chromosome contains much of the structural and metabolic information
necessary for survival, this information is carried repeatedly on many different genes
(Brisson et al., 2012; Caimano et al., 2011; Schutzer et al., 2011). In fact, many of the
genes in the Borrelia genome are identical (Brisson et al., 2012; Schutzer et al., 2011).
Bacterial plasmids generally carry information for virulence, exotoxins, endotoxins, or
special enzymes. Borrelia plasmids carry information vital for survival, including the
outer surface protein genes (Brisson et al., 2012; Caimano et al., 2011; Schutzer et al.,
2011). In addition, no virulence factors have been discovered on any of the known
plasmids (Brisson et al., 2012; Rosa et al., 2005).
Additional components of the bacterial cell wall and membrane with functional
importance are the outer surface proteins (Osp). Six outer surface proteins (A through F)
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have been identified, but only three have identified functions in the infection cycle
(Kenedy, Lenhart, & Akins, 2012; Pal et al., 2000). Outer surface protein A (OspA) plays
a role in replication in and infection of the Ixodes tick vector (Hartiala et al., 2008;
Kenedy, Lenhart, & Akins, 2012; Pal et al., 2000). This protein is only produced when
Borrelia is in the tick’s gut and plays a role in binding to TROPSA receptors in the midgut region of the tick (de Silva, Fish, Burkot, Zhang, &Fikrig, 1997; de Silva, Telford III,
Brunet, Barthold, &Fikrig, 1996; Hartiala et al., 2008; Kenedy, Lenhart, & Akins, 2012;
Pal et al., 2004a; Schwan, Piesman, Golde, Dolan, & Rosa, 1995). Once the tick begins
feeding on either the natural host or the human host, production of OspA stops and
Borrelia no longer expresses this protein on the surface (de Silva et al., 1997; de Silva et
al., 1996; Hartiala et al., 2008; Kenedy, Lenhart, & Akins, 2012; Schwan et al., 1995).
OspA was a target for the Lyme vaccine because OspA is found only in the tick stage of
infection, but the vaccine is no longer produced due to poor sales in the United States (de
Silva et al., 1997; de Silva et al., 1996; Schwan et al., 1995).
Outer surface protein B (OspB) is found in conjunction with OspA on the
bacterial cell surface when Borrelia is in the mid-gut of the Ixodes tick (de Silva et al.,
1997; de Silva et al., 1996; Hartiala et al., 2008; Kenedy, Lenhart, & Akins, 2012;
Neelakanta et al., 2007; Schwan et al., 1995). While not much is known about the
function of OspB, a study by Neelakanta et al. (2007) confirmed the importance of OspB
in binding of Borrelia burgdorferi to the epithelial lining of the Ixodes tick. In addition,
Hartiala et al. (2008) suggested that OspB plays a role in immune system evasion by
preventing phagocytosis by neutrophils at the site of initial infection. This role was
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previously presented by Bundoc and Barbour (1989), but little evidence was provided to
support this earlier claim.
While OspA and OspB are expressed by Borrelia burgdorferi within the Ixodes
tick vector, down-regulation and reduced expression of these two proteins occurs once
the blood meal commences and the bacterium enters the mammalian host (de Silva et al.,
1997; de Silva et al., 1996; Kenedy, Lenhart, & Akins, 2012; Neelakanta et al., 2007;
Schwan et al., 1995). Outer surface protein C (OspC) is expressed for a short while
during Borrelia migration from the mid-gut to the salivary glands and upon first entering
the mammalian host (Carrasco et al., 2015; Grimm et al., 2004; Kenedy, Lenhart, &
Akins, 2012; Neelakanta et al., 2007; Pal et al., 2004a; Stewart et al., 2006; Tilly et al.,
2006). The shift from OspA/OspB production to OspC production is related to the pH
changes that occur in the mid-gut of the tick during the blood meal (Tilly et al., 2006).
Pal et al. (2004b) found that OspC is present in greater numbers than OspA or
OspB during migration of the bacteria to the salivary glands of the tick, but Grimm et al.
(2004), Tilly et al. (2006), and Stewart et al. (2006) all found that OspC was not required
for Borrelia motility or adherence to the tick salivary glands. It seems that OspC plays a
vital role during early infection of the mammalian host (because OspC expression downregulates after 2 weeks post infection), but this role was unclear (Carrasco et al., 2015;
Grimm et al., 2004; Stewart et al., 2006; Tilly et al., 2006). In a study conducted by
Carrasco et al. (2015), OspC is important for evading phagocytosis by macrophages at
the site of the infection. This phagocytic evasion allows the organism to colonize the
mammalian host during the early stage of infection (Carrasco et al., 2015).
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According to Samuels (2011), one role of OspC is binding to mammalian
plasminogen (an important protein for dissolving blood clots). Onder et al. (2012)
suggested that the binding between plasminogen and OspC on the surface of B.
burgdorferi provided a few advantages. First, plasminogen binding helped the bacteria
cross over multiple cell membranes: from tick mid-gut to salivary glands; from tick
salivary glands into mammalian skin; from skin at bite site to mammalian blood stream
(Onder et al., 2012). Second, plasminogen helps to break down antibodies and deactivates
parts of the complement system (Onder et al., 2012). Each of these factors provides
support for the importance of OspC for B. burgdorferi infection of mammalian cells.
OspC is not required for tick re-infection from the mammalian host (Tilly et al.,
2006). In a study with mice infected with an OspC mutant form of Borrelia burgdorferi,
naïve ticks were infected with the OspC mutant form after feeding on infected mice (Tilly
et al., 2006). Both Tilly et al. (2006) and Stewart et al. (2006) suggest that OspC plays a
role in either evading the mammalian host’s innate immune system or recognition of the
mammalian host tissue. Neither group provided adequate evidence to support either
hypothesis, but Onder et al. (2012) provided evidence to support both.
Stewart et al. (2006) suggested that genetic variations in OspC may allow for
evasion of the innate immune system and subsequent dissemination from the initial site
of infection, but the research did not support this conclusion. OspC gene expression
down-regulates within two weeks post-infection, right at the time dissemination from the
initial tick bite normally occurs (Grimm et al., 2004). This early research suggested that if
OspC is important for dissemination in the host, down-regulation of the gene for OspC
and reduction in the expression of OspC would not occur at this point of the infection
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cycle. Recent research by Onder et al. (2012) show that OspC helps the bacteria get into
the bloodstream for dissemination, but is not necessary for the actual spread of the
infection.
Samuels (2011) suggested that because OspC is considered a dominant
immunogen, production shuts down to prevent antibody production. This shutdown
would prevent adaptive and memory immune responses, but would not affect the innate
immune system. Carrasco et al. (2015) suggest that OspC plays a role in evading innate
immune system responses like macrophage phagocytosis. Onder et al. (2012) suggest that
OspC serves as a plasminogen receptor that helps break down antibodies. The role of
OspC in the immune process is still under investigation. While the functions of these
outer surface proteins in the mammalian hosts are not completely understood, their
interactions within the tick vector are important.
The Vector
The vector for Lyme disease is the Ixodes tick (Figure 1). Four primary species
have been identified as a carrier for Borrelia burgdorferi: Ixodes scapularis in the eastern
United States, Ixodes pacificus in the western United States, Ixodes ricinus in Europe,
and Ixodes persulcatus in Europe and Asia (Borchers et al., 2015; Caimano et al., 2012;
Mead, 2015; Rosa et al., 2005; Suss, Klaus, Gerstengarbe, & Werner, 2008). The tick
becomes infected, usually during the larval stage of its life cycle, by feeding on an
infected endemic host (Caimano et al., 2012; Mead, 2015; Subak, 2003). These hosts tend
to be small mammals and birds (Caimano et al., 2012; Subak, 2003). In the United States,
Peromyscus leucopus (white-footed mouse) is the primary reservoir (Caimano et al.,
2012; Subak, 2003).
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Figure 1. Ixodes scapularis tick sizes (CDC, 2015)

The Life Cycle
Ixodes ticks are born uninfected with Borrelia burgdorferi because passage of the
bacteria does not occur through transovarial routes (Borchers et al., 2015; Rosa et al.,
2005). As shown in Figure 2, Ixodes ticks lay eggs in May of the first year of their two
year life cycle (CDC, 2015; Subak, 2003). Eggs hatch releasing larvae in the summer
months (CDC, 2015; Subak, 2003). In order to continue to the next stage of development,
larvae must feed and tend to feed on smaller mammals like Peromyscus leucopus
(Caimano et al., 2012; Mead, 2015; Rosa et al., 2005; Subak, 2003). It is at this point that
the tick becomes infected with Borrelia burgdorferi (Caimano et al., 2012; Mead, 2015;
Rosa et al., 2005; Subak, 2003). The tick is infected with the Borrelia bacteria for life and
can transmit the bacteria to any other organism it feeds on (Borchers et al., 2015;
Caimano et al., 2012; Rosa et al., 2005; Subak, 2003).
The larvae become dormant over the winter and molt into the nymph stage in the
spring (CDC, 2015; Caimano et al., 2012; Subak, 2003). A second blood meal must be
taken at this time in order for the final stage of development to occur (Caimano et al.,
2012; Subak, 2003). Humans and larger animals like deer and dogs are the prime target
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for nymphal feeding (Caimano et al., 2012; Rosa et al., 2005; Subak, 2003). Nymphs
develop into adults that are able to lay eggs and begin the cycle again (Caimano et al.,
2012; Rosa et al., 2005; Subak, 2003).

Figure 2. Tick two-year life cycle (CDC, 2015)
Larvae become infected with Borrelia during the blood meal and remain in the
tick midgut until the tick enters the nymph stage (Rosa et al., 2005). At this point,
Borrelia expresses both OspA and OspB (Rosa et al., 2005). The bacteria do not invade
any other tissues within the tick until after becoming a nymph and the second blood meal
occurs (Rosa et al., 2005). With the pH changes that occur during the second blood meal,
OspA and OspB production is down-regulated and OspC production is up-regulated as
the bacteria move from the midgut of the tick to the salivary glands (Caimano et al.,
2012; Kenedy, Lenhart, & Akins, 2012; Rosa et al., 2005). Once in the salivary glands,
Borrelia can be transferred to the next organism bitten (Borchers et al., 2015; Caimano et
al., 2012; Rosa et al., 2005).
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Borrelia is not transferred immediately to the new host (Caimano et al., 2012;
Rosa et al., 2005). Ticks must be attached more than 24 hours for the transfer to occur
because during the first 24 hours of attachment, little blood is actually taken in by the tick
(Borchers et al., 2015; Caimano et al., 2012; Dai et al., 2010; Hynote, Mervine, &
Stricker, 2012; Rosa et al., 2005). After 48 hours of attachment, blood meal intake by the
tick increases rapidly and poses the largest chance for transfer of Borrelia to the new host
(Dai et al., 2010). While the minimum number of spirochetes required to cause infections
in humans in not currently known, the infective dose of Borrelia in mice models suggest
as few as 18 bacteria can lead to infection (Borchers et al., 2015).
Incidence Rates
Because Lyme disease is a vector-borne disease, each new case reported to the
CDC is considered a new infection. In addition, Lyme disease is endemic to only 14
states in the United States. These states are mostly located in the eastern United States
and correspond to the habitat of the Ixodes scapularis tick. Incidence rates for Lyme
disease for each state used in the study are shown in Table 2 (CDC, 2015).
Table 2
Incidence Rate by State of Residence of Study Participants for 2014 (CDC, 2015)
State of residence

Incidence rate (per 100,000 people)

Lyme disease cases (count)

Connecticut

47.8

2,360

Massachusetts

54.1

5,304

New Hampshire

46.9

724

New Jersey

29.0

3,286

New York

14.4

3,736

Pennsylvania

50.6

7,487

Vermont

70.5

599
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The lower incidence rate in New York is related to the fact that New York has a
state population of 19.75 million people, 8.5 million that live in New York City alone
(US Census Bureau, 2015). Living in a large urban setting reduces your risk for exposure
to the Lyme disease tick and lowers your risk for developing Lyme disease. According to
CDC data, New York (n = 3,736) had more reported cases than Connecticut (n = 2,360)
in 2014, but due to the population differences between the two states, Connecticut has a
higher incidence rate (CDC, 2015). The other states with low numbers of confirmed cases
but high incidence rates follow the same pattern – the overall population size is lower in
states like Vermont and New Hampshire (US Census Bureau, 2015).
Risk Factors
Behavioral and environmental risk factors for tick-borne diseases have been
studied since the early 90’s. Risk factors associated with Lyme disease specifically have
been studied in Pennsylvania, Maryland, New Jersey, California, Wisconsin, Rhode
Island and Connecticut, all highly endemic states for Lyme disease and the normal habitat
for the Ixodes tick that serves as the vector for Lyme disease. These studies examined the
following risk factors: location of primary residence, activities associated with tick
habitat contact, and pet or animal ownership. Occupational risk was also examined.
In the one of the earliest studies, Glass et al. (1995) performed a case-control
study (n = 47/492) in Baltimore County, Maryland for incident cases in 1989 and 1990.
This study focused on environmental factors associated with tick habitat and interaction
venues for tick/human interactions. Study results suggested that living close to a forest
increased the risk for contact with a tick and the subsequent development of Lyme
disease by a factor of three for those individuals who lived at the forest edge (Glass et al.,
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1995). As the distance between living space and forest increases, risk drops accordingly
(Glass et al., 1995). In addition, living in a highly developed urban area provided a
protective effect (Glass et al., 1995). Glass et al. (1995) were the only researchers to find
this protective effect, although other studies did support distance from forested areas as a
reduced risk for contracting Lyme disease.
Ley, Olshen, and Reingold (1995) examined common outdoor activities that could
provide an opportunity for a tick-human interaction. The case-control study took place in
California with 101 cases and 107 controls (Ley, Olshen, &Reingold, 1995). During the
period 1992-1997, California had only 581 confirmed Lyme disease cases so the case
sample size for the study period of June 1991-December 1992 provided a large case
population (CDC, 2015).
Results of this study did not identify any activities that were significantly
associated with contracting Lyme disease. Activities selected for examination included a
variety of yard work activities, like gardening, clearing brush, and stacking wood, and
leisure activities, like hiking, biking, camping, and fishing (Ley et al., 1995). The study
did not examine distance of the home from a wooded area, but did examine whether a
fenced in or natural yard was present (Ley et al., 1995).
These results are in direct contrast with the studies by Glass et al. (1995), Orloski
et al. (1998), and Belongia et al. (1999) discussed in this review. Ley et al. (1996)
suggested that this contrast may be due to the fact that California is a very populous state
with 29 million people living there in 1990 (US Census, 2001). A sample size of 101
confirmed cases would not be representative of the entire state and significance levels
would be difficult to reach (Ley et al., 1995). In addition, California covers a large
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surface area with many different climates present across the state. Tick habitat
availability would vary significantly across the many distinct climate areas in California,
further diluting the potential for significant differences in Lyme disease risk (Ley et al.,
1995).
In an earlier study (n = 83) in California conducted by Lane et al. (1992), outdoor
risk factors for Lyme disease were also examined. Of the variables examined as a
potential risk factor for Lyme disease, only woodcutting (OR = 4.8; 95% CI 1.01-23.10)
showed statistical significance (Lane et al., 1992). In addition, living in a “natural” area
(with a home close to a wooded area) was considered an increased risk but the statistical
measures were not provided for this risk, so the level of risk can’t be quantified from the
reported data (Lane et al., 1992). Lane et al. (1992) were the only researchers to report a
significant difference in risk between females and males (OR = 2.3; 95% CI 0.94-5.81)
infected with Lyme disease. Sex data was collected in the studies conducted by Glass et
al. (1995), Ley et al. (1996), Klein et al. (1996), Orloski et al. (1998), and Belongia et al.
(1999) but were not analyzed as a potential risk factor for developing Lyme disease.
Klein, Epps, and Hunt (1996) specifically studied environmental factors and
activities in children. In this case-control study (n = 44/44), twenty four environmental
factors and 45 activities were examined for increased risk for Lyme disease in the
northeastern endemic states of Maryland, New Jersey, and Pennsylvania (Klein et al.,
1996). Based on the findings of this study, the only significant risk for Lyme disease in
children is the presence of deer ticks in the home and yard (OR = 3.05; 95%CI 0.97-9.89)
(Klein et al., 1996). Unfortunately, the authors did not provide what specific
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environmental factors or activities were surveyed so no comparisons can be drawn with
the other studies examined in this literature review.
Orloski et al. (1998) performed a case-control (n = 51) study that examined both
behavioral and environmental factors for Lyme disease. Results showed the typical
bimodal age distribution (<11 years and 40-60 years peaks), month of onset (May, June,
or July), presence of erythema migrans (EM) rash (87%), and sex distribution (males in
the younger age group; females in the older age group) as that reported by the Centers for
Disease Control and Prevention (Orloski et al., 1998). In addition, living near wooded
areas (OR = 15.0; 95CI) and clearing heavy brush (OR = 4.0; 95CI) on their properties
produced the greatest risk for contracting Lyme disease. Lastly, rock walls present on the
property also showed an increased risk for Lyme disease because rock walls provide a
good habitat for small mammals, like the white-footed mouse, that serve as reservoir
hosts for Borrelia burgdorferi (Orloski et al., 1998).
In contrast to the study by Glass et al. (1995), Orloski et al. found that living in an
urban environment did not produce a protective effect (Orloski et al., 1998). Outdoor
activities like walking, hiking, or jogging in grassy or wooded areas, gardening or lawn
mowing, and hunting or fishing did not increase the risk for developing Lyme disease
(Orloski et al., 1998). Cat ownership also did not increase the risk, but dog ownership
was not tested and no reason for the exclusion was given (Orloski et al., 1998).
In a study by Belongia et al. (1999), dog ownership was identified as a risk factor
for Lyme disease due to the fact that dog owners tend to actively check for and remove
ticks from their pet dogs. Surprisingly, this study was one of the few conducted with dog
ownership as a variable. Belongia et al. (1999) included cat ownership as a variable but
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found no correlation between cat ownership and increased risk for Lyme disease. Other
factors identified to increase the risk of contracting Lyme disease include: living in a
rural area on a property with more than two acres of land, living near a farm, clearing
heavy brush from property or land near property, hiking or jogging on forest paths, and
camping (Belongia et al., 1999). Surprisingly, and in direct contrast to the studies by
Glass et al. (1995) and Orloski et al. (1998), living near a wooded area and/or having a
rock wall or wood pile on the property produced no significant increase in the risk for
developing Lyme disease (Belongia et al., 1999). In addition, occupational exposures
were not identified as a significant risk factor (Belongia et al., 1999).
Piacentino and Schwartz (2002) conducted a review of the extensive literature on
occupational exposure risk of contracting Lyme disease. Workers identified as having a
potential increased risk include: forestry workers and lumberjacks, farm workers, military
personnel, veterinarians, and other workers who spend large amounts of time outdoors
(Piacentino & Schwartz, 2002). Forty one articles were culled from the vast number of
articles pertaining to occupational risk of Lyme disease. After careful examination of this
literature, Piacentino and Schwartz concluded that there was no evidence to support an
increased occupational risk of “symptomatic, clinically confirmed Lyme disease” in any
of the categories of outdoor workers (Piacentino & Schwartz, 2002, p. 82).
These result directly supported the study by Smith, Wileyto, Hopkins, Cherry, and
Maher (2001) where no increased occupational risk of Lyme disease for outdoor workers
was found. The authors conducted the largest case-control study (n = 294/449) to date
that examined occupational, behavioral, and environmental risk factors for Lyme disease.
While this study showed the same bimodal distribution of cases by age as the data
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reported by the CDC (2015), males did not make up more cases in the lower age range
and females did not make up more cases in the 40-60 year age range (Smith, Wileyto,
Hopkins, Cherry, & Maher, 2001).
Similar to the studies by Glass et al. (1995) and Orloski et al. (1998), living in a
rural setting increased the risk of developing Lyme disease three times over the risk
associated with living in an urban setting (Smith et al., 2001). In fact, living in a single
family home increased the risk for developing Lyme disease 2 ½ times over living in a
multi-family dwelling (Smith et al., 2001). In addition, living within 100 feet of a wooded
area increased the risk of developing Lyme disease 4-5 fold (Smith et al., 2001). This
result is in line with the findings of Glass et al. (1995) and Orloski et al. (1998) but is in
direct contrast to the findings of Belongia et al. (1999).
Additional findings identified the following increased risk activities: gardening
more than four hours per week (OR = 1.83; CI 1.21, 2.54); walking or jogging in the
woods (OR = 1.48; CI 1.09, 2.00); and picnicking in non-traditional locations (OR =
1.47; CI 1.02, 2.12) (Smith et al., 2001). There was no increased risk associated with
camping, which was surprising considering most of the other studies found an increased
risk for camping (Belongia et al., 1999; Glass et al., 1995; Orloski et al., 1998; Smith et
al., 2001).
A more recent study identified which examined risk factors for Lyme disease was
conducted by Vazquez et al. (2008). The purpose of this case-control study (n =
709/1,128) was to examine personal protective measures utilized by the sample
population, but a few occupational, environmental, and activity variables were measured
as well. Hiking, camping, pet ownership, and proximity of the home to a wooded area
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were not associated with increased Lyme disease risk (Vazquez et al., 2008). In addition,
the only occupation with a positive association with increased risk for Lyme disease was
farming (Vazquez et al., 2008).
The most recent study identified on risk factors for Lyme disease was conducted
by Finch et al. (2014). This study (N = 486 participants/ 105 properties) focused mainly
on peridomestic methods of Lyme disease transmission, including pet ownership and
shrub cover at the edge of a property. Finch et al. (2014) focused mainly on shrub cover,
but surveyed land owners about pet ownership, occupational and recreational activities,
and prevention methods. Results suggested that the density of shrub cover and time spent
outdoors was correlated to an increased risk of Lyme disease. As with the study
conducted by Vazquez et al. (2008), pet ownership did not increase the risk for Lyme
disease (Finch et al., 2014).
With the results from studies by Finch et al. (2014), Vazquez et al. (2008),
Piacentino and Schwartz (2002), and Smith et al. (2001), occupational exposure to Ixodes
ticks does not increase an individual’s risk of developing Lyme disease. Environmental
factors, like living in a wooded area, may or may not increase the risk of developing
Lyme disease (Belongia et al., 1999; Glass et al., 1995; Klein et al., 1996; Lane et al.,
1992; Ley et al., 1995; Orloski et al., 1998; Smith et al., 2001). Activities, like camping,
hunting, hiking, or jogging in wooded areas, may or may not increase your risk of
developing Lyme disease as well (Belongia et al., 1999; Glass et al., 1995; Klein et al.,
1996; Lane et al., 1992; Ley et al., 1995; Orloski et al., 1998; Smith et al., 2001). With
the conflicting data provided by these studies, additional information on risk factors for
Lyme disease is needed.
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Immune System Response
In order to understand the sex differences found in the immune response to Lyme
disease, one must first examine the immune system response to the bacterial pathogen in
general. Borrelia burgdorferi enters the host through the tick bite. The tick provides some
protection to the bacteria upon injection into the host because the tick also injects certain
molecules that insure the tick can feed undetected. These molecules prevent immune
system activation by preventing the activation of immune cells including neutrophils, Blymphocytes, T-lymphocytes and dendritic cells, as well as preventing the release of early
cytokines and antimicrobial peptides (Radolf et al., 2012; Schuijt et al., 2008). One
molecule used is Salp-15 (Schuijt et al., 2008). Salp-15 prevents CD4+ T-lymphocyte
(helper T-cell) activation by binding to its cellular receptor (Schuijt et al., 2008). In
addition, using the Salp-15 protein helps Borrelia to prevent the activation of the
complement system and, if activated, allows evasion of the complement system proteins
(Schuijt et al., 2008).
Toll-like receptors (TLR2 and TLR1) on macrophages and dendritic cells
circulating within the skin are activated by binding to lipoproteins (OspA) on the surface
of Borrelia, causing the release of key cytokines to initiate the immune system response
to the invading pathogen (Radolf et al., 2012; Shin et al., 2008). This response can be
either a TH1-cell or a TH2-cell response. During a TH1-cell response, cytokines gamma
interferon (IFN-γ), transforming growth factor – beta (TGF-β) and interleukin-2 (IL-2) is
released (Romagnani, 2000). During a TH2-cell response, cytokines (IL-4, IL-5, IL-6, IL9, IL-10, IL-13) may be released, depending on the stimulus (Romagnani, 2000). Specific
cytokines released in response to Borrelia infection includes tumor necrosis factor alpha
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(TNF-α), transforming growth factor beta (TGF-β1), interleukins (IL-1, IL-6, IL-10, IL17) and interferons (IFN-α, IFN-γ) (Glickstein et al., 2003; Radolf et al., 2012; Sehgal &
Khurana, 2015; Widhe et al., 2002). The functions of the various cytokines are shown in
Table 3.
Table 3
Cytokine Functions (Owen, Punt, & Stranford, 2013)
Cytokine
Tumor Necrosis Factor
Alpha
(TNF-α)
Transforming Growth
Factor – beta (TGF-β1)

Secreted by
Macrophages
Neutrophils
T-lymphocytes
Macrophages
T-lymphocytes

Interleukin -1 (IL-1)
Interleukin – 6 (IL-6)

Macrophages
Macrophages
TH2-lymphocytes

Interleukin – 10 (IL-10)

B-lymphocytes
T-lymphocytes
Dendritic Cells
TH-lymphocytes

Interleukin – 17 (IL-17)
Alpha – Interferon (IFN-α)
Gamma – Interferon (IFNγ)

Macrophages
Dendritic Cells
TH1-lymphocytes
TC-lymphocytes

Effects
Inflammation

Inhibits T-cell and B-cell
proliferation; Inhibits
macrophages
Inflammation
Proliferation of Blymphocytes; Antibody
production
Regulatory cytokine

Inflammation; neutrophil
recruitment
Increases MHCI
expression
Activates macrophages;
Increases MHCI and
MCHII expression

Release of these cytokines initiate the inflammatory response, calls other immune
cells to the site of infection, and activate B-lymphocyte differentiate and proliferation
(Radolf et al., 2012; Widhe et al., 2002). While neutrophils are recruited early in the
infection process, T- lymphocyte (both CD4+ and CD8+) activation leads to the
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production of the EM rash in infected tissue (Glickstein et al., 2003; Radolf et al., 2012;).
B-lymphocytes are not activated during the EM rash and the early localized portion of the
infection cycle (Radolf et al., 2012).
Activation of B-lymphocytes occurs once Borrelia leaves the initial infection site
and enters the bloodstream where it can come in contact with B-lymphocytes in the
spleen during normal transport through the body (Radolf et al., 2012). Antibody
production occurs in a two-fold process – IgM antibodies are produced first, but don’t
persist for very long (Radolf et al., 2012). IgG antibodies take longer to be produced, but
last longer in tissues and circulation (Radolf et al., 2012). Antibodies are produced
against many of the outer surface proteins (Osp), including OspA and OspC even though
these proteins don’t seem to play a role outside of the tick host (Liang et al., 2004; Radolf
et al., 2012). In addition, the lipoprotein VlsE is found on the surface of the organism but
can demonstrate significant variation in structure, leading to the need for multiple
antibodies against this specific protein to offer protection (Kenedy, Lenhart, & Akins,
2012; Radolf et al., 2012).
One of the primary identified differences between the male and female sex is the
presence of the steroid hormone estrogen. While estrogen’s primary role in the body is
during the reproductive cycle in women, estrogen does have an effect on the immune
system (Baker et al., 2011; Bullard et al., 2012; Pennell et al., 2012). Several immune
cells have membrane bound cell receptors that bind estrogen, which leads to the
activation and amplification of a signal transduction cascade (Pennell et al., 2012). These
immune cells include: B-lymphocytes, T-lymphocytes, dendritic cells, neutrophils,
macrophages, and natural killer (NK) cells (Pennell et al., 2012).
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In addition, binding of estrogen by immune cells can initiate a cell-specific
response. Binding of estrogen to B-lymphocytes increases proliferation and antibody
production (Pennell et al., 2012). Binding of estrogen by TH-lymphocytes leads to
increased production of IL-10, which also leads to increased proliferation of and antibody
production in B-lymphocytes (Pennell et al., 2012). Estrogen inhibits IL-1 and IL-6,
reducing the inflammatory response of effected tissue (Bullard et al., 2010).
TNF-α and IL-1, along with IFN-γ, initiate the inflammatory response in vascular
tissue, allowing more fluid and immune cells to enter into the site of the tick bite (Baker
et al., 2003). This response occurs in both sexes, although IL-1 production is inhibited by
estrogen in women (Bullard et al., 2010; Pennell et al., 2012). Estrogen increases the
amount of IgM and IgG antibodies produced by women and can induce IgM and IgG
production if administered to men (Oertelt-Prigione, 2012). Unfortunately, testosterone
inhibits IgM and IgG production by reducing the amount of IL-6 produced (OerteltPrigione, 2012). Lastly, estrogen tends to produce a TH2-lymphocyte response, which
includes increased B-lymphocyte activation and release of IL-4, IL-5, and IL-9 cytokines
(Pennell et al., 2012). Androgens in males produce a TH1-lymphocyte response, where
IFN-γ is the primary cytokine released and CD4+ and CD8+ T-lymphocytes are activated
(Pennell et al., 2012).
Infection with Borrelia burgdorferi causes the release of the following cytokines
in both male and female cases: tumor necrosis factor alpha (TNF-α), transforming growth
factor beta (TGF-β1), interleukins (IL-1, IL-6, IL-10, IL-17) and interferon (IFN-α, IFNγ) (Glickstein et al., 2003; Radolf et al., 2012; Sehgal & Khurana, 2015; Widhe et al.,
2002). Estrogen leads to inhibition of IL-1 and IL-6 secretion, providing a reduced
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inflammatory effect and a reduction in the proliferation and antibody production by Blymphocytes in females that would not be found in males (Pennell et al., 2012). In
addition, estrogen causes an increase in the production of IL-10, a regulatory cytokine
that helps to control inflammation, further reducing the inflammatory response (Pennell
et al., 2012). IL-10 production is stimulated by testosterone in men (Giefing-Kroll et al.,
2015).
Since the inflammatory response serves as an important factor to keep an
infection localized and allow additional immune cells to enter the infection site, this
reduction in the inflammatory response could lead to increased symptom frequency and
severity in female cases. Reduced inflammation also allows the bacteria to spread from
the site of infection to other locations, like the joints and nervous system. Lastly,
androgens in males produce CD8+ T-lymphocyte activation, which helps to clear the
infection at the initial infection site (Giefing-Kroll et al., 2015). While the focus of the
current study was not based on estrogen levels, the effect of estrogen on the immune
system’s response to an invading pathogen provides support for the reported sex
differences.
Sex Differences
While sex differences in risk factors for Lyme disease was discussed by only
Lane et al. (1992), sex differences for other diseases have been identified. Cardiovascular
disease (CVD) sex differences have been documented and continue to be studied
(DeVon, Ryan, Ochs, & Shapiro, 2008; Dey et al., 2009; Kure et al., 2016; Norris,
Dasgupta, & Kirkland, 2007). CVD symptom presentation can be markedly different in
males and females (DeVon et al., 2008; Dey et al., 2009; Norris et al., 2007). Males
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suffering from CVD tend to present with the typical symptom of chest pain that radiates
out to the left arm (DeVon et al., 2008; Dey et al., 2009; Norris et al., 2007). Women
suffering from CVD tend to present with non-typical symptoms like pain in the back,
neck, or jaw, shortness of breath, or indigestion (DeVon et al., 2008; Dey et al., 2009;
Norris et al., 2007). This variation in symptom presentation often keeps women from
seeking needed medical care early. In addition, non-typical symptom presentation
increases the chances for misdiagnosis and administration of the wrong treatment when
treatment delays can be life threatening (DeVon & Zerwic, 2002; Kure et al., 2016).
One hypothesis for the sex differences in CVD hinges on estrogen. Estrogen, a
female sex hormone, is believed to have cardio-protective effects because women
develop less CVD prior to menopause than men of the same age, but the risk of
developing CVD becomes equal between men and women after menopause (Baker et al.,
2003; Murphy et al., 2011). Estrogen not only controls the female menstrual cycle, but
also plays a key role in regulating many other body mechanisms. One of those
mechanisms is the inflammatory response (Murphy et al., 2011).
Estrogen regulates several key cytokines responsible for the inflammatory
response (Bullard et al., 2010). First, estrogen inhibits production of interleukin-1 (IL-1)
by direct action and through promoting the production of interleukin-4 (IL-4) and
interleukin-10 (IL-10), which also inhibit IL-1 production (Bullard et al., 2010). IL-1 is
the cytokine responsible for the initiation of the inflammatory response (Bullard et al.,
2010). While estrogen levels remain in the normal physiological range, protection from
inappropriate or excessive inflammation remains (Baker et al., 2003; Bullard et al.,

54
2010). Once menopause occurs, this protective effect is reduced with reduced estrogen
concentrations (Bullard et al., 2010).
Parkinson’s disease is another condition that displays sex differences in symptom
presentation. In a cohort study (n = 253) by Haaxma et al. (2006), women developed
symptoms of Parkinson’s disease up to two years later than men. In addition, women
suffered more frequently with dyskinesias at disease onset then men who tended to
present with more bradykinesias/rigidity (Haaxma et al., 2006). Higher estrogen levels in
women have been hypothesized to have protective value against Parkinson’s disease
development (Currie, Harrison, Trugman, Bennett, & Wooten, 2004; Haaxma et al.,
2006; Liu et al., 2012). Unfortunately, not all research supports this theory (Lyons,
Hubble, Troster, Pahwa, &Koller, 1998; Strijks, Kremer, &Horstink, 1999). In a study of
630 Parkinson’s patients conducted by Lyons et al. (1998), the sex differences in
symptom presentation was supported but estrogen as a protective factor against
Parkinson’s disease was not.
Autoimmune diseases affect only 8% of the entire population but almost 80% of
those affected are women (Fairweather, Petri, Coronado, & Cooper, Jr., 2012; Ngo et al.,
2014; Quintero et al., 2012). Diseases such as RA (2-3:1 female to male ratio), SLE (9:1
female to male ratio), MS (2-3:1 female to male ratio), scleroderma (up to 14:1 female to
male ratio), and Sjogren’s syndrome (9:1 female to male ratio) are especially prominent
in women (Fairweather et al., 2012; Ngo et al., 2014; Quintero et al., 2012; Whitacre,
2001). All of these diseases display an inflammatory response of some type by the
immune system that leads to the outward signs and symptoms of the disorder. These
types of autoimmune diseases contradict what is known and accepted about the protective
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anti-inflammatory effects of estrogen, but inflammation that remains for extended periods
of time leads to tissue damage as well (Casimir et al., 2010). Unfortunately, it is not only
the anti-inflammatory response that does the damage in autoimmune disease; selfantibodies cause long-term tissue destruction and damage (Whitacre, 2001).
Estrogen regulates B-lymphocyte production and differentiation through IL-4 and
IL-10 (Bullard et al., 2010). IL-4 increases the production of new B-lymphocytes that
will ultimately produce IgG and IgE antibodies (Bullard et al., 2010). In addition, IL-10
increase B-lymphocyte activation and stimulates antibody production (Bullard et al.,
2010). Lastly, estrogen promotes helper (CD4+) T-lymphocyte differentiation, increasing
the body’s ability to activate B-lymphocytes (Bullard et al., 2010). This activity
ultimately leads to the ability to produce large amounts of self-antibodies and
autoimmune disease. Women tend to have a higher CD4+ T-lymphocytes numbers than
men when in the healthy state, so increased activation and differentiation can lead to a
disease state quickly (Whitacre, 2001).
So far, all of the diseases examined here are chronic diseases and Lyme disease is
caused by an infectious agent. How are sex differences between these two vastly different
types of conditions connected? First, Lyme disease is commonly misdiagnosed as an
autoimmune disease (Savely, 2010). Frequently, a patient is bitten by a tick in an area
where the tick and/or bite is not easily seen – back of the body, hairline, armpits, and
groin (Bennet, Stjernberg, & Berglund, 2007; Savely, 2010). The American College of
Rheumatology estimates the number of tick bites that goes unnoticed to be between 1025% (Kalish, 2013). In addition, patients don’t always remember being bitten by a tick at
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all. In a study conducted in the Netherlands, the number of cases of Lyme disease where
the participant didn’t remember a tick bite was as high as 34% (Hofhuis et al., 2013).
This misinformation often leads the physician to look at other illnesses with
similar symptoms (Savely, 2010). Lyme disease may be misdiagnosed as any of the
following disease: autoimmune diseases including but not limited to RA, MS, and SLE,
along with non-autoimmune diseases like Parkinson’s disease and early onset Alzheimer
disease (Savely, 2010). This misdiagnosis is based on symptoms that can mimic any or
all of these conditions.
Sex and Age Differences
According to the CDC (2015), males in all age categories under age 70 suffer
more frequently from confirmed Lyme disease than females of the corresponding age
(Figure 3).

Figure 3. Confirmed cases of Lyme disease by sex and age, United States, 2001-2010
(CDC, 2015)
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The immune system undergoes extensive changes as a person ages (Giefing-Kroll
et al., 2015). Innate immune cells, like macrophages and dendritic cells, lose the ability to
effectively present foreign antigens to T-lymphocytes for activation (Giefing-Kroll et al.,
2015). In addition, thymus function declines with age so T-lymphocyte maturation is
reduced leading to fewer T-lymphocytes available to fight infection (Giefing-Kroll et al.,
2015). Lastly, effective antibody production also declines with age (Giefing-Kroll et al.,
2015). Sex-differences of the immune system level off with declining production of
estrogen by the ovaries as a woman ages (Giefing-Kroll et al., 2015).
Aging has also been shown to have an effect on the cytokines and immune cells
of innate immunity. Castle (2000) discusses the effects of aging on specific cytokines, all
of which are induced by infection with Borrelia burgdorferi. Production of IL-6 increases
with age-related changes to the immune system (Castle, 2000). Increased production of
IL-6 has two effects: 1) IL-6 inhibits macrophage activity and 2) increased B-lymphocyte
antibody production (Castle, 2000). Production of IL-10 also increases with age-related
changes to the immune system. Increased IL-10 production also has two effects: 1)
increased anti-inflammatory effects and 2) inhibition of the TH1-lymphocyte response
(Castle, 2000). Lastly, TNF-α production increases with age leading to increased
inflammatory responses in the individual (Castle, 2000). Even though immune system
function changes with age and sex, the symptoms of Lyme disease produced by these
changes may be an important tool in early diagnosis of the disease.
Symptoms of Lyme Disease
Lyme disease displays a wide array of symptoms based on the stage of the
infection. Many of the symptoms can be mistaken easily for another disease or condition.
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Stages of infection include: early localized Lyme disease, early disseminated Lyme
disease, and late Lyme disease (Binder et al., 2012; Borchers et al., 2015; Donta, 2012;
Girschick et al., 2009). In addition to these three stages, two separate conditions have
been discussed in the literature – post-treatment Lyme disease syndromes and chronic
Lyme disease (Aucott et al., 2012; Cairns & Goodwin, 2005; Cameron, 2010; Wormser
et al., 2006).
Early Localized Lyme Disease
In this stage of infection, symptoms include mild flu-like symptoms, headache,
fatigue, and malaise (Binder et al.., 2012; Borchers, 2015; Donta, 2012; Girschick et al.,
2009). During this stage, the characteristic “bull’s eye” erythema migrans (EM) rash will
also appear (Binder, 2012; Borchers, 2015; Donta, 2012; Girschick et al., 2009; Miraflor
et al, 2016). The EM rash begins at the site of the tick bite as a raised red rash with a
clear central area (Moore, 2015; Muellegger, 2004). To differentiate between a true EM
rash and an allergic response to the tick bite, the rash should be monitored over time
(Muellegger, 2004; Tibbles & Edlow, 2007). The classic EM rash will start out as a small
round to oval lesion, but will increase in size to at least 5 cm in diameter (Binder et al.,
2012; Borchers et al., 2015; Donta, 2012; Girschick et al., 2009; Tibbles & Edlow, 2007).
An allergic response to the tick bite will decrease in diameter over time (Muellegger,
2004).
The EM rash appears in 70-80% of Lyme disease patients but takes on the
characteristic “bull’s eye” appearance only 20% of the time (Aucott et al., 2012; Johnson
& Stricker, 2004; Muellegger, 2004). Other, non-traditional appearances of the EM rash
include: homogenous red lesions with no central clearing; secondary lesions;
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vesiculopustular lesions; and lesions with bruising, which typically occur on the calves
(Aucott et al., 2012).
One of the few reported sex differences with Lyme disease is related to the EM
rash. In two separate studies, females were more likely to develop the EM rash than their
male counterparts and of those females who developed the EM rash; the rash was more
likely to appear in the non-typical form (Bennet et al., 2007; Strle et al., 2013). Strle et al.
(2013) conducted a retrospective chart review of 15,539 patients over the age of 15 years
diagnosed with an EM rash between 1990 and 2009. Results confirmed that 58% of the
EM diagnoses were in women (Strle et al., 2013). This research was conducted in a single
medical center in Slovenia, so confounding related to different diagnostic methods were
minimized (Strle et al., 2013).
Bennet et al. (2007) conducted a retrospective study in Sweden of 123,495 patient
records for the presence and appearance of the EM rash. Results showed that 20% more
women were diagnosed with EM rash than men during the years 1997-2003 (Bennet et
al., 2007). Of those women diagnosed with the EM rash, 40% of them displayed the nontypical presentation of the EM rash (Bennet et al., 2007).
Bennet et al. (2007) also reported that a few other European studies had similar
results for the higher prevalence of EM rash in women but after reviewing these
additional studies, the results were not as reported. In the Bennet et al. study, German
cases of EM rash in females were reported at 55%, but the actual study by Mehnert and
Krause (2005) stated that 55% of reported Lyme disease cases in Germany were female.
Mehnert and Krause did not report the percentage of EM rash cases in terms of females
or males. The same was true for the Stanek et al. (1987) study. Bennet et al. reported that
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the number of cases of EM rash in females in Austria was 60%, but Stanek et al. reported
that 60% of reported Lyme disease cases in Austria were females with no distinction in
EM rash appearance (Stanek et al., 1987).
Although evidentiary support was weak for the Bennet et al. (2007) study, study
data did display sex differences in EM reporting and appearance. Unfortunately, all
reported studies were conducted in Europe where the Borrelia strain varies significantly
from the Borrelia strain found in the United States. Studies within the United States
where Borrelia burgdorferi sensu stricto is the predominant strain must be conducted.
An additional study was conducted by Schwarzwalder, Schneider, Lydecker, and
Aucott (2010). This was a retrospective case series study of 125 patients from a Maryland
clinic (Schwarzwalder et al., 2010). Early Lyme disease symptoms of EM rash and flulike symptoms were measured for sex differences (Aucott et al., 2013). No significant sex
differences were found within the study population, but the authors contribute these
results to the small sample size and the difficulty with confirming true early cases of
Lyme disease via serology (Aucott et al., 2013).
Early Disseminated Lyme Disease
This stage of infection occurs when the bacteria leave the initial site of infection
and spread to other body tissues. Typical symptoms that coincide with the spread of the
bacteria include neurological symptoms like meningitis and facial palsies (Binder et al.,
2012; Borchers et al., 2015; Donta, 2012; Franz & Krause, 2003; Girschick et al., 2009;
Muellegger, 2004; Wormser et al., 2006). Secondary EM rash lesions may appear at sites
distant from the initial tick bite, but these lesions are more common in children than
adults (Girschick et al., 2009). Cardiac complications can occur in untreated patients that
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include various degrees of atrioventricular block (Alao & Decker, 2012). Heart
complications tend to resolve with treatment (Alao & Decker, 2012). Finally, mild
musculoskeletal symptoms may appear (Girschick et al., 2009).
The hallmark of this stage of infection is the development of neurological
symptoms, but meningitis and facial palsies can have other causes besides the Borrelia
bacteria. Unfortunately, treatment is different for Borrelia burgdorferi infection than
treatment given for facial palsies of other etiology. Determining the cause of the
neurologic symptoms is paramount in providing appropriate treatment.
Bremell and Hagberg (2011) conducted a study of 109 Swedish patients with
some form of facial nerve palsy. The purpose was to identify clinical markers to increase
the speed and accuracy for diagnosis of the causative agent of the palsy (Bremell &
Hagberg, 2011). Bell’s palsy is generally treated with corticosteroids, while Lyme
neuroborreliosis is treated with antibiotics (Bremell & Hagberg, 2011). Unfortunately, an
inaccurate diagnosis would, at best, provide treatment that would not help the patient at
all, and in the case of Lyme neuroborreliosis, would actually hurt the patient more
(Bremell & Hagberg, 2011). Results of the study demonstrated that in confirmed
neuroborreliosis cases, patients displayed a significantly higher number of mononuclear
cells in extracted cerebrospinal fluid than patients without neuroborreliosis (Bremell &
Hagberg, 2011). Unfortunately, even with early diagnosis and proper treatment, Lyme
neuroborreliosis may persist.
In a follow-up case control study conducted in Sweden five years after the initial
study, recovery rate was only 73% in children (n = 84/84) diagnosed with and treated for
Lyme neuroborreliosis (Skogman et al., 2012). Where facial palsy was the primary
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symptom, partial facial palsy remained in 13% of subjects (Skogman et al., 2012). In
addition, balance issues and persistent pain was found in 14% of subjects (Skogman et
al., 2012). This impairment underscores the need for diagnosis in the earliest stage of
infection to prevent these long term outcomes.
Late Lyme Disease.
If left untreated, Lyme disease can progress to late stage infection. This stage
occurs months to years after the initial tick bite and is most commonly associated with
arthritis in the large joints of the limbs (Binder et al., 2012; Borchers et al., 2015; Donta,
2012; Girschick et al., 2009). Additionally, advanced neurological and cardiac symptoms
can be found (Binder et al., 2012; Borchers et al., 2015; Donta, 2012; Girschick et al.,
2009). In the United States, arthritis is the most common late stage affliction (Alao &
Decker, 2012; Bennet et al., 2007; Borchers et al., 2015). In Europe, acrodermatitis
chronica atrophicans (ACA) can also manifest in late stage infections due to chronic skin
infection by Borrelia burgdorferi (Alao & Decker, 2012).
In a European study conducted by Strle et al. (2013), sex differences were present
for arthritis symptoms. Within the patient sample (n = 60) diagnosed with Lyme arthritis,
three quarters of the patients were male (Strle et al., 2013). This significant difference
was supported even when the possibility of misdiagnosis was controlled for (Strle et al.,
2013). In the same study, males diagnosed with Lyme neuroborreliosis made up 60% of
the study population (Strle et al., 2013). These findings have not been supported by other
published research in the United States or Europe to date.
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Posttreatment Lyme Disease Syndrome
Controversy surrounds the existence of post-treatment Lyme disease syndrome.
At its core, the controversy centers around the efficacy of current treatment guidelines for
Lyme disease and whether longer courses of antibiotics are needed for complete
eradication of the Borrelia burgdorferi from a patient. When diagnosed early and the
treatment regimen is completed, most patients find relief from signs and symptoms of
Lyme disease (Borchers et al., 2015; Deluca et al., 2013; Lantos, 2011; Moore, 2015).
Unfortunately, in up to 10-15% of those patients who are not diagnosed early or complete
a standard course of antibiotics, symptoms may persist after treatment is complete
(Aucott, Crowder, & Kortte, 2013; Deluca et al., 2013). Persistent symptoms include
musculoskeletal complaints including myalgia and arthralgia; headache; fatigue; and
cognitive symptoms like difficulty concentrating and memory loss (Aucott, Crowder, &
Kortte, 2013; Deluca et al., 2013; Lantos, 2011).
Based on the clinical practice guidelines for Lyme disease created by the
Infectious Disease Society of America (IDSA), post-treatment Lyme disease does not
exist (Lantos et al., 2010; Wormser et al., 2006). According to the IDSA, the standard
course of 21-days of antibiotics will kill the Borrelia bacteria and any persistent
symptoms may be related to co-infection with another organism or just the normal aches
and pains of daily life (Wormser et al., 2006). Unfortunately, this explanation does not
take into the account the large number of patients who experience persistent symptoms
after treatment is complete (Deluca et al., 2013).
In order to address the IDSA’s claim that there is no scientific evidence to support
a diagnosis of post-treatment Lyme disease syndrome, Aucott, Crowder, and Kortte
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(2013) designed a study to develop and support an operational definition for posttreatment Lyme disease syndrome so that further studies can be standardized and data can
be collected. The study included 71 cases (14 matched controls) that entered the study
with a diagnosis of Lyme disease via the presence of the EM rash (Aucott et al., 2013).
Subjects were followed for a period of up to two years post diagnosis (Aucott et al.,
2013). Based on results from this study, the following operational definition of posttreatment Lyme disease is proposed by Aucott et al.:
Inclusion criteria were as follows:


Documented Lyme disease with evidence of systemic disease



Treatment using doxycycline (FDA approved treatment regimen), resulting in
the resolution of objective manifestation of disease



Onset of any of the following subjective symptoms within 6 months of the
diagnosis of Lyme disease and persistence of continuous or relapsing
symptoms for at least a 6 month period after completion of antibiotic therapy:
o Endorsement of fatigue at a level higher than pre-infection
o At least 3 areas of the body affected by musculoskeletal pain
o Complaints of difficulty finding words, difficulty focusing or
concentrating, or memory impact



A composite T-score < 45 (less than ½ standard deviation below normative
mean) on SF-36

Exclusion criteria were as follows:


Active co-infection



Other underlying disease or condition that explains symptoms
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Previously diagnosed fibromyalgia or chronic fatigue syndrome



Undiagnosed or unexplained complaints of musculoskeletal pain or fatigue
before diagnosis of Lyme disease (pg. e3).

By establishing this operational definition, Aucott et al. (2013) looked to provide a
framework for future research on posttreatment Lyme disease syndrome so that evidence
either for or against this condition can be collected.
Each stage of Lyme disease has clearly defined symptoms experienced by
patients. These symptoms, along with severity of symptoms, will be used to determine
what other factors may contribute to symptom presentation in Lyme disease sufferers.
Theoretical Framework
The theoretical framework of the study follows the CDC outbreak investigation
model. In this model, the relationship between a variable under study and a disease like
Lyme disease can be examined (Reingold, 1998). The typical descriptive epidemiology
factors corresponding to person, place, and time are identified and relationships between
potential exposures or risk factors and the disease in question are explored (Reingold,
1998; Roher, 2013). While Lyme disease does not fall into the typical infectious disease
category that would be examined as an outbreak, Lyme disease is a vector-borne disease
and is well suited to the outbreak investigation model. In fact, the outbreak investigation
model was initially used to identify the causative agent for Lyme disease after a
significant number of cases of arthritis appeared in a group of children in the area of
Lyme, Connecticut (Sternbach & Dibble, 1996).
Lyme disease is currently the most frequently reported vector-borne illness in the
United States (Binder et al., 2012). Considering that Lyme disease may be underreported
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by as high as 12 times, determining the factors that lead to this underreporting becomes
paramount. Differences in symptom presentation and reporting based on
sociodemographic factors like biological sex or age may hold the answers to identifying
more cases earlier in the infection cycle, when treatment is most effective. This study will
provide insights into the factors effecting symptom presentation and severity for Lyme
disease.
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Chapter 3: Research Method
Introduction
This chapter contains a review the methodology associated with studying
symptom presentation and severity for Lyme disease. I explain the research design along
with the rationale for the selection of a case-control research design. In addition, I clearly
describe the study population and the clinic and college where data collection occurs.
Recruitment methods, informed consent methods, and sampling methods will be
discussed. I provide information on instrument selection, validity, and reliability as well.
Variables will be discussed in terms of research questions generated. In addition, I review
statistical analysis methods. Lastly, I discuss the protections in place for the study
subjects w along with how the final report of findings to subjects will occur.
Research Design and Approach
In this study I employed a case-control study design because this study examined
factors associated with symptom presentation and severity in Lyme disease patients
compared to unaffected control subjects. ROSS scales from the primary care clinic and
college were reviewed to provide insight into variations in symptom presentation and
severity. This data is retrospective and aligns well with the case-control study design.
Case control study designs are often used to study rare diseases within the
population because the number of subjects needed to reach statistical significance is
smaller than the number of subjects needed for a cohort study design (Mann, 2003;
Schulz & Grimes, 2002; Song & Chung, 2010). With 33,000 cases diagnosed in 2011 in
the United States (population 310 million), Lyme disease would be considered a rare
disease (CDC, 2015; US Census Bureau, 2014). Other rare diseases that have previously
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been studied by a case-control study design include, but are not limited to: certain types
of cancer (breast, ovarian, esophageal, prostate, colon, and pancreatic); psychiatric
disorders (schizophrenia and bipolar disorder); infectious diseases (neonatal tetanus and
Nipah virus); and autoimmune disorders such as SLE (Schulz & Grimes, 2002; Song &
Chung, 2010).
A key advantage to the case control study design is the ability to examine multiple
variables that may or may not be associated with a specific disease (Song & Chung,
2010). In the case of Lyme disease, there are a wide variety of potential exposures to the
Ixodes scapularis tick, the key vector in the spread of Lyme disease. In addition, Lyme
disease shows a bivariate bimodal age distribution, with the largest number of cases
occurring in males under 13 years old and females over the age of 40 (CDC, 2015).
Variables including sociodemographic variables (age and sex), seasonal variables (month
of diagnosis, month of exposure), symptoms present, and severity of symptoms were
examined during this case-control study.
Unfortunately, the case-control study design has a few disadvantages as well. The
primary disadvantage for the case-control study design is the potential for bias (Pannucci
et al., 2010; Song & Chung, 2010). The two main types of bias that must be considered
when designing a case-control study are sampling bias and recall bias (Mann, 2003;
Pannucci et al., 2010; Song & Chung, 2010). Sampling bias may be difficult to control
for in a case-control study because the cases already represent a biased sample since they
have the condition under study (Mann, 2003; Song & Chung, 2010). With a rare disease
or condition, random sampling of a population is difficult since so few individuals may
have the condition (Mann, 2003; Song & Chung, 2010). Careful selection of controls
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must be performed to reduce the impact of sampling bias (Mann, 2003; Pannucci et al.,
2010; Song & Chung, 2010).
The best way to reduce sampling bias is to make sure that the controls are
matched as closely as possible to the case population (Mann, 2003; Pannucci et al., 2010;
Song & Chung, 2010; Zondervan, Cardon, & Kennedy, 2002). Matching must be done
carefully because any variable selected to match the controls with the cases cannot be
assessed as a variable for the study (Song & Chung, 2010; Zondervan et al., 2002).
Because sex and age were two variables under investigation in this study, controls could
not be matched to cases based on these criteria. In order to ensure that comparisons could
be made between the case and control groups, frequency matching was used to provide
consistency within and between the two groups (Song & Chung, 2010). For example,
frequency matching makes sure that the percentage of males in the case group is the same
as the percentage of males in the control group (Song & Chung, 2010). Thus, frequency
matching was used for sex and age variables in this study.
Matching was used among cases and controls on the basis of state of residence.
Lyme disease is endemic to 14 states, primarily in the Northeastern United States (CDC,
2015). These states include Pennsylvania, New York, New Jersey, Connecticut,
Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, Rhode Island,
Vermont, Virginia, and Wisconsin (CDC, 2015). Because the primary care clinic treats
patients from all over the country, cases and controls were matched on state of residence
to ensure that the potential exposure to the Ixodes tick is equal between the two groups.
In addition, Lyme disease is a vector-borne disease that, if caught early, can be
cured with a 21-28 day course of antibiotics (Gerstenblith & Stern, 2014). Lyme disease
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is therefore reported in incidence rates because each case reported to the National
Notifiable Disease Surveillance System (NNDSS) represents a newly diagnosed
infection. The nature of disease reporting between the states and the CDC may also lead
to underreporting of the disease, over reporting of the disease, and/or false surveillance
numbers due to misdiagnosis of the infection (CDC, 2015). States used in this study were
all Lyme endemic states. The current study’s population (N = 591) came primarily from
New York (39%) and Pennsylvania (42%), which is consistent with the high incidence
rates reported for both states by the CDC (2015).
The second type of bias, recall bias, occurs when cases recall exposures more
frequently than controls. This often occurs because the cases spend more time trying to
determine what exposure may have led to their disease state (Pannucci et al., 2010;
Schulz & Courtright, 2002). One way to overcome this type of bias is to use information
gathered prior to the beginning of the study (Mann, 2003; Pannucci et al., 2010). With the
current study, access to patient records for prior symptoms and complaints was possible,
and they were examined as part of the data collection process.
In addition, the primary care site collects symptoms and severity of symptoms via
the ROSS scale at every visit as part of the routine intake patient information. This
symptom and severity information was part of the patients’ medical records and was the
primary source of data for the cases in the current study. All controls filled out a ROSS
scale describing symptoms experienced within the previous week, which also helps to
minimize recall bias.
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Setting and Sample Population
Research was conducted at a primary care clinic in New York State. The clinician
for this study is a primary care physician who also treats acute and chronic Lyme disease
patients. According to clinic records, more than 500 new Lyme disease patients are
treated each year, along with an equal number of recurrent Lyme disease patients
(Clinical partner, personal communication, April 2014). In addition to primary care, the
clinician has been a renowned and published Lyme disease researcher since the early part
of the 1990s (Lyme Project, n.d.). Study participants came from the primary care clinic’s
patient population.
Cases were defined as adult subjects (≥ 18 years of age) who met one of the
following diagnostic criteria: (a) patient presents with a physician confirmed EM rash; (b)
patient has a positive EIA and/or Western Blot laboratory result for IgG and IgM
antibodies; or (c) patient has a score of 5 or higher on the Burrascano Diagnostic Criteria
for Lyme Disease scale (Burrascano, 2005). These criteria meet both the Infectious
Disease Society of America (IDSA) and the International Lyme and Associated Diseases
Society (ILADS) diagnostic guidelines (Cameron, Johnson, & Maloney, 2014; Wormser
et al., 2006). Lyme disease cases were selected and confirmed by the clinical partner, a
Lyme disease specialist. Cases were randomly selected by the physician, based on the
weekly appointment schedule during the study period.
Because the primary care clinic could not provide enough controls for the study
population, a secondary data collection site was added to the study. Controls were
selected from adult patients (≥ 18 years of age) from the primary care clinic in New York
State and the 4-year liberal arts college in Pennsylvania who do not suffer from Lyme
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disease. Participants may suffer from other diseases or conditions. All controls were
Lyme disease free as determined by: (a) never having had a tick bite; (b) having no
evidence of EM rash; or (c) no prior laboratory testing for or diagnosis of Lyme disease
by a physician. Study controls were as likely as cases to develop Lyme disease. Controls
were selected at a 1:2 case/control ratio to address the sampling bias introduced by
nonrandom selection of participants. Unfortunately, because sex and age were two
variables of interest in this study, matching of cases and controls along these lines could
not occur. Matching based on state of residence was performed to insure that exposure to
the Ixodes tick was the same between cases and controls.
Sample size calculation is dependent on the types of statistical analyses planned to
analyze the data. Each specific type of statistical analysis requires a slightly different
number of participants in order to meet the minimal number for statistical significance
(Cohen, 1992; Munro, 2005; Schlesselman, 1982). In order to satisfy all statistical
analysis methods, the largest sample size was used. Based on the methods described in
the statistical analysis section and tables provided by Cohen (1992) and a thorough power
analysis performed using the Open Epi toolkit as described below, a minimum sample
size of 120 cases and 240 controls was required (Dean & Sullivan, 2015). The actual
sample size (N = 591) more than met this value with 203 cases and 388 controls included
in the study. This value was above the minimum calculated value needed for statistical
significance, met a 1:2 case to control ratio to address non-random sampling bias, and
provided a larger sample size than had been examined previously by other researchers.
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Power Analysis
For all power analyses, the sample size of 120 cases and 240 controls were used.
For the EM rash symptom, the CDC (2015) and Aucott et al. (2012a) suggested that the
EM rash is found in 70% of the individuals who are diagnosed with Lyme disease. This
value (70%) was used to represent the percent of exposure among cases. Because the EM
rash can be confused with many different types of rashes, determining what to use for the
percent of exposure among controls was a little more difficult. After careful
consideration, bacterial induced skin rashes were used as the comparison since Lyme
disease is caused by a bacterial infection. According to Ki and Rotstein (2008), 10% of
the population suffers from a bacterial induced rash. This value (10%) was used to
represent the percent of exposure among controls.
Table 4
Power for Unmatched Case-Control Studies – EM Rash

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity
correction

Input data
95
120
70
240
10
21
100%
100%

For the arthritis symptom, the CDC (2015) reports that 31% of individuals who
are diagnosed with Lyme disease report arthritis as a symptom. Arthritis associated with
Lyme disease is often misdiagnosed as RA because of the similarity between the
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symptoms of these two conditions (Savely, 2010). This value (31%) was used to
represent the percent of exposures among cases. In addition, the CDC also reports that the
annual incidence for RA is between 0.5-1.0%. One percent was used to represent the
percent of exposure among controls for the power analysis.
Table 5
Power for Unmatched Case-Control Studies – Arthritis

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity
correction

Input data
95
120
31
240
1
44
100%
100%

For the Bell’s palsy symptom, the CDC (2015) reports the percentage of
diagnosed Lyme disease patients that suffer from Bell’s palsy is 9%. This value (9%) was
used to represent the percent of exposure in cases. According to Tiemstra and Khatkhate
(2007), Bell’s palsy is found in 0.023% of the population. This value (0.023%) was used
to calculate the percent of exposure in controls.
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Table 6
Power for Unmatched Case-Control Studies – Bell’s Palsy

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity
correction

Input data
95
120
9
240
0.023
430
97.73%
96.02%

For cardiac symptoms, the most prevalent cardiac symptom found in diagnosed
Lyme disease patients is AV block, which is found in only 1% of the diagnosed Lyme
disease patients (CDC, 2015). This value (1%) was used to represent the percent of
exposure among cases. AV block in the general population is rare, but the incidence does
increase somewhat with age (Sandesara & Olshansky, 2012). At age 20 years, the
incidence is only 0.5-2 %. This value increases up to 5% at age 60 years. A power
analysis was done for each incidence representing the percent of exposures among
controls.
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Table 7
Power for Unmatched Case-Control Studies – AV Block Age 60 Years

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity
correction

Input data
95
120
1
240
5
0.19
47.19%
31.61%

Table 8
Power for Unmatched Case-Control Studies – AV Block Age 20 Years

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity correction

Input data
95
120
1
240
0.5
2
10.25%
12.42%

According to this power analysis, the sample size was inadequate to find this rare
condition. A sample size analysis was performed to identify the correct sample size to
use. Based on this analysis, the potential to identify a significant difference between the
cases and controls will be difficult. The sample size at 20 years is unrealistic based on the
available population of cases at the primary care clinic where the study will take place
(Table 9). At age 60 years, the sample size recommended is a little more realistic, but this
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value is based on having this large number of patients above 60 years of age, which is
also not possible at the primary care clinic (Table10).
Table 9
Sample Size for Unmatched Case-Control Study – AV Block Age 20 Years

Two-sided confidence level(1-alpha)
Power(% chance of detecting)
Ratio of Controls to Cases
Hypothetical proportion of controls with
exposure
Hypothetical proportion of cases with
exposure:
Least extreme Odds Ratio to be detected:
Kelsey
Sample Size - Cases
Sample Size Controls
Total sample size:

Input data
95
80
2
2
0.99
0.49
Fleiss

1889
3777

1770
3540

Fleiss with
CC
1916
3831

5666

5310

5747

Table 10
Sample Size for Unmatched Case-Control Study – AV Block Age 60 Years

Two-sided confidence level(1-alpha)
Power(% chance of detecting)
Ratio of Controls to Cases
Hypothetical proportion of controls with
exposure
Hypothetical proportion of cases with
exposure:
Least extreme Odds Ratio to be detected:
Kelsey
Sample Size - Cases
259
Sample Size 517
Controls
Total sample size:
776

Input data
95
80
2
5
0.99
0.19
Fleiss
228
456

Fleiss with CC
264
528

684

792
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Lastly, mild cognitive impairment was considered. This group of symptoms is
difficult to identify the percentage to use for cases because these symptoms are often only
seen in those patients diagnosed with post-treatment Lyme disease disorder and/or
chronic Lyme disease. Because the existence of these conditions is still controversial,
finding a study that provided the incidence or prevalence of these symptoms was
impossible. While the symptoms are listed as present, incidence rates were not calculated
for the sample population or the sample populations were too small to generalize to the
broader Lyme positive cases. In literature available from the International Lyme and
Associated Diseases Society (ILADS), neurological symptoms, like memory or
concentration issues, are found in 15-40% of Lyme patients (Caliendo et al., 1995).
Unfortunately, this study was one of the most recently published articles on cognitive
impairment in Lyme disease.
In order to determine a percentage to use for controls, mild cognitive impairment
was used as the search criteria and included similar symptoms to those found in Lyme
disease patients (memory issues, attention issues, confusion, etc.). Because Alzheimer’s
disease and dementia are accepted diagnoses, there were many more articles available
with these symptoms. Unfortunately, these symptoms in the general population are often
only found in older individuals (60 years +). In a study conducted by Iverson et al.
(2011), mild cognitive impairment was found in 8.2% of the population within the 20-54
year age group. According to the CDC (as published in the MMWR for May 2013), mild
cognitive impairment was found in 12% of the population between the ages of 60-74
years. Katz (2012) determined that mild cognitive impairment in the population over 70
years was 9.9%.
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Multiple power analyses were performed to cover the range of ages discussed
here. Because the clinician for this study, a respected Lyme disease specialist, treats
many post-treatment Lyme disease and chronic Lyme disease cases at the primary care
clinic, the odds of examining the records of a patient experiencing mild cognitive
impairment was increased. Using the 40% value for the percentage of exposure in cases
and the 8.2% value for the percentage of exposure in controls, a power analysis was
conducted (Table 11). In addition, multiple power analyses were conducted to find the
lowest percent of exposure in cases acceptable with the available sample size. Table 12
shows the minimum of 19% exposure in cases power analysis. Below 19% exposure in
cases, additional patients must be added.
Table 11
Power for unmatched case-control studies – MCI symptoms 20-54 years age group

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity
correction

Input data
95
120
40
240
8.2
7.5
100%
100%
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Table 12
Power for unmatched case-control studies – MCI symptoms 20-54 years age group

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity
correction

Input data
95
120
19
240
8.2
2.6
82.48%
78.01%

Because this study will include ages over 54, an additional power analysis was
conducted that used the 40% for exposure in cases and 12% for exposure in controls
(Table 13). In addition, another power analysis was done to test the lower end of required
percentage for exposure in cases. As shown in Table 14, a minimum of 24% exposure in
cases will be required at this sample size to reach the 80% power minimum. While this
value is slightly higher than the 19% required for the lower age group, this value should
be achievable within the primary care clinic patient population.
Table 13
Power for unmatched case-control studies – MCI symptoms 60+ years age group

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity correction

Input data
95
120
40
240
12
4.9
99.99%
99.99%
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Table 14
Power for unmatched case-control studies – MCI symptoms 60+ years age group

Two-sided confidence interval (%)
Number of cases
Percent of exposure among cases (%)
Number of controls
Percent of exposure among controls (%)
Odds Ratio
Power based on:
Normal approximation
Normal approximation with continuity
correction

Input data
95
120
24
240
12
2.3
81.49%
77.37%

Based on this power analysis, the sample size was adequate to find a significant
difference for the three major symptoms associated with Lyme disease in the United
States (EM rash, arthritis, and Bell’s palsy). For the rare symptom of AV cardiac block,
the sample size selected for this study was inadequate to find a significant difference
between cases and controls. Because AV cardiac block is rare, the expectation of finding
cases with this symptom was small. Mild cognitive impairment (MCI) is found in the
later stages of infection, post –treatment, and chronic Lyme disease, but is rare in the
general population at ages below 60 years. Because the clinician treats patients in the
later stages of infection, the potential for identifying these symptoms at the required
percent exposure in cases was high. Significant differences between cases and controls
may be found at the suggested sample size.
Level of significance (α) will be set at 0.05 following a review of the relevant
literature and based on the statistical work of Cohen (1992). Probability (p) values will
follow that a p-value < 0.05 resulted in rejection of the null (H0) hypothesis and
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acceptance of the alternate (HA) hypothesis. With a p-value > 0.05, the null hypothesis
was accepted. According to Cohen (1992), the effect size is the impact the independent
variable has on the dependent variable. Based on the statistical method chosen for
analysis, the effect size varied from 0.30 to 0.50 for a medium to large effect (Cohen,
1992). In addition, Cohen suggests setting the power of the study at 0.80 (Munro, 2005;
Cohen, 1992).
Research Instrument
Data was collected using a modified Burrascano Symptom Checklist (ROSS
Scale) that is based on the Wahler Physical Symptoms Inventory (PSI), which has been
demonstrated previously to have a high level of internal consistency on test-retest scores
over several different subgroups (Wahler, 1968). The PSI collects data on the frequency
of general symptoms associated with most any illness, but does not address severity of
symptoms. A modified version of the PSI was created by Burrascano (2008) to address
the specific symptoms associated with Lyme disease and the severity of those symptoms.
A modified version of the Burrascano Symptoms Checklist (ROSS Scale) was created to
address the needs of this study. The modified Burrascano Symptoms Checklist (Ross
Scale) that was used in this study can be obtained by request.
In addition to symptoms present, symptom severity, and symptom frequency,
demographic data (age, sex, state of residence) and the seasonality of infection/time since
tick exposure (month of diagnosis and/or month of tick bite were collected from the
patients’ medical records via the ROSS Scale and Chart review.
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Data Collection and Analysis
Research questions one through five were answered through a thorough review of
patient medical records and the ROSS Scale. Symptoms at the initial patient visit (related
to Lyme disease diagnosis for cases and at first visit for controls) were collected and
transcribed onto the modified Burrascano Symptom Checklist (ROSS Scale) (Burrascano,
2008).
All forms were numbered upon return (by the primary care clinic staff for cases)
which ensured that each form was linked to a specific record in the Microsoft Access
database where the ROSS scale results were stored and managed. The ROSS scales were
NOT linked to a specific person by the numbering system, as there was no personal
information on the ROSS scale that could identify an individual.
Analysis of data allowed for either the null hypothesis to be accepted or rejected
so that the alternate hypothesis can be accepted. Independent variables included
biological sex, age, time since tick exposure, month of diagnosis and/or tick exposure.
Dependent variables included symptoms, symptom severity, and symptom frequency.
Computation of Variables
The independent variables for this study included age, sex, and time since
exposure to the Ixodes tick. State of residence was collected to match cases and controls.
Analysis was not performed using this variable because the primary care clinic was found
within the Lyme disease endemic region identified by the CDC. Finding cases or controls
from a non-endemic Lyme disease state for comparison was more difficult with the
participant population available and required the addition of the secondary collection site
(college).
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The age variable was defined based on the CDC’s surveillance groupings and
included the following breakdown: < 20 years; 20-24 years; 25-29 years; 30-34 years; 3539 years; 40-44 years; 45-49 years; 50-54 years; 55-59 years; 60-64 years; 65-69 years;
70-74 years; >75 years (CDC, 2015). Age categories may have been combined into 10
year intervals only if there are more than six categories with less than five subjects. Age
category combination was not required. Biological sex included male and female
categories.
Seasonality of infection variables included month of tick exposure and month of
diagnosis. Based on CDC data (2015), most Lyme disease diagnoses occur during the
months of June, July, and August. In addition, the winter months (December through
March) contain the fewest reported Lyme disease diagnoses (CDC, 2015). Months with
less than five diagnoses may have been combined into seasons (Spring, Summer, Fall,
Winter) for statistical analysis. Combining months into seasons was not required at the
time of analysis.
Independent variables were compared to the dependent variables of symptom
presentation, symptom severity, and symptom frequency. Symptom presentation was
examined for absence or presence of the described symptom using the modified
Burrascano Symptom Checklist (ROSS Scale) instrument and calculated using the
symptom index scoring system described below.
Symptom Index
Symptoms from the modified Burrascano Symptoms Checklist (ROSS Scale)
were grouped together into six categories for analysis purposes. Grouping of symptoms
into categories is common for diseases like fibromyalgia (Wolfe et al., 2010) and chronic

85
fatigue syndrome (Hickie et al., 2006), which are as difficult to diagnose as the later
stages of Lyme disease. The six categories matched the major groups of reported
symptoms in the NNDSS database and include: 1) musculoskeletal; 2) neurological; 3)
cognitive; 4) cardiac; 5) general; and 6) cutaneous. The general category included the
following symptoms: fever, sore throat, persistent swollen glands, unexplained weight
loss or gain, nausea, diarrhea, and pain in the genital area. The musculoskeletal category
included symptoms related to joint pain, stiffness, and swelling along with muscle
stiffness, twitches, and aches/pain. The neurological category included facial paralysis
(Bell’s palsy) and other symptoms associated with cranial neuropathy, as well as
meningitis not related to known bacterial or viral agents. The cognitive category included
symptoms associated with memory, concentration, and speech difficulties. The cardiac
category included chest pain, heart palpitations, or evidence of heart block. Lastly, the
cutaneous category included the EM rash and other unexplained skin manifestations.
The frequency scale measured how often a patient experienced particular
symptoms within the week prior to their appointment at the primary care clinic. The one
week time frame was used to minimize recall bias on the part of the participant.
Categories on the frequency scale included: never, 1-2 days, 3-4 days, 5-6 days, and
everyday/7 days. The severity scale measured how the symptom affected the daily life of
the participant. Categories on the severity scale included: not affected (0), slight/barely
noticeable (1), minor problem but noticeable (2), moderate problem that interferes with
some daily activities (3), major problem that interferes with most daily activities (4), and
disabling problem (5) (Stricker et al., 2011).
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An overall score (12 points) was calculated for the symptom index. Each category
was worth 2 points of the total score – 1 point for severity and 1 point for frequency.
Symptom scores in each category were averaged to reach this 2 point total.
This overall score was used to make comparisons between the Lyme positive case group
and the Lyme negative control group, controlling for covariates like age, sex, and time
since exposure to the Ixodes tick. Additional analysis made comparisons based on each
symptom category that contributed to the total score. For example, if the symptom index
score of the case group was based entirely on musculoskeletal and cutaneous symptoms,
these category scores were compared between the case and controls by multivariate
analysis methods.
Comparisons between cases and controls were conducted using the two way table
and calculating the odds ratio for each symptom category reported. Since both cases’ and
controls’ ROSS Scales provided information, these comparisons were easily made for
each symptom category reported. This information provided insight into the symptoms
that could be used for early diagnosis of Lyme disease.
In addition, univariate and bivariate statistical analyses were used. Univariate
analysis allowed for descriptive statistics to be generated. Bivariate methods allowed
comparisons to be made between two different variables to determine what, if any,
relationship existed between these variables. The Chi-square test (if the data is normally
distributed), the Kruskal-Wallis test, the odds ratio, and the odds ratio with the MantelHaenszel method (for age-adjusted comparison) were used to analyze the data and
provided evidence to determine whether to accept or reject the null hypotheses (Munro,
2005).
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In addition to the described univariate and bivariate statistical analyses,
multivariate regression analysis was conducted on certain independent and dependent
variable combinations. The independent variables age and sex were included in the
analysis regardless of their association with the dependent variables after bivariate
analysis based on evidence from previous literature (Katz, 2006). Independent or
dependent variables were excluded from the multivariate regression analysis if there was
a lot of missing data associated with that specific variable.
RQ1: Is the presentation of symptoms in Lyme disease-positive patients
associated with the sociodemographic variables age and sex as assessed by patient
medical record and ROSS Scale survey review?
H01 Lyme disease symptom presentation is not associated with the
sociodemographic variables age and sex as assessed by patient reported
symptoms recorded in patient medical records or on the ROSS Scale survey.
Ha1 Lyme disease symptom presentation is associated with the
sociodemographic variables age and sex as assessed by patient reported
symptoms recorded in patient medical records or on the ROSS Scale survey.
RQ2: Is the severity of symptoms in Lyme disease positive patients associated
with the sociodemographic variables age and sex as assessed by patient medical
record and ROSS Scale survey review?
H02: Lyme disease symptom severity is not associated with the
sociodemographic variables age and sex as assessed by patient reported
symptoms recorded in patient medical records or on the ROSS Scale survey.
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Ha2: Lyme disease symptom severity is associated with the sociodemographic
variables age and sex as assessed by patient reported symptoms recorded in
patient medical records or on the ROSS Scale survey.
RQ3: Is the presentation of symptoms associated with the diagnosis of Lyme
disease as assessed by patient medical record and ROSS Scale survey review?
H03: Lyme disease symptom presentation is not associated with the diagnosis
of Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
Ha3: Lyme disease symptom presentation is associated with the diagnosis of
Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
RQ4: Is the severity of symptoms associated with the diagnosis of Lyme disease
as assessed by patient medical record and ROSS Scale survey review?
H04: Lyme disease symptom severity is not associated with the diagnosis of
Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
Ha4: Lyme disease symptom severity is associated with the diagnosis of Lyme
disease as assessed by patient reported symptoms recorded in patient medical
records or on the ROSS Scale survey.
RQ5: Is Lyme disease symptom presentation and severity associated with
seasonality of infection variables as assessed by medical record and the ROSS
Scale survey review?
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H05: Lyme disease symptom presentation and severity are not associated with
the seasonality of infection variables as assessed by patient medical record
and the ROSS Scale survey review.
Ha5: Lyme disease symptom presentation and severity are associated with the
seasonality of infection variables as assessed by patient medical record and
the ROSS Scale survey review.
Statistical Analysis
Statistical analysis was performed with SPSS (version 21). Statistical tests
included the Chi-square test (if the data are normally distributed) or the Kruskal-Wallis
test (if the data are not normally distributed), which allowed for comparisons between the
control group and the study population for specific symptoms and independent variable
comparisons (Munro, 2005). A Chi-Square test was performed for age distribution
categories and symptom presentation. This test was performed because the sample size is
well over 60 participants and there were more than five participants in each age category
(Munro, 2005). An ANOVA (with the Tukey Post Hoc test) was performed comparing
age and symptom frequency and severity scores, because both of these categories had
more than two groups (Munro, 2005). Lastly, an odds ratio was calculated both with and
without the Mantel-Haenszel method (Munro, 2005).
In addition to the described univariate and bivariate statistical analyses, regression
analysis was conducted on certain independent and dependent variable combinations. The
independent variables age and sex were included in the analysis regardless of their
association with the dependent variables after bivariate analysis based on evidence from
previous literature (Katz, 2006). Independent or dependent variables were excluded from
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the multivariate regression analysis if there was a lot of missing data associated with that
specific variable.
Since the goal of this research was to identify additional potential factors to use
for the earliest possible diagnosis of Lyme disease, an analysis based on the use of the
information from this study for diagnosis was performed. Once associations between
symptoms and/or symptom severity and the independent variables were determined, the
sensitivity, specificity, positive predictive value, and the negative predictive values were
calculated for the groups of symptoms. These values describe the ability of the test to
identify correctly those individuals who have a disease. An ROC plot was generated to
graphically show the data provided to help determine if the variables under investigation
could be used to diagnose Lyme disease.
Protection of Human Participants
Participation in this study was completely voluntary. Study participants received a
thorough explanation of the purpose of the study and the role the participant would play
in the study. Each participant received an informed consent form prior to inclusion in the
study. Participants were given an explanation of the study, a description of how to fill out
the ROSS Scale, allowed to ask additional questions, and were told that returning the
completed ROSS Scale was evidence of their consent to be included in the study.
Participant privacy has been maintained throughout the course of the study by
coding each participant record to avoid the use of participant names or other identifying
information. Coded records have been kept on a password protected computer and in a
locked filing cabinet. In addition, the study was approved by the Walden University
Institutional Review Board (approval number 10-30-14-00049220) and the Keystone
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College Institutional Review Board (approval number 2015-000559) prior to data
collection and again after the addition of the secondary data collection site.
Dissemination of Findings
Because the primary care clinic’s participant population comes from all over the
United States, study participants will receive information about the study results through
a report mailed directly to their home. Researcher contact information will be provided to
each study participant in case a participant has any questions about the study or the
results. In addition, updates on publication or presentation of results will be provided to
both the study clinician and study participants through post card updates.
In addition, a presentation of study results was given at the college that served as
a secondary data collection site. The presentation was advertised through normal
channels on the college campus, including the daily e-newsletter, announcements at
meetings, and on the college website. Participants interested in the study results, as well
as the general public, was encouraged to attend. Approximately, 120 individuals attended
the presentation.
Summary
This study examined the factors associated with symptom presentation and
severity in Lyme disease through a case-control methodology. Data was collected at a
primary care clinic through an examination of patient records and ROSS Scale analysis.
Data was collected at the secondary college site and analyzed through ROSS Scale
analysis. The symptom index score was used to aid in the analysis portion of the study.
Data collected provided information to either support or reject the null hypothesis for
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each research question based on univariate, bivariate, and multivariate statistical analysis
methods.
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Chapter 4: Results
Introduction
Lyme disease is currently one of the most frequently reported vector-borne
diseases (Binder, Telschow, & Meyer-Hermann, 2012; Borchers et al., 2015; Mead,
2015). According to the CDC (2015), Lyme disease is likely underreported by a factor of
12, leaving approximately 300,000 cases untreated. Successful treatment of Lyme disease
requires early diagnosis and treatment. Delayed treatment may lead to long-term
functional disability (Aucott et al., 2013; Johnson et al., 2011). The purpose of this study
was to identify potential differences in the way Lyme disease symptoms are presented
based on sex and/or age differences in order to help identify Lyme disease cases that
might go undiscovered or misdiagnosed. In addition, a comparison was also made
between symptom presentation and seasonality of infection to determine if symptoms
vary based on month of tick exposure.
In this chapter, I will reiterate the research questions and hypotheses, describe the
process of data collection and the addition of a secondary data collection site, discuss the
modifications to the data collection procedures, describe the final make-up of the sample
population, present the results obtained from data collection, and provide the statistical
analysis methods used and results.
Data Collection Process
Data was collected at two collection sites, a primary care clinic that specializes in
Lyme disease treatment and a small, 4-year liberal-arts college campus. The secondary
collection site was added because the primary care clinic could not provide enough
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controls for the study population. At both data collection sites, cases and controls were
determined as follows.
Cases (n = 203) were defined as adult subjects (≥ 18 years of age) who met one of
the following diagnostic criteria: (a) patient presents with a physician confirmed EM
rash; (b) patient has a positive EIA and/or Western Blot laboratory result for IgG and
IgM antibodies; or (c) a score of 5 or higher on the Burrascano Diagnostic Criteria for
Lyme Disease scale (Burrascano, 2005). These criteria meet both the Infectious Disease
Society of America (IDSA) and the International Lyme and Associated Diseases Society
(ILADS) diagnostic guidelines (Cameron, Johnson, & Maloney, 2014; Wormser et al.,
2006). Lyme disease cases were selected and confirmed by the clinical partner, a Lyme
disease specialist. Cases were randomly selected by the physician, based on the weekly
appointment schedule during the study period.
Controls (n = 388) were selected from adult subjects (≥ 18 years of age) who did
not suffer from Lyme disease at the primary care clinic, family members of Lyme disease
patients at the primary care clinic, and employees and students at a small, 4-year liberal
arts college. Participants who suffered from illnesses other than Lyme disease were not
excluded from the study. All controls were Lyme disease free at the time of selections as
determined by: (a) never having had a tick bite; (b) having no evidence of EM rash; or (c)
no prior laboratory testing for or diagnosis of Lyme disease by a physician. Controls were
selected at an approximate 1:2 case/control ratio to address the sampling bias introduced
by non-random selection of participants.
Because sex and age were two variables of interest in this study, matching
between cases and controls based on sex or age could not occur. Matching based on state

95
of residence was done to insure that exposure to the Ixodes scapularis tick was the same
between cases and controls. Participants were only included if they lived in one of the 14
states endemic for Lyme disease and the habitat for the Ixodes scapularis tick. These
states included: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota,
New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont,
Virginia, and Wisconsin. In addition, both cases and controls had to be available from a
particular state to be considered for inclusion in the study.
At both data collection sites, the ROSS scale, an abbreviated and modified version
of the Burrascano Symptom Scale, was used (Burrascano, 2008). The ROSS scale was
administered to every participant at patient registration, as is standard procedure for
intake at the primary care clinic. The ROSS scale became a permanent part of each
patient’s record and was used by the physician and staff to track symptom frequency and
severity visit to visit. Each ROSS scale was scanned into the patient’s record, deidentified, numbered and placed into a folder for entry as a participant into the study.
These de-identified ROSS scales were collected once per week from the clinic over a
period of four months.
At the secondary site, the ROSS scale was administered to several different
populations including faculty, professional staff, hourly staff, and students. Information
was distributed to the entire campus community about the study through daily
newsletters, social media, and mass emails. This distribution of information was designed
to increase interest in participation in the study. Data was then collected at large group
meetings. The ROSS scale was passed out to all individuals in attendance. Informed
consent forms were discussed and the study was explained.
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Any questions from the group were answered as clearly as possible and directions
were given on how to fill out the ROSS scale, highlighting key questions that required a
response. Sex, date of birth, and state of residence questions were specifically discussed
as important variables within the study. After completing this discussion, an envelope
was left with the person in charge of the group for immediate return of the ROSS scale by
participants. Instructions were also provided for on-campus mail return, scanning and
email return, and/or drop box return of the ROSS scale, if the participants preferred to
take the ROSS scale with them to fill out in private. Returning the completed form by any
of the methods available was considered consent to participate in the study. The response
rate at the college site was 84% and included primarily controls (Table 15). Response rate
at the primary care clinic was 93%, and included both cases and controls (Table 15).
Table 15
Participant Response Rates by Collection Site and Return Method
Oncampus
mail

Medical clinic
(site 1)

College
campus
(site 2)

Collection site

Email

Drop
box

Office
staff

Response
rate * (%)

Cases

Controls

0

0

0

357

94

232

125

2

0

291

0

84

5

288

*Number of participant responses includes all participants collected prior to the application of exclusion criteria.

The college ROSS scales were numbered upon return, which ensured that each
form was linked to a specific record in the Microsoft Access database, where the ROSS
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scale results were stored and managed. The ROSS scales were NOT linked to a specific
person by the numbering system, as there was no personal information on the ROSS scale
that could identify a specific individual. Data collected from the primary care clinic used
the same numbering system. The numbering system served a secondary purpose at the
primary care clinic. In order to distribute information about the completed study to all
participants, the primary care office staff used the numbers to identify which patients
were included in the study. This identifying list was only available to the primary care
office staff.
Exclusion Criteria
Completed forms were reviewed with the primary care physician to verify
inclusion as a case or control for this study from a clinical standpoint. Because controls
must NOT be Lyme disease positive, any indicators from the symptom checklist for a
potential undiagnosed Lyme disease patient were reviewed carefully for appropriate
case/control placement or exclusion from the study. No undiagnosed Lyme diseases cases
were identified through this review. Forms containing ROSS scale data that was
incomplete for the major study variables were excluded from the study. The ROSS scale
does collect additional data that is not included in the current study, so if this additional
data was incomplete, the ROSS Scale was not excluded.
Data collected was entered into Microsoft Access for storage and management.
All records were double-checked for accuracy and completeness of required information.
After review for accuracy in data entry, data records were reviewed to verify inclusion in
the study. A total of 650 ROSS scales were completed and collected from participants. A
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total of 591 participants were included in the final study analysis. Participants were
removed for the following reasons.
Age under 18 years. Because the primary care site treats very few patients under
the age of 18 years, the office staff did not pay special attention to the age requirement
for the study and provided eleven ROSS scales for patients who were 17 years old.
Participants must be 18 years of age for inclusion in the study, so these participants were
excluded.
No date of birth listed. One of the major study variables is age. Without a
birthdate listed, there was no way to determine how old the participant was so
participants without a date of birth were excluded from the study. In addition, a few of
the respondents listed the date the ROSS scale was completed as the date of birth. For the
same reason, these respondents were excluded from the study.
State of Residence. State of residence was used to match cases and controls to
address the non-random nature of participant selection. In addition, all participants
needed to come from one of the 14 Lyme endemic states for inclusion in the study. The
Lyme endemic states correspond to the habitat of the Ixodes tick, the vector for Lyme
disease in the United States. Three participants were removed for not listing a state of
residence at all. Seventeen additional participants were removed for not living in a Lyme
endemic state because exposure to the Ixodes tick would not be possible thus eliminating
the potential for developing Lyme disease. These participants lived in California,
Georgia, Michigan, Tennessee, Texas, and Wyoming. Parts of northern California have a
high incidence of Lyme diseases (even though the state as a whole has a low incidence of
Lyme disease), but the tick vector is different in the western United States (Borchers et
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al., 2015; Deluca et al., 2013). Ixodes pacificus is the tick vector in the western states and
Ixodes scapularis is the tick vector in the eastern United States (Borchers et al., 2015;
Deluca et al., 2013). While this variation in vector species may not have an effect on the
study outcome, keeping the exposure possibilities as similar as possible within the study
population was important.
An additional study participant was removed because the participant was from the
United Kingdom. This participant was removed for two reasons: (a) there were no
controls available from the same country for comparison; and (b) the causative agent and
vector for Lyme disease is different in Europe than the causative agent in the United
States (Borchers et al., 2015; Caimano et al., 2012). In Europe, the primary tick vector is
Ixodes ricinis, which is different from the primary vector in the United States (Borchers
et al., 2015; Caimano et al., 2012). In addition, the causative agent in Europe can be one
of three bacteria, Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii (Borchers et
al., 2015; Caimano et al., 2012). Each of these agents produces distinctly different
symptom outcomes (Borchers et al., 2015; Deluca et al., 2013). European cases of Lyme
disease tend to produce more neurological symptoms; American cases of Lyme disease
tend to produce more musculoskeletal symptoms, which have been linked to the species
of Borrelia that causes the infection (Borchers et al., 2015; Mead, 2015; Stanek et al.,
2011).
Lastly, additional participants were excluded from the study that lived in
Maryland, Rhode Island, and Wisconsin. Even though all three of these states are
considered Lyme endemic states, all participants were controls. There were no reported
Lyme cases from any of these states in the study population for comparison.
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Study Population
The study population consisted of cases (n = 203) and controls (n = 388) that were
similar in composition. Cases consisted of both females (n = 130) and males (n = 73)
ranging in age from 18 years to 75+ years (Table 16). Controls consisted of both females
(n = 268) and males (n = 120) also ranging in age from 18 years to 75+ years (Table 16).
According to the CDC (2015), males in all age categories under age 70 suffer more
frequently from confirmed Lyme disease (Figure 4). This age difference was not
supported when recruiting case participants into this study (Figure 5). As shown in Figure
5 and Table 16, female cases outnumber male cases by almost 2:1. Most of the female
cases were between the ages of 40-65 years. This discrepancy with the CDC’s confirmed
cases data may be due to the primary care clinic’s much larger population of female cases
over male cases to recruit.
Table 16:
Age Distribution of Study Lyme Disease Cases
Age Range
<20
25
30
35
40
45
50
55
60
65
70
75
80
85
90

Female Cases
(64%)
6
2
6
9
12
17
18
24
10
11
7
5
2
0
1

Male Cases
(36%)
6
6
8
2
5
11
5
7
6
9
2
4
1
1
0

Female Controls
(67%)
133
37
10
4
7
10
10
11
12
10
10
5
4
3
2

Male Controls
(33%)
38
16
6
10
6
14
9
8
4
6
7
2
2
1
0
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Figure 4. Frequency distribution of Lyme disease cases by gender – General population

Figure 5. Frequency distribution of Lyme disease cases by gender – Study population
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States of residence for both cases and controls included Connecticut,
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, and Vermont
(Table 17). All of these states are considered Lyme-endemic states by the CDC (2015).
Table 17
State of Residence of Study Participants by Case/Control
State of
Residence
CT
MA
NH
NJ
NY
PA
VT
Total

Female Case
16
2
2
9
89
8
4
130

Female Control
9
1
2
19
64
168
3
268

Male - Case
17
0
0
6
46
3
1
73

Male Control
6
1
0
12
34
66
1
120

Total (%)
48 (8)
4 (0.7)
4 (0.7)
46 (8)
233 (39)
247 (42)
9 (2)
591 (100)

In order to ensure that the sample population was as uniform as possible,
matching based on state of residence and frequency matching was performed. State of
residence matching (as shown in Table 17) required at least one case and one control
from a state in order for the study participant to remain in the study. Frequency matching
based on sex was performed so that the sample population did not contain a single sex in
cases or controls. Females made up 64% of the case population and 69% of the control
population. Males made up 36% of the case population and 31% of the control
population. In addition, a case-control ration of 1:2 was used to reduce sampling bias.
Lastly, random sampling was utilized as much as possible given the fact that cases
needed to be Lyme disease positive for inclusion. At the primary care site, cases were
selected at random based on the daily appointment schedule. In addition, controls were
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selected based on the daily appointment schedule (for non-Lyme disease patients) or
because the control was at the primary care site with a patient. At the secondary site,
ROSS scales were distributed at a variety of meetings on campus to anyone who was in
attendance at the meeting. This method for selection of meetings and campus groups
allowed for some random sampling of the population.
While educational level was not a variable under study, the secondary site was a
college campus so matching based on educational level became an important
consideration as advanced educational level can change socioeconomic status and effect,
specifically, access to health care (Heck & Parker, 2002; Saydah, Imperatore, & Beckles,
2013). Because all but five of the cases came from the primary care site, a comparison of
cases between collection sites was not necessary. Comparisons between controls
collected at each site were performed.
Overall, 51% of the study population had at least a high school diploma and 44%
of the population had completed at least a baccalaureate degree (Table 18). According to
the United States Census Bureau (2014), 30% of the population of the United States over
the age of 18 years old has at least a high school diploma. In addition, 29% of the
population of the United States over the age of 18 years old has at least a baccalaureate
degree. Site 1 females with a college degree made up 5% of the control population and
site 2 females with a college degree made up 4% of the control population. Site 1 males
with a college degree made up 5% of the control population and site 2 males with a
college degree made up 0.5% of the control population. Site 1 females with a graduate
degree made up 7% of the control population and site 2 females with a graduate degree
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made up 3% of the control population. Lastly, males with a graduate degree at both sites
made up 4% of the population.
Table 18
Education Level Comparison for Cases/Controls from Both Study Sites
Education
Level

Female
Case
Site 1

Female
Case
Site 2

Female
Control
Site 2
(%)
0

Male
Case
Site 1

Male
Case
Site 2

0

Female
Control
Site 1
(%)
2

Male
Control
Site 2
(%)
0

Total
(%)

0

Male
Control
Site 1
(%)
1

Unassigned

2

3

College
Graduate
Graduate
School
H.S.
Graduate
Technical
School
Total

39

0

20 (5)

15 (4)

32

0

20 (5)

2 (0.5)

12 (3)

13

0

15 (4)

18 (4)

23

163

19

2

4

58

0

2

0

4

0

2

0

128
(22)
133
(22)
300
(51)
19 (3)

46

1

28 (7)

28

3

11
126

4

75

190

71

2

42

78

8 (2)

588*
(100)

*Three participants did not list educational level on the ROSS Scale.

The age variable was defined based on the CDC’s surveillance groupings and
included the following breakdown: < 20 years; 20-24 years; 25-29 years; 30-34 years; 3539 years; 40-44 years; 45-49 years; 50-54 years; 55-59 years; 60-64 years; 65-69 years;
70-74 years; >75 years (CDC, 2015). Age categories were not combined into 10 year
intervals because there were not more than six categories with less than five participants.
Table 19 shows an age range distribution for cases and controls collected from the
primary care site and the secondary college site. Ages within the case and the control
populations were well matched in all age categories with the exception of the <20 years
and the 20-24 years age categories. Many more controls over cases are present in both of
these age categories. This inconsistency between age categories should not
disproportionally affect the results of the study because the controls should not be
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experiencing symptoms of Lyme disease more frequently than cases or at a more severe
level if the symptoms under study can truly be used as an indicator of the presence of
Borrelia burgdorferi.
Table 19
Age Distribution of Sample Population
Age
Range
<20

Female
Case
Site 1
4

Female
Case
Site 2
2

Female
Control
Site 1
1

Female
Control
Site 2
132

Male
Case
Site 1
5

Male
Case
Site 2
1

Male
Control
Site 1
0

Male
Control
Site 2
38

25

2

0

1

36

6

0

1

15

30
35
40
45
50
55
60
65
70
75
80
85
90
Grand
Total

5
9
12
17
17
24
10
11
12
2
0
0
1
126

1
0
0
0
1
0
0
0
0
0
0
0
0
4

4
1
6
7
8
6
9
8
8
4
4
3
2
72

6
3
1
3
2
5
3
2
2
1
0
0
0
196

8
2
4
11
5
7
6
9
2
4
1
1
0
71

0
0
1
0
0
0
0
0
0
0
0
0
0
2

2
2
2
4
8
6
4
4
4
2
2
1
0
42

4
8
1
1
4
2
0
2
3
0
0
0
0
78

Total
(%)
183
(33)
61
(10)
30 (5)
25 (4)
27 (5)
43 (7)
45 (8)
50 (9)
32 (5)
36 (6)
31 (5)
13 (2)
7 (1)
5 (1)
3 (1)
591
(100)

A power analysis was conducted to determine an adequate sample size to find
statistically relevant results (see chapter 3 for the full analysis discussion). Based on this
power analysis, the sample size of cases (n = 203) and controls (n = 388) was adequate to
find a significant difference for the three major symptoms associated with Lyme disease
in the United States (EM rash, arthritis, and Bell’s palsy). For the rare symptom of AV
cardiac block, the sample size selected for this study was inadequate to find a significant
difference between cases and controls. Because AV cardiac block is rare, the expectation
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of finding cases with this symptom was small. Mild cognitive impairment (MCI) is found
in the later stages of infection, post–treatment, and chronic Lyme disease (Caliendo et al.,
1995), but is rare in the general population at ages below 60 years (Iverson et al., 2011;
Katz, 2012; CDC, 2015). Because the primary care clinic treats patients in the later stages
of infection, the potential for identifying these symptoms at the required percent exposure
in cases was high.
Level of significance (α) for the statistical analysis was set at 0.05 following a
review of the relevant literature and based on the statistical work of Cohen (1992).
Probability (p) values followed that a p-value ≤ 0.05 resulted in rejection of the null (H0)
hypothesis and acceptance of the alternate (Ha) hypothesis. With a p-value > 0.05, the
null hypothesis was accepted, because a large p-value suggests that the null hypothesis is
more likely to be true given the specific set of test parameters (Munro, 2005)
According to Cohen (1992), the effect size is the impact the independent variable
has on the dependent variable. Based on the statistical method chosen for analysis, the
effect size varied from 0.30 to 0.50 for a medium to large effect (Cohen, 1992). In
addition, Cohen suggests setting the power of the study at 0.80 (Munro, 2005).
Symptom Index
Symptoms were grouped together into six categories for analysis purposes. The
six categories matched the major groups of reported symptoms to the NNDSS database
and included: 1) musculoskeletal; 2) neurological; 3) cognitive; 4) cardiac; 5) general;
and 6) cutaneous. The general category included the following symptoms: fatigue, fever,
chills, headaches, sore throat, persistent swollen glands, dizziness, lightheadedness,
nausea, diarrhea, and night sweats. The musculoskeletal category included the following
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symptoms: painful joints, stiff neck, back pain, stiff joints, and sore muscles. The
neurological category included facial paralysis (Bell’s palsy), blurred vision, eye pain, ear
ringing, jaw pain, testicular/pelvic pain, and tingling/burning/numbness. The cognitive
category included the following symptoms: disturbed sleep, poor concentration, memory
loss, irritability, crying, and sadness/depression. The cardiac category included chest pain
and heart palpitations. Lastly, the cutaneous category included the presence of the EM
rash.
The frequency scale measured how often a patient experienced the listed
symptoms within the week prior to filling out the ROSS scale. The one week time frame
was used to minimize recall bias on the part of the participant. Categories on the
frequency scale included: never, 1-2 days, 3-4 days, 5-6 days, and everyday/7 days
(Table 20). The severity scale measured how each specific symptom affected the daily
life of the participant (Table 20). Categories on the severity scale included: not affected
(0), slight/barely noticeable (1), minor problem but noticeable (2), moderate problem that
interferes with some daily activities (3), major problem that interferes with most daily
activities (4), and disabling problem (5) (Stricker et al., 2011).
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Table 20
Frequency and Severity Symptom Score Breakdown
Frequency

Frequency Score

Severity

Severity Score

Never

0.2

Not Affected (0)

0.17

1-2 Days

0.4

0.34

3-4 Days

0.6

4-5 Days

0.8

Every Day/7 Days

1.0

Slight/Barely
Noticeable (1)
Minor Problem but
Noticeable (2)
Moderate Problem that
Interferes with Some
Daily Activities (3)
Major Problem that
Interferes with Most
Daily Activities (4)
Disabling Problem (5)

0.51
0.68

0.85

1.00

An overall score (12 points) was calculated for the symptom index. Each of the
six symptom categories was worth 2 points of the total score – 1 point for severity and 1
point for frequency. Symptom scores in each category were assigned a value (which is a
fraction of 1 point based on the level of frequency and severity shown in Table 20),
totaled, and averaged to reach this 2 point total.
To illustrate a symptom index calculation in Table 21, a female case reported a
list of symptoms experienced the week prior to filling out the ROSS scale. For frequency
scores, there were five potential responses (never, 1-2 days, 3-4 days, 5-6 days, and
everyday/7 days). Each of these responses was assigned a numerical value in 0.2
increments as shown in Table 20. For severity scores, there were six potential responses
ranging from zero (no effect on daily life) to five (severely disrupts daily activities). Each
of these responses was also assigned a numerical value that was 1/6th of the 1 point
allowed for severity (Table 21). Scores were recorded, grouped into the six categories of
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symptoms, and then averaged to determine the frequency and severity score for that set of
symptoms.
Table 21
Female Case Reported Symptoms and Scores
Symptoms
Category
Musculoskeletal
Neurological
General
Cognitive
General
General
General
Cognitive
General
Cognitive
General
General
Musculoskeletal
Cognitive
Cognitive
Musculoskeletal

Reported Symptom

Frequency Frequency Severity Severity
Score
Score
Back Pain
Everyday
1
4
0.85
Blurred Vision
1-2 Days
0.4
0
0.17
Chills
3-4 Days
0.6
1
0.34
Disturbed Sleep
Everyday
1
4
0.85
Dizziness
1-2 Days
0.4
1
0.34
Fatigue/Tiredness
3-4 Days
0.6
4
0.85
Headaches
Everyday
1
4
0.85
Irritability
Everyday
1
4
0.85
Lightheadedness
1-2 Days
0.4
1
0.34
Memory Loss
5-6 Days
0.8
4
0.85
Nausea
1-2 Days
0.4
1
0.34
Night Sweats
3-4 Days
0.6
1
0.34
Painful Joints
Everyday
1
5
1
Poor Concentration 5-6 Days
0.8
4
0.85
Sadness/Depression 3-4 Days
0.6
0
0.17
Sore Muscles
Everyday
1
5
1

Using the data displayed in Table 21, the female case reported the following five
musculoskeletal symptoms: back pain, painful joints, stiff joints, stiff neck, and sore
muscles. Based on the scale in Table 20, a frequency of everyday is awarded a 1.0 score.
Since all of the symptoms were experienced every day, the average score for the five
symptoms is 1.0 (the third column in Figure 6).
To calculate the severity score for the musculoskeletal symptoms, the severity
score shown in Table 20 was used. Three of the symptoms were considered (by the
participant) to be disabling (score of 5 on the severity scale) and were assigned a severity
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score of 1.0. Two of the symptoms were considered major problems that interfere with
most daily activities (score of 4 on the severity scale) and were assigned a severity score
of 0.85 for each. To calculate the final severity score, the average of the five scores ([1.0
+ 1.0 + 1.0 + 0.85 + 0.85]/5) resulted in a severity score of 0.94 (the fourth column in
Figure 6).
Lastly, each symptom category score was added together to compose the final
symptom index score (the last column in Figure 6). An example symptom index score is
shown in Figure 6 below.
General

Musculoskeletal

Cognitive

Neurological

Cardiac

Cutaneous

Freq

Sev

Freq

Sev

Freq

Sev

Freq

Sev

Freq

Sev

Freq

Sev

0.44

0.34

1.00

0.94

0.40

0.34

0.47

0.34

0.00

0.00

0.50

0.50

Symptom
Index

5.27

Figure 6. Symptom index score card showing total symptom index score and frequency
and severity scores for each symptom category.
Results
Symptom Frequency
Overall symptom frequency scores were calculated by adding the calculated
frequency scores for each of the six symptom categories together. From Figure 6 above,
frequency scores for general (0.44), musculoskeletal (1.00), cognitive (0.40),
neurological (0.47), cardiac (0.00), and cutaneous (0.50) symptoms were combined to
represent the overall symptom frequency score. A comparison was made of the overall
symptom frequency score based on sex of the participant. Results are shown in Table 22
below. Because individual scores displayed a broad range of scores, individual scores
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were combined into the categories listed in Table 22 for analysis to increase the number
of participants in each category.
Table 22
Frequency Score for Participants
Frequency
Score
0.00 – 0.99
1.00 – 1.99
2.00 – 2.99
3.00 – 3.99
4.00 – 4.99
5.00 – 5.99
6.00

Female Case

Female Control

Male Case

Male Control

5
5
55
44
20
1
0

120
79
55
10
4
0
0

13
47
13
0
0
0
0

49
44
23
4
0
0
0

Both male and female controls displayed an overall frequency score on the lower
end of the scale (less than 3.00) with only 14 female controls scoring above 3.00.
Noteworthy is the fact that male cases also had frequency scores below 3.00, while
female cases were clustered primarily between 2.00 and 5.00. Figure 7 shows the
distribution of score by cases and controls.

Figure 7. An overall frequency comparison between cases and controls based on sex of
participant.
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Univariate statistical analysis of frequency scores between cases and controls
(Table 24), as well as between male and female cases (Table 23), support this
arrangement as statistically significant [χ2 (15, N = 588) = 290.42, p < 0.05; χ2 (5, n =
203) = 122.04, p < 0.05].
Table 23
Frequency Scores in Cases by Sex

Pearson Chi-Square
Likelihood Ratio
N of Valid Cases

Value

df

122.036a
144.646
203

5
5

Asymp. Sig.
(2-sided)
.000
.000

Table 24
Frequency Scores by Cases/Controls

Pearson Chi-Square
Likelihood Ratio
N of Valid Cases

Value

df

290.418a
289.682
588

15
15

Asymp. Sig.
(2-sided)
.000
.000

Raw data is shown below for breakdown by age of the overall frequency scores
for cases (Table 25) and controls (Table 26). Most of the overall frequency scores for
cases were between 1.00 and 5.00, while most of the overall frequency scores for controls
were below 3.00.
In order to compare case and control overall frequency scores and the age
category variable, the Kruskal-Wallis test was conducted. Initially, an ANOVA was
conducted because both the age category and the frequency scores had multiple levels
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within the groups. Unfortunately, the Levene’s Test of Equality of Error Variances was
0.011, which is not larger than the p-value of 0.05. This test looks for homogeneity
within the samples (Munro, 2005). This low score suggested that the test sample is not
normally distributed. The Kruskal-Wallis test is a non-parametric test that does not
require the sample population to be normally distributed across the age groupings.
Based on the Kruskal Wallis test comparison (Table 27), whether a participant
was a case or a control was correlated to both the age group category, [χ2 (1, N = 591) =
84.80, p = 0.00] and the symptom frequency score, [χ2 (1, N = 591) = 118.43, p = 0.00]
as shown in Table 28.
Table 25
Overall Frequency Scores of CASES by Age Groups
Freq
Score
0.00-0.99
1.00-1.99
2.00-2.99
3.00-3.99
4.00-4.99
5.00-5.99
6.00

<20
3
4
1
1
0
0
0

>75
0
2
1
3
0
0
0

2024
2
4
1
1
0
0
0

2529
2
4
7
0
1
0
0

3034
1
4
3
2
2
0
0

3539
1
3
8
5
0
0
0

4044
4
6
6
6
3
0
0

4549
2
4
11
3
4
0
0

5054
1
5
8
14
4
1
0

5559
1
3
7
1
1
0
0

6064
1
8
5
5
3
0
0

6569
1
2
4
3
1
0
0

7074
0
3
6
0
0
0
0
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Table 26
Overall Frequency Scores of CONTROLS by Age Group
Freq Score
0.00 - 0.99
1.00 - 1.99
2.00 - 2.99
3.00 - 3.99
4.00 - 4.99
5.00 - 5.99
6.00

<20
64
41
24
0
1
0
0

>75
5
3
4
0
0
0
0

2024
43
28
16
0
2
0
0

2529
6
5
4
0
0
0
0

3034
7
7
1
0
1
0
0

3539
1
4
3
1
0
0
0

4044
8
3
2
3
1
0
0

4549
6
8
7
0
0
0
0

5054
7
8
4
1
0
0
0

5559
6
3
4
2
0
0
0

6064
5
3
5
2
0
1
0

6569
6
9
3
2
0
0
0

Table 27

Table 28

Kruskal-Wallis Comparison

Overall Frequency Score by

7074
3
1
1
3
0
0
0

Case/Control and Age Categories
Case or
Control
Case
Frequency
Control
Score
Total
Case
Age
Control
Category
Total

N

Mean
Rank
203 397.73
388 242.77
591
203 384.53
388 249.68
591

ChiSquare
df
Asymp.
Sig.

Frequency
Score
118.429

Age
Category
84.800

1
.000

1
.000

RQ1: Is the presentation of symptoms in Lyme disease-positive patients associated with
the sociodemographic variables age and sex as assessed by patient medical record and
ROSS Scale survey review?
H01: Lyme disease symptom presentation is not associated with the
sociodemographic variables age and sex as assessed by patient reported symptoms
recorded in patient medical records or on the ROSS Scale survey.
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Ha1: Lyme disease symptom presentation is associated with the sociodemographic
variables age and sex as assessed by patient reported symptoms recorded in
patient medical records or on the ROSS Scale survey.
Based on the statistical evidence presented, the null hypothesis can be rejected and the
alternate hypothesis for research question one can be accepted – Lyme disease symptom
presentation is associated with the sociodemographic variables age and sex as assessed by
patient reported symptoms recorded in patient medical records.
Symptom Severity
A comparison was made between the overall severity score and the sex of the
participants. Results are presented in Table 29 and Figure 8. As with the frequency
scores, overall severity scores for male cases and controls and female controls are less
than 3.00. Female cases’ overall severity scores ranged from 1.00 – 5.00.
Table 29
Overall Severity Scores by Participant
Severity
Score
0.00 – 0.99
1.00 – 1.99
2.00 – 2.99
3.00 – 3.99
4.00 – 4.99
5.00 – 5.99
6.00

Female Case
12
34
46
28
10
0
0

Female
Control
141
95
24
6
2
0
0

Male Case
29
32
11
1
0
0
0

Male Control
63
42
12
3
0
0
0
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Figure 8. A comparison of the overall severity score between cases/controls based on
sex.
After Chi-Square analysis, results (Table 30) indicate that there is a correlation
between sex of the participant and the overall symptom severity score [χ2 (4, N = 591) =
20.94, p = 0.00]. In addition, statistical analysis (Table 31) suggests that there is a
significant difference between cases and controls based on overall symptom severity
score [χ2 (4, N = 591) = 106.39, p = 0.00]. Lastly, the comparison (Table 32) between
overall symptom severity scores and participant age also suggests a significant
correlation [χ2 (48, N = 591) = 106.81, p = 0.00].
Table 30
Overall Severity Scores by Sex

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

20.937a
26.455
17.523

4
4
1

591

Asymp. Sig.
(2-sided)
.000
.000
.000
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Table 31
Overall Severity Scores Between Cases and Controls

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

106.394a
106.483
103.092

4
4
1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

Table 32
Overall Severity Scores by Age Categories

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

106.807a
111.154
32.938

48
48
1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

RQ2: Is the severity of symptoms in Lyme disease positive patients associated with the
sociodemographic variables age and sex as assessed by patient medical record and ROSS
Scale survey review?
H02: Lyme disease symptom severity is not associated with the
sociodemographic variables age and sex as assessed by patient reported
symptoms recorded in patient medical records or on the ROSS Scale survey.
Ha2: Lyme disease symptom severity is associated with the sociodemographic
variables age and sex as assessed by patient reported symptoms recorded in
patient medical records or on the ROSS Scale survey.
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Based on the statistical evidence presented, the null hypothesis can be rejected and the
alternate hypothesis for research question two can be accepted – Lyme disease symptom
severity is associated with the sociodemographic variables age and sex as assessed by
patient reported symptoms recorded in patient medical records.
In order to discuss how the presentation and severity of symptoms are associated
with the diagnosis of Lyme disease (RQ3 and RQ4), the specific categories of symptoms
were examined individually first for an effect on accurate diagnosis. The overall
symptom score was then examined for an effect on accurate diagnosis of Lyme disease.
Symptom categories of Musculoskeletal, Neurological, Cognitive and Cutaneous were
examined because the study population size was adequate in power to identify a
statistically relevant correlation if one was present. General symptoms were reviewed
because these symptoms are common indicators of many other diseases and conditions,
as well as indicators for Lyme disease. Cardiac symptoms, due to their rare occurrence in
both the general and Lyme disease populations, required a much larger sample population
than was feasible for this study (CDC, 2015; Sandesara & Olshansky, 2012). Analysis
based on the cardiac symptom category was not performed individually, but the cardiac
category symptom scores were included in the total symptom index score calculations
and the overall effect calculations.
General Symptoms
The general symptoms category contains a variety of symptoms that can be an
indicator of many different diseases, including Lyme disease. General symptoms
examined included fatigue, fever, chills, headaches, sore throat, persistent swollen glands,
dizziness, lightheadedness, nausea, diarrhea, and night sweats. Early localized Lyme
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disease presents as fever, chills, fatigue, headache, and the erythema migrans rash
(discussed separately next).
Based on Chi-square analysis of the general symptom category (Tables 35 & 36),
significant differences were found between cases and controls [χ2freq (4, N = 591) =
105.468, p = 0.00; χ2sev (4, N = 591) = 71.243, p = 0.00] (Tables 33 & 34), but not based
on sex [χ2freq (4, N = 591) = 5.403, p > 0.05; χ2sev (4, N = 591) = 6.496, p > 0.05]. In
addition, analysis was performed comparing frequency and severity with the age variable.
ANOVA analysis (Table 37) showed a significance based on both frequency score (p =
0.000) and severity score (p = 0.019) when compared to age. The Tukey post-hoc
analysis showed the significance was between the < 20 years category and the 40-44
years, 45-49 years, and the 60-64 years categories for frequency, but showed no real
significance between age groups based on general symptom severity scores (Tables 38 &
39).
Table 33
General Symptom Frequency vs Case/Control

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

105.468a
115.894
96.333

4
4
1

591

Asymp. Sig. (2sided)
.000
.000
.000
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Table 34
General Symptom Severity vs Case/Control

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

71.243a
76.269
64.690

4
4
1

Asymp. Sig. (2sided)
.000
.000
.000

591

Table 35
General Symptom Frequency by Sex

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

5.403a
5.412
1.629

4
4
1

Asymp. Sig.
(2-sided)
.248
.248
.202

591

Table 36
General Symptom Severity by Sex

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

6.496a
6.496
2.083

4
4
1

591

Asymp. Sig.
(2-sided)
.165
.165
.149
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Table 37
General Symptom Frequency Comparison via ANOVA by Age

Between
Groups
Within Groups
Total

Sum of
Squares
66.327

df
12

771.337
837.665

578
590

Mean
Square
5.527

F

Sig.

4.142

.000

1.334

Table 38
General Symptom Tukey Post-Hoc Analysis by Age
(I) Age
Category

(J) Age Category

<20 Years

20-24 Years
25-29 Years
30-34 Years
35-39 Years
40-45 Years
45-49 Years
50-54 Years
55-59 Years
60-64 Years
65-69 Years
70-74 Years
>75 Years

Mean Difference
(I-J)
-.06910
-.58249
-.36821
-.76381
-.77297*
-.83646*
-.57441
-.55294
-.89202*
-.24148
-.78418
-.44757

Std. Error

Sig.

.15264
.23887
.23887
.24642
.20291
.19762
.18595
.23540
.21556
.22901
.29648
.28903

1.000
.418
.946
.097
.010
.002
.099
.482
.003
.998
.286
.944

Table 39
General Symptom Severity Comparison via ANOVA by Age

Between
Groups
Within Groups
Total

Sum of
Squares
32.533

df

Mean Square

F

Sig.

12

2.711

2.044

.019

766.566
799.100

578
590

1.326
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Erythema Migrans Rash
According to the CDC (2015), the erythema migrans (EM) rash “occurs in
approximately 60 to 80 percent of infected persons” (para. 1). This ratio was also
supported by other studies (Aucott, Seifert, & Rebman, 2012a). Based on this percentage,
the EM rash is currently used as a diagnostic tool for Lyme disease. The presence of the
EM rash with a known tick exposure can be used to diagnose Lyme disease without any
further laboratory testing (Aucott, Crowder, Yedlin, &Kortte, 2012; CDC, 2015).
This 60-80% of cases ratio was not supported by the current study. According to
the data collected (Table 40), only 28% of participants experienced the EM rash. Of the
28% of participants who experience the EM rash, female cases constituted 61% of the
cases that experienced the rash.
Table 40
EM Rash Presence by Case Sex

EM Rash
Present

Male

Female

Total

% of Total
Case
Population

Yes
No
Total

22
50
72

34
94
128

56
144
200

28
72
100

% of
Cases
with EM
Rash
Male
38
34
72

% of
Cases
with EM
Rash
Female
61
67
128

Three participants were unsure whether they experienced the EM rash and were excluded from the analysis.
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Figure 9. Comparison of cases and controls who displayed the EM rash by sex of
participant.
Based on Chi-Square analysis of EM rash in males and females (Table 41), the
relationship was not significant [χ2 (1, n = 200) = 0.546, p > 0.05]. When comparing the
presence of EM rash between cases and controls (Table 42), the relationship was
significant [χ2 (1, N = 588) = 120.076, p < 0.05]. This relationship supports using the EM
rash as a diagnostic tool, but does not show a statistically relevant difference based on sex
of the patient.
Table 41
EM Rash by Sex

Pearson Chi-Square
Continuity
Correctionb
Likelihood Ratio
Fisher's Exact Test
N of Valid Cases

Value

df

.364a
.193

1
1

Asymp. Sig.
(2-sided)
.546
.660

.362

1

.548

200

Exact Sig.
(2-sided)

Exact Sig.
(1-sided)

.623

.328
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Table 42
EM Rash in Cases vs. Controls

Pearson Chi-Square
Continuity
Correctionb
Likelihood Ratio
Fisher's Exact Test
N of Valid Cases

Value

df

120.076a
116.848

1
1

Asymp. Sig.
(2-sided)
.000
.000

132.662

1

.000

Exact Sig.
(2-sided)

Exact Sig. (1sided)

.000

.000

588

Analysis was also conducted based on the age of the participants. As shown in
Table 43, presence of the EM rash in women was present primarily in cases over the age
of 35, with the largest number of female cases with EM rash falling in the 50-54 year age
category.
Table 43
EM Rash Comparison by Sex and Age Categories
Age Categories
<20
>75
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
Grand Total

Female - Case
No
Yes
4
1
3
1
3
0
5
0
9
0
8
4
11
4
15
2
17
9
7
2
8
4
3
4
1
3
94
34

Male - Case
No
Yes
3
1
1
1
5
0
6
2
2
2
3
1
9
1
5
2
6
0
2
2
5
5
1
2
2
3
50
22

Total
9
6
8
13
13
16
25
24
32
13
22
10
9
200

125
A comparison was made between the age categories (as listed in the Table 43
above) and the presence of the EM rash. The results (Table 44) suggest a statistical
significance between age and presence of the EM rash [χ2 (12, = 200) = 21.43, p < 0.05],
although the level of significance is relatively small (p = 0.044). Kruskal Wallis testing
(because the data was not normally distributed) was unable to support this level of
significance (p = 0.05), suggesting age and presence of the EM rash were not related.
Table 44
Age vs Presence of EM Rash

Pearson ChiSquare
Likelihood Ratio
N of Valid Cases

Value

df

21.426a

12

Asymp. Sig.
(2-sided)
.044

22.405
200

12

.033

Musculoskeletal Symptoms
Because Lyme disease caused by Borrelia burgerferi tends to produce
musculoskeletal symptoms in the United States, these symptoms were examined next for
diagnostic use (Stanek et al., 2011). The musculoskeletal symptoms category included
painful joints, stiff joints, stiff neck, back pain, and sore muscles. Analysis was conducted
using sex, age, and case/control comparisons. Population sample size (N = 591) for the
musculoskeletal category was slightly different than that used for the EM rash analysis.
Three participants were unsure about the presence of the EM rash, so these participants
were excluded from the EM rash analysis. Data was available for these three participants
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for the other symptom categories, so these participants were included in the rest of the
symptom analyses.
Breakdown of musculoskeletal symptoms frequency scores are shown in Table 45
and Figure 10. Of note, male (Mcase) cases experienced musculoskeletal symptoms
across the entire range of frequency categories with the score evenly distributed across
the scores. Female cases (Fcase) were also distributed across all frequency levels, but the
largest concentration of scores was located in the highest musculoskeletal symptom
frequency score. Additionally, both male (Mcontrol) and female (Fcontrol) controls
experienced musculoskeletal symptoms across all score categories with the highest
concentration of scores at the lowest end of the scale.
Table 45
Musculoskeletal Symptom Frequency Score by Sex and Case/Control
Frequency
Score
0.00-0.20
0.21-0.40
0.41-0.60
0.61-0.80
0.81-1.00

Female Case

Female Control

Male Case

Male Control

7
12
24
27
60

140
53
33
15
27

10
17
17
16
13

53
23
28
9
7
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Figure 10. Comparison of musculoskeletal frequency scores by case/control and sex of
participant.
Initial descriptive statistics demonstrated that all participants (N = 591) could be
included in the analysis. Upon Chi-Square analysis, relationships between the frequency
score for musculoskeletal symptoms compared to sex (Table 46), age (Table 47), and
case or control (Table 48) displayed a significant correlation [χ2 (4, N = 591) = 19.85, p =
0.01; χ2 (48, N 591) = 120.34, p = 0.00; χ2 (4, N = 591) = 148.74, p = 0.00].
Table 46
Musculoskeletal Frequency Score vs Sex

Pearson ChiSquare
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

19.852a

4

Asymp. Sig.
(2-sided)
.001

20.645
1.671

4
1

.000
.196

591
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Table 47
Musculoskeletal Frequency Scores vs. Age

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

120.344a
123.063
49.507

48
48
1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

Table 48
Musculoskeletal Frequency Score vs Case/Control

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value
148.736a
159.936
145.614

df
4
4
1

Asymp. Sig. (2-sided)
.000
.000
.000

591

After performing Levene’s Test of Equality of Error Variances, the significance
value was 0.059, which is higher than the alpha value of 0.05. Because the test statistic
was higher than the accepted level of significance, the values being tested were normally
distributed and a one way analysis of variance (ANOVA) was performed (Munro, 2005).
When comparing the musculoskeletal frequency score with case/controls or male/female,
differences found were significant, F (1, 1) = 74.51, p = 0.00; F(1,1) = 8.33, p = 0.00
respectively. In addition, comparison of the musculoskeletal frequency scores with
cases/controls and male/female variables together produced a significant result, F (1,1) =
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8.03, p = 0.01. Further post hoc analysis was not performed on these variables because
there were only two categories for each variable.
When examining the musculoskeletal frequency score with the age variable by
ANOVA, initial results implied a lack of significance between age as a whole and the
musculoskeletal frequency score. Post hoc analysis, via the Tukey post hoc test,
comparing frequency scores of each age group with each other age group did show some
areas of significance (highlighted in yellow). The <20 years age group was significantly
different from most of the other age groups with the exception of the 20-24 years, 25-29
years and the >75 years age groups (Table 49). The 20-24 years age group was only
significantly different from the 40-44 years and the 50-54 years age groups. The other
age groups were not significantly different from each other, with the exception of those
groups that were significantly different from the <20 years age group and mentioned
previously.
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Table 49
Tukey Post Hoc Test Comparing Musculoskeletal Frequency Score with Age Categories
(Partial Table)

Dependent Variable: Frequency Score
(I) Age
Category

Tukey
HSD

(J) Age
Category

Mean
Difference
(I-J)

Std.
Error

Sig.

-.3041
-.6836
-1.0407*
-1.1479*
-1.3384*
-1.0590*
-1.6196*
-1.1824*
-1.0646*
-.8898*
-1.2655*
-1.0368

.17107
.26771
.26771
.27618
.22741
.22148
.20840
.26383
.24159
.25667
.33228
.32393

.860
.342
.007
.003
.000
.000
.000
.001
.001
.032
.010
.073

20-24 Years
25-29 Years
30-34 Years
35-39 Years
40-45 Years
45-49 Years
<20 Years
50-54 Years
55-59 Years
60-64 Years
65-69 Years
70-74 Years
>75 Years

95% Confidence
Interval
Lower
Upper
Bound Bound
-.8734
.2652
-1.5745 .2073
-1.9316 -.1499
-2.0670 -.2288
-2.0951 -.5816
-1.7960 -.3220
-2.3131 -.9261
-2.0603 -.3044
-1.8685 -.2606
-1.7439 -.0357
-2.3713 -.1598
-2.1147 .0412

Musculoskeletal symptom severity scores were also calculated. Scores were
broken down by sex and case or control status (Table 50). Female (Fcase) cases had a
more even distribution of scores across all severity levels with the highest scores in the
top severity level. Male (Mcase) cases had lower severity scores overall. Female
(Fcontrol) and male (Mcontrol) controls had the highest number of individuals
experience little to no discomfort associated with their musculoskeletal symptoms (as
expected), but also had participants experience symptoms across the entire range of
scores in higher numbers than expected.
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Table 50
Musculoskeletal Severity Score for Male/Female Cases and Controls

Severity Score
0.00-0.20
0.21-0.40
0.41-0.60
0.61-0.80
0.81-1.00

Female Case
15
29
24
23
39

Female Control
158
48
32
16
14

Male Case
15
24
20
5
9

Male Control
63
27
18
11
1

Musculoskeletal symptoms severity scores were also statistically analyzed.
Comparisons were made between these severity scores for cases/controls (Table 51),
males/females (Table 52), and with the various age categories (Table 53). Pearson ChiSquare analysis suggested a significant relationship between musculoskeletal severity and
being a case or control [χ2 (4, N = 591) = 116.54, p = 0.00]; being a male or female [χ2
(4, N = 591) = 14.55, p = 0.01]; and with age [χ2 (48, N = 591) = 128.36, p = 0.00].
Table 51
Musculoskeletal Severity Score vs Case/Control

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

116.537a
122.993
107.236

4
4
1

591

Asymp. Sig.
(2-sided)
.000
.000
.000
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Table 52
Musculoskeletal Severity Score vs Sex

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

14.553a
15.454
2.452

4
4
1

Asymp. Sig.
(2-sided)
.006
.004
.117

591

Table 53
Musculoskeletal Severity Score vs Age Category

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

128.359a
129.435
24.788

48
48
1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

Neurological Symptoms
Neurological symptoms are the hallmark of the second stage of Lyme disease
infection (early disseminated Lyme disease) where the B. burgdorferi bacteria leave the
initial site of infection and spreads to other areas of the body, including the nervous
system. Neurological symptom data collected included: facial numbness (Bell’s palsy);
blurred vision, eye pain, ear ringing, and jaw pain (cranial nerve involvement),
testicular/pelvic pain, and tingling/burning/numbness. Variables compared with symptom
frequency and severity scores included case/control, sex, and age. All participants (N =
591) were included in the analysis.
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Neurological symptom frequency scores (Table 54 and Figure 11) vary in their
distribution between cases and controls. Both male (Mcase) and female (Fcase) cases
display a more even distribution across the scale of scores available. Conversely, male
(Mcontrol) and female (Fcontrol) controls’ scores are heavily skewed to one side of the
scale of available scores with a sharp decrease in the number of controls that experience
these symptoms more than once per week.
Table 54
Neurological Symptom Frequency Scores by Sex and Case/Control
Frequency
Score
0.00-0.20
0.21-0.40
0.41-0.60
0.61-0.80
0.81-1.00

Female Case

Female Control

Male Case

Male Control

14
26
30
29
31

182
45
19
14
8

14
14
16
16
13

76
23
12
6
3

Figure 11. Comparison of the neurological symptom frequency score between
cases/controls and by sex of participant.
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Comparison was first performed based on the neurological symptom category
frequency score. As shown in Table 55, Chi-Square analysis comparing frequency scores
of cases and controls supported a significant difference between cases and controls based
on neurological symptom frequency scores [χ2 (4, N = 591) = 184.76, p = 0.00]. In
addition, Chi-Square analysis based on age (Table 56) supported a significant difference
based on age of participant [χ2 (48, N = 591) = 155.81, p = 0.00].
Table 55
Neurological Symptom Frequency Score by Case/Control

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

184.755a
195.642

4
4

177.378

1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

Table 56
Neurological Symptom Frequency Score by Age Category

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

155.810a
158.491

48
48

72.536

1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

Not surprisingly, Chi-Square analysis based on sex (Table 57) did not support a
significant difference between the frequency a neurological symptom was experienced
and the sex of the participant [χ2 (4, N = 591) = 1.15, p = 0.89]. Both male and female
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cases displayed a broad distribution of frequency scores, so the lack of significance
between the sexes based on the data collected was not unexpected.
Table 57
Neurological Symptom Frequency Score by Sex

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

1.151a
1.148

4
4

.015

1

Asymp. Sig.
(2-sided)
.886
.887
.902

591

Next, neurological symptom severity scores were examined. Comparisons were
made between neurological symptom severity scores and case/control, sex, and age
categories. Aggregate data can be found in Table 58 and Figure 12 below. As with the
neurological symptom frequency scores, the neurological symptom severity scores
displayed a similar distribution. Male (Mcase) and female (Fcase) cases experienced
neurological symptoms with varying degrees of severity across all possible score
categories. In comparison, male (Mcontrol) and female (Fcontrols) controls experienced
neurological symptoms mainly on the less severe end of the severity scale, if at all.
Table 58
Neurological Symptom Severity Scores by Sex and Case/Control
Severity Score
0.00-0.20
0.21-0.40
0.41-0.60
0.61-0.80
0.81-1.00

Female Case
22
36
33
25
14

Female Control
201
34
21
9
3

Male Case
20
21
16
10
6

Male Control
88
16
8
6
2
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Figure 12. Comparison of neurological symptom severity score between cases and
controls by sex of participant.
Statistical analysis was performed. Chi-Square analysis supported a significant
difference between the neurological symptom severity scores of cases and controls [χ2 (4,
N = 591) = 165.51, p = 0.00], as well as neurological symptom severity scores found
between age categories [χ2 (48, N = 591) = 163.85, p = 0.00]. Results for these analyses
are found in Tables 59 and 60 below.
Table 59
Neurological Symptom Severity Score by Case/Control

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

165.551a
171.980

4
4

145.122

1

591

Asymp. Sig.
(2-sided)
.000
.000
.000
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Table 60
Neurological Symptom Severity Score by Age Category

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

163.854a
166.690

48
48

44.193

1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

As with the neurological symptom frequency score, the neurological symptom
severity score comparison based on sex of the participant (Table 61) did not support a
significant difference between the severity levels of neurological symptoms experienced
by males and females [χ2 (4, N = 591) = 0.445, p = 0.98]. This finding was not surprising
based on the distribution of neurological symptom severity scores reported.
Table 61
Neurological Symptom Severity Score by Sex

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

.445a
.445

4
4

.045

1

Asymp. Sig.
(2-sided)
.979
.979
.832

591

Cognitive Symptoms
The last area for individual examination was cognitive symptoms frequency and
severity scores. These scores were compared with case/control status, male/female sex,
and the various age categories. All participants (N = 591) were included in this analysis.
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Cognitive symptoms included in this category were: disturbed sleep, poor concentration,
memory loss, irritability, crying, and sadness/depression.
Cognitive symptom frequency scores were examined first for significant
differences across all variable categories. Aggregate data for cognitive symptom
frequency scores based on sex and case/control status are shown in Table 62 and Figure
13. Both male (Mcase) and female (Fcase) cases experienced cognitive symptoms across
a broad range of frequencies in an almost even distribution across categories. Male
(Mcontrol) and female (Fcontrol) controls experienced cognitive symptoms infrequently
(Table 62 & Figure 13).
Table 62
Cognitive Symptom Frequency Scores by Sex and Case/Control
Frequency
Score
0.00-0.20
0.21-0.40
0.41-0.60
0.61-0.80
0.81-1.00

Female Case

Female Control

Male Case

Male Control

14
26
30
29
31

182
45
19
14
8

14
14
16
16
13

76
23
12
6
3
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Figure 13. Comparison of cognitive frequency scores between cases and controls based
on sex of the participants.
Chi-Square analysis of cognitive symptom frequency scores in cases and controls
(Table 63) confirmed a significant difference [χ2 (4, N = 591) = 141.71, p = 0.00]
between how often an individual with Lyme disease experiences cognitive issues and
how frequently an individual who does not have Lyme disease experiences these same
symptoms. In addition, a significant difference was found between the different age
categories (Table 64) based on cognitive symptom frequency score [χ2 (48, N = 591) =
148.61, p = 0.00].
Table 63
Cognitive Symptom Frequency Score by Case/Control

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

141.713a
151.486

4
4

140.018

1

591

Asymp. Sig.
(2-sided)
.000
.000
.000
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Table 64
Cognitive Symptom Frequency Score by Age Category

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

148.616a
151.897

48
48

43.250

1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

As with neurological symptom frequency, cognitive symptoms (Table 65)
occurred no more frequently in male or female participants [χ2 (4, N = 591) = 5.22, p =
0.27]. This outcome was slightly less expected than the outcome observed for the
neurological symptom frequency because the cognitive frequency raw data shows an
upward trend in scores for females while the male cognitive frequency scores remain
fairly steady across all frequency categories (Figure 13).
Table 65
Cognitive Symptom Frequency by Sex

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

5.216a
5.301

4
4

.730

1

Asymp. Sig.
(2-sided)
.266
.258
.393

591

Severity scores for the cognitive symptom category followed a similar pattern to
the cognitive symptom frequency scores with a significant difference shown in the
severity of cognitive symptoms experienced between cases and controls [χ2 (4, N = 591)
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= 105.23, p = 0.00] (Table 66) and between the various age categories [χ2 (48, N = 591) =
83.61, p = 0.01] (Table 67). Significant differences in the severity of cognitive symptoms
between males and females were absent [χ2 (4, N = 591) = 5.66, p = 0.23] (Table 68).
Table 66
Cognitive Symptom Severity by Case/Control

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

105.230a
112.883

4
4

89.192

1

Asymp. Sig.
(2-sided)
.000
.000
.000

591

Table 67
Cognitive Symptom Severity by Age Category

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

83.610a
83.519

48
48

12.701

1

591

Asymp. Sig.
(2-sided)
.001
.001
.000
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Table 68
Cognitive Symptom Severity by Sex

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value

df

5.656a
5.853

4
4

1.908

1

Asymp. Sig.
(2-sided)
.226
.210
.167

591

For each symptom category analyzed, differences between cases and controls and
between age categories were supported. Because these categories were developed to help
diagnose Lyme disease, variations between cases and controls would be important to
identify. Interestingly, there were no significant differences between male and female
symptom presentation in these four categories, but from a diagnostic stand point,
determining that there is no difference between male and female symptom presentation is
also an important finding.
RQ3: Is the presentation of symptoms associated with the diagnosis of Lyme disease as
assessed by patient medical record and ROSS Scale survey review?
H03: Lyme disease symptom presentation is not associated with the diagnosis
of Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
Ha3: Lyme disease symptom presentation is associated with the diagnosis of
Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
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RQ4: Is the severity of symptoms associated with the diagnosis of Lyme disease as
assessed by patient medical record and ROSS Scale survey review?
H04: Lyme disease symptom severity is not associated with the diagnosis of
Lyme disease as assessed by patient reported symptoms recorded in patient
medical records or on the ROSS Scale survey.
Ha4: Lyme disease symptom severity is associated with the diagnosis of Lyme
disease as assessed by patient reported symptoms recorded in patient medical
records or on the ROSS Scale survey.
Based on the reported statistical analyses and the resultant significant differences
between cases and controls for musculoskeletal, neurological, cognitive, and cutaneous
symptoms in both the frequency of experienced symptoms and the severity of those
symptoms, the null hypothesis can be rejected and the alternative hypothesis can be
accepted for both RQ3 and RQ4. Musculoskeletal, neurological, cognitive, and cutaneous
symptom frequency and severity can be used to help diagnose Lyme disease.
Odds Ratio
Odds ratios were calculated (using the OpenEpi calculator) for the
musculoskeletal, neurological, cognitive and cutaneous symptom categories (Dean,
Sullivan, & Soe, 2015). These odds ratios were based on the symptom frequency score
only for the specific symptom category, since this score represents the presence of the
symptom. All participants were included in the calculations with the exception of the
odds ratio calculation for the cutaneous symptom category. This group had three
participants who were not sure whether the EM rash was present or not, so these three
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participants were excluded from the odds ratio calculation. The odds ratios were
calculated as shown in Figure 14.

Figure 14. Odds ratio calculation chart.
According to the odds ratio calculation, the likelihood of an individual
experiencing musculoskeletal symptoms with Lyme disease is 11 (95% CI: 6.34, 18.49)
times higher than experiencing those symptoms in the absence of Lyme disease. Because
the confidence interval is greater than and does not contain 1.0, there is a significant
difference between the cases and controls based on the presence of musculoskeletal
symptoms (Table 69). This result supports the statistical analysis discussed previously.
Table 69
Musculoskeletal Symptoms Odds-Based Estimates and Confidence Limits
Point Estimates
Type

Confidence Limits
Value

Lower, Upper

Type

CMLE Odds Ratio*

10.79

Odds Ratio
Etiologic fraction in
pop.(EFp|OR)
Etiologic fraction in
exposed(EFe|OR)

10.83

6.434, 18.93¹
6.258, 19.67¹
6.342, 18.49¹

Mid-P Exact
Fisher Exact
Taylor series

83.16%

75.32, 91.01

90.77%

84.23, 94.59

Next, the odds ratio was calculated for the presence of neurological symptoms in
study participants. Based on this calculation, the likelihood of an individual experiencing
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neurological symptoms with Lyme disease is 12 (95% CI: 7.90, 19.48) times more likely
than experiencing neurological symptoms in the absence of Lyme disease. Because the
95% confidence interval is larger than and does not include 1.0, the results for
neurological symptom odds ratio analysis are significant between cases and controls in
this study. The odds ratio results (Table 70) support the statistical relevance determined
by the statistical analysis discussed previously.
Table 70
Neurological Symptoms Odds-Based Estimates and Confidence Limits
Point Estimates
Type
CMLE Odds Ratio*

Confidence Limits
Value

Lower, Upper

12.34

7.937, 19.66¹
7.77, 20.18¹

Odds Ratio
Etiologic fraction in pop.(EFp|OR)
Etiologic fraction in exposed(EFe|OR)

12.4

7.9, 19.48¹

79.26%
91.94%

71.97, 86.54
87.34, 94.87

Type
Mid-P
Exact
Fisher
Exact
Taylor
series

*Conditional maximum likelihood estimate of Odds Ratio
(P)indicates a one-tail P-value for Protective or negative association; otherwise one-tailed exact P-values are for a
positive association.
° ¹ 95% confidence limits testing exclusion of 0 or 1, as indicated
P-values < 0.05 and confidence limits excluding null values (0,1, or [n]) are highlighted.

The odds ratio was then calculated for the presence of cognitive symptoms in
study participants. Based on this calculation, the likelihood of an individual experiencing
cognitive symptoms with Lyme disease is 10 (95% CI: 5.24, 17.30) times more likely
than experiencing cognitive symptoms in the absence of Lyme disease. Because the 95%
confidence interval is larger than and does not include 1.0, the results for cognitive
symptom odds ratio analysis are significant between cases and controls in this study. The
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odds ratio results (Table 71) support the statistical relevance determined by the statistical
analysis discussed previously.
Table 71
Cognitive Symptoms Odds-Based Estimates and Confidence Limits
Point Estimates
Type
CMLE Odds Ratio*

Confidence Limits
Value

Lower, Upper

9.486

5.347, 17.92¹
5.175, 18.81¹

Odds Ratio
Etiologic fraction in pop.(EFp|OR)
Etiologic fraction in exposed(EFe|OR)

9.516

5.235, 17.3¹

83.76%
89.49%

74.99, 92.53
80.9, 94.22

Type
Mid-P
Exact
Fisher
Exact
Taylor
series

*Conditional maximum likelihood estimate of Odds Ratio
(P)indicates a one-tail P-value for Protective or negative association; otherwise one-tailed exact P-values are for a
positive association.
° ¹ 95% confidence limits testing exclusion of 0 or 1, as indicated
P-values < 0.05 and confidence limits excluding null values (0,1, or [n]) are highlighted.

Lastly, the odds ratio was calculated for the presence of cutaneous symptoms in
study participants. Based on this calculation, the likelihood of an individual experiencing
cutaneous symptoms with Lyme disease is 144 (95% CI: 19.72, 1048.73) times more
likely than experiencing cutaneous symptoms in the absence of Lyme disease. Because
the 95% confidence interval is larger than and does not include 1.0, the results for
cutaneous symptom odds ratio analysis are significant between cases and controls in this
study. The odds ratio results (Table 72) support the statistical relevance determined by
the statistical analysis discussed previously. This result also supports the common use of
the presence of the EM rash as a diagnostic tool for Lyme disease.
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Table 72
Cutaneous Symptoms Odds-Based Estimates and Confidence Limits
Point Estimates
Type
CMLE Odds Ratio*

Confidence Limits
Value

Lower, Upper

142.9

27.55, 2931¹
24.12, 5797¹

Odds Ratio
Etiologic fraction in pop.(EFp|OR)
Etiologic fraction in exposed(EFe|OR)

143.8

19.73, 1049¹

26.91%
99.3%

20.76, 33.05
94.93, 99.9

Type
Mid-P
Exact
Fisher
Exact
Taylor
series

*Conditional maximum likelihood estimate of Odds Ratio
(P)indicates a one-tail P-value for Protective or negative association; otherwise one-tailed exact P-values are for a
positive association.
° ¹ 95% confidence limits testing exclusion of 0 or 1, as indicated
P-values < 0.05 and confidence limits excluding null values (0,1, or [n]) are highlighted.

Symptom Index Score
The symptom index score was evaluated as a diagnostic tool for Lyme disease. As
stated previously, an overall symptom index score can be achieved based on a maximum
score of two for each of the six symptom categories. The symptom index score was first
evaluated by multiple linear regression based on the age and sex variables. All
participants (N = 591) were included in this analysis. Symptom index scores were
calculated as shown in Figure 6.
The multiple regression analysis was performed to determine if the
sociodemographic factors sex and age could be used to predict the presence of Lyme
disease based on the symptom index score. Based on the linear model, sociodemographic
factors are significantly related to the symptom index score [F (2, 588) = 34.98, p = 0.00]
and account for approximately 10% of the variance (R2 = 0.106) between the symptom
index scores and the age groups tested. This correlation is considered a weak, positive
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correlation; for each incremental increase in age group, there is a small increase in
symptom index score.
When looking at each individual factor’s effect, age is the only factor that
displayed any significant results (p = 0.00) when holding the sex variable constant (Table
73). When holding the age variable constant, sex (p > 0.05) is not a significant
contributor to the symptom index score. Based on the multiple regression model, for each
increase in age category, the symptom index score increase by a factor of 0.2. In addition,
the symptom index scores for females are 0.18 points higher than those found in male
participants but these variations do not reach the level of significance.
Table 73
Multiple Regression Analysis Results

Model

Unstandardized
Coefficients

Standardized
Coefficients

Std.
Error
(Constant)
2.379
.291
1 Sex
-.178
.193
Age Category
.200
.024
a. Dependent Variable: Symptom Index
B

t

Sig.

8.177
-.922
8.356

.000
.357
.000

Beta
-.036
.327

95.0%
Confidence
Interval for B
Lower Upper
Bound Bound
1.808
2.951
-.557
.201
.153
.247

Next, the symptom index score was evaluated by construction a receiver operating
characteristic (ROC) curve to determine whether the symptom index score can be a valid
method for diagnosing Lyme disease. The resultant ROC curve for symptom index scores
in cases vs. controls is shown in Figure 15.
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Figure 15. ROC curve comparing the symptom index scores of participants with case vs
control status.
The area under the curve (AUC) can be used to show the validity of a diagnostic
test (Kumar & Indrayan, 2011). With an AUC value equal to 1 showing a perfect
diagnostic test, AUC values should be as close to 1 as possible. The AUC for the ROC
curve shown in Figure 15 is 0.88, as shown in Table 74. This result supports using the
symptom index score as a diagnostic tool for Lyme disease.
Table 74
Area Under the Curve
Test Result Variable(s): Symptom Index
Area
.878

Std. Errora

Asymptotic
Sig.b

.015

.000

Asymptotic 95% Confidence Interval
Lower Bound
.850

Upper Bound
.907

The test result variable(s): Symptom Index has at least one tie between the positive actual state group and the
negative actual state group. Statistics may be biased.
a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5

From the ROC curve, the optimal diagnostic cut-off value can be determined
based on the sensitivity and specificity needs for the accurate diagnosis of the disease.
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Because these two values are inversely proportional to each other, increasing sensitivity
leads to a decrease in specificity (Kumar & Indrayan, 2011). If you increase sensitivity to
correctly identify all cases of Lyme disease (true positives), you lose the ability to
correctly identify all those individuals who don’t have Lyme disease (specificity) at the
same time (true negatives). Using any symptom index score above zero for diagnosis
provides 99.5% sensitivity but 28% specificity (Table 75). Anyone who has Lyme
disease will be diagnosed with Lyme disease, but there will be a large number of Lyme
disease negative individuals who are also diagnosed as positive for Lyme disease. Using
the ROC curve, a symptom index score of 3.7 points as a cut-off point will provide an
82% sensitivity and a 78% specificity, providing some balance to the diagnostic test and
a more informed approach to disease diagnosis (Table 76).
Table 75
High Sensitivity/Low Specificity Using Symptom Index Score > 0.00
Parameter
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
Diagnostic Accuracy

Estimate

Lower - Upper 95% CIs

99.51%
27.58%
41.82%
99.07%
52.28%

(97.26, 99.91¹ )
(23.37, 32.23¹ )
(37.5, 46.27¹ )
(94.94, 99.84¹ )
(48.26, 56.28¹ )
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Table 76
Moderate Sensitivity/Specificity Using Symptom Index Score > 3.69
Parameter
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
Diagnostic Accuracy

Estimate

Lower - Upper 95% CIs

81.77%
77.84%
65.87%
89.09%
79.19%

(75.89, 86.48¹ )
(73.44, 81.68¹ )
(59.82, 71.45¹ )
(85.32, 91.98¹ )
(75.73, 82.27¹ )

Based on the ROC analysis and the multiple linear regression analysis, the
symptom index score can be used as another tool in the arsenal for diagnosing Lyme
disease.
Seasonality of Infection
Seasonality of infection variables included month of tick exposure and month of
diagnosis. Based on CDC data (2015), most Lyme disease diagnoses occur during the
months of June, July, and August. In addition, the winter months (December through
March) contain the fewest reported Lyme disease diagnoses (CDC, 2015).
As shown in Figure 16, the distribution of reported month of exposure to the
Ixodes scapularis tick or the month of symptom onset (for those cases that did not recall a
tick bite) differs from the distribution of cases by month reported to the Centers for
Disease Control and Prevention shown in Figure 17 (CDC, 2015). The greatest number of
cases in this study occurred in May (n = 34) and June (n = 29) with May showing the
most cases in the study. According to CDC data, July is the month with the greatest
number of cases overall (CDC, 2015). In addition, study participants reported January
with a large number of cases (n = 21) where CDC data suggests that January and
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February have the lowest number of reported cases (CDC, 2015). The study distribution
directly contradicts CDC data showing the summer months as the most likely months for
disease onset (CDC, 2015).
Figure 16: Total Number of Cases per Month

Number of Cases

40
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Figure 16. Total number of Lyme disease cases per month within the study population.

Figure 17. Confirmed cases of Lyme disease by month of disease onset – United States,
2001-2010 (CDC, 2015).
A few cases (n = 21) were removed from this analysis due to missing data for
either tick bite exposure or month of initial symptom appearance. Either of these dates
could be used in the analysis because initial symptoms occur 3-10 days after infection
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with the Borrelia burgdorferi bacteria (CDC, 2015). If bitten by an Ixodes scapularis tick
that is in the nymphal stage, a person may not necessarily notice the bite, but would
experience the same symptoms at disease onset. When both dates were present, date of
tick bite exposure was used in the analysis.
Statistical analysis was conducted using SPSS (ver. 21). Descriptive statistics for
the symptom index scores used for analysis are shown in Table 77. A comparison was
made between the symptom index score for all cases and the month of diagnosis of Lyme
disease. The Chi-square results are shown in Table 78. Results show a p-value of 0.371,
which is greater than the accepted p-value of 0.05. Month of diagnosis is not related to
the symptom index score.
Table 77
Symptom Index Score
N
Symptom Index
Score
Valid N (listwise)

174

Minimum Maximum Mean
.84

9.20

4.4171

Std.
Deviation
1.93778

174

Table 78
Month of Diagnosis vs Symptom Index Score

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear Association
N of Valid Cases

Value
1643.505a
759.037
.003
174

df
1617
1617
1

Asymp. Sig. (2-sided)
.317
1.000
.958
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RQ5: Is Lyme disease symptom presentation and severity associated with seasonality of
infection variables as assessed by medical record and the ROSS Scale survey review?
H05: Lyme disease symptom presentation and severity are not associated with
the seasonality of infection variables as assessed by patient medical record
and the ROSS Scale survey review.
Ha5: Lyme disease symptom presentation and severity are associated with the
seasonality of infection variables as assessed by patient medical record and
the ROSS Scale survey review.
Because the symptom index score encompasses both symptom presentation and severity
of symptoms, neither of these characteristics are associated with the seasonality of
infection of Lyme disease. The null hypothesis is accepted.
Summary
Based on the analysis and results presented, Lyme disease symptom presentation
and severity was affected by the sociodemographic variables age and sex. Assessing
frequency and severity scores independently provided significant differences between
cases and controls based on age and sex. Unfortunately, these differences between the
sexes were not maintained when examining most symptom categories individually.
In addition, Lyme disease symptom presentation and severity can be used as a
diagnostic tool (in the form of the total symptom index score), although differences
between the sexes cannot be used reliably. Musculoskeletal symptoms appeared to show
a distinct difference based on both age and sex, but the other symptom categories did not
maintain this difference.
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Lastly, seasonality of Lyme disease infection was not associated with symptom
presentation or severity of reported symptoms. There was no correlation between the
month of tick exposure and the severity and frequency of Lyme disease symptoms.
Overall, the study proposed that the differences in symptom presentation based on
age and sex could lead to a decrease in the rate of misdiagnosis and under-diagnosis of
Lyme disease in the general population. The finding that there were few differences
between males and females in their experience of Lyme disease symptoms is important.
Many hard to diagnose autoimmune diseases can be mistaken for Lyme disease and are
found more prominently in one sex over the other. Removing sex from the diagnosis can
help narrow the diagnostic search for root cause of disease. The following chapter will
extrapolate on these ideas more fully.
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Chapter 5: Discussion, Conclusions and Recommendations
Introduction
Although Lyme disease is currently the most frequently reported vector-borne
illness in the United States, recent evidence from the CDC suggests that the estimates of
Lyme disease prevalence from the National Notifiable Disease Surveillance System
(NNDSS) may be inaccurate and actual prevalence levels may be much higher (Binder et
al., 2012; Borchers et al., 2015; CDC, 2015; Mead., 2015). Lyme disease typically
presents with many symptoms that can be mistaken for a wide variety of other diseases,
which can complicate the diagnosis. Unfortunately, the only way to ensure complete
recovery after treatment with no long term functional disabilities is to receive treatment
while still in the early localized stage of infection (Aucott et al., 2013; Miraflor et al.,
2016).
The purpose of this study was to determine the predictive value of symptom
frequency and severity to diagnose Lyme disease at an earlier stage of infection, and the
possible confounding effects of sex, age, and seasonality of infection. The results of this
study suggest that novel diagnostic symptom patterns can significantly predict a
diagnosis of Lyme disease at an earlier stage of infection, which may lead to dramatic
improvements in health outcomes for afflicted patients.
Females over 30 years of age experienced musculoskeletal symptoms more
frequently and with greater severity than their male counterparts. In addition, the
presence of the musculoskeletal, neurological, cognitive, and cutaneous symptoms
observed in this study served as a useful diagnostic tool because musculoskeletal
symptoms appear 11 times more frequently in Lyme disease cases than in controls;
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neurological symptoms appear 12 times more frequently in Lyme disease cases than in
controls; cognitive symptoms appear 10 times more frequently in Lyme disease cases
than in controls; and cutaneous symptoms appear 144 times more frequently in Lyme
disease cases than in controls. Based on the receiver operator characteristic (ROC)
analysis, the symptom index score, generated to measure symptom frequency and
severity, can be used as a diagnostic tool. Unfortunately, no significant relationship was
found between seasonality of infection and the symptom index score measured in this
study, so the month of diagnosis was not related to the frequency or severity of
participant symptoms. The implications of the study findings in terms of advancing
knowledge in Lyme disease research will be discussed further in this chapter.
Interpretation of the Findings
Symptom Frequency and Severity
Symptom frequency and severity scores were compared between cases and
controls, males and females, and between different age groups. Significant differences
were found between cases and controls, based on sex of participants, and between certain
age groups based on symptom frequency and severity scores. Lyme disease cases of both
sexes experienced selected symptoms more frequently and with greater severity than
controls. In addition, significant differences were seen based on the age of the participant.
The specific symptom categories that contribute most to the identified difference will be
discussed in this chapter.
Sex differences. The identified differences between male and female symptom
frequency and severity scores provided some interesting results. One of the primary
differences between the male and female sex is the presence of the steroid hormone
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estrogen. While estrogen’s primary role in the body is during the reproductive cycle in
women, estrogen does have an effect on the immune system (Baker et al., 2011; Bullard
et al., 2012; Pennell et al., 2012). Molecular research suggests a possible sex basis with
estrogen regulation of the immune system response to Borrelia burgdorferi, and is an
area for future research. The focus of the current study was not based on estrogen levels,
but the effect of estrogen on the immune system’s response to an invading pathogen
provides support for the reported sex differences found in this study.
Few studies have been conducted in the United States that discuss sex and age
differences in relation to Lyme disease infection. Wormser and Shapiro (2009) found that
females were more likely to suffer from the chronic stages of infection than other stages,
although the authors do not feel this difference is related to an inherent difference
between males and females. Wormser and Shapiro attributed this increase in females with
chronic Lyme disease to misdiagnosis of Lyme disease in the earlier stages of infection.
According to the most recent available surveillance data analyzed by the CDC, 53.1% of
reported cases of Lyme disease were male (Bacon et al., 2008). Based on the 2001-2010
surveillance data, more males suffered from confirmed Lyme disease than females across
all age groups (up to age 70 years) in the United States (CDC, 2015). Data collected in
the current study does not support this trend.
European studies have found sex and age differences in Lyme disease incidence.
In a German study conducted by Wilkings and Stark (2014), 55.3% of the Lyme disease
cases in the study were female (N = 18,894). In addition, women aged 25 – 69 years old
had an increased rate of diagnosed Lyme disease (Wilkings & Stark, 2014). The data
collected by Wilking and Stark supports the data collected by Bochnickova, Szilagyiova,
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and Celec (2014) in Slovakia, Strle et al. (2013) in Slovenia, and Bennet, Stjernberg, and
Berglund (2007) in Sweden that showed a higher incidence of Lyme disease in females
over males. The current study supports the European data, but contradicts the few studies
conducted in the United States. The lack of current studies on sex differences in Lyme
disease in the United States shows an important area for continued research in the future.
Erythema migrans rash. The hallmark sign of early stage Lyme disease is the
presence of the EM rash (Binder et al, 2012; Donta, 2012; Miraflor et al., 2016).
According to Aucott et al. (2012), the EM rash appears in 70 – 80% of Lyme disease
cases, but takes on the classic bull’s eye appearance only 20% of the time. In a study
conducted by Stonehouse, Studdiford, and Henry (2010), the classic bull’s eye
appearance may actually occur in as few as 9% of cases sampled. The CDC (2015)
reported that 60 – 80% of Lyme disease cases report the EM rash. Miraflor et al. (2016)
reported that 50 – 80% of Lyme disease cases display the EM rash.
One of the few reported sex differences with Lyme disease is related to the EM
rash. In two separate studies, females were more likely to develop the EM rash than their
male counterparts and of those females who developed the EM rash; the rash was more
likely to appear in the nontypical form (Bennet et al., 2007; Strle et al., 2013). The
studies conducted by Aucott et al. (2012), Stonehouse, Studdiford, and Henry (2010) and
the CDC (2015) did not report sex differences in EM rash presentation.
The EM rash percentage (50-80%) reported by the CDC (2015), Miraflor et al.
(2016), and Aucott et al. (2012) was not supported by the current study. According to the
data collected, only 28% of case study participants experienced the EM rash, as opposed
to 60 – 80% of cases reported by Aucott et al. (2012). Of the 28% of participants who
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experienced the EM rash, female cases constituted 61% of the cases that experienced the
rash. The EM rash percentage found in the current study supported recent research
conducted by Strle et al. (2013), which determined that the EM rash was found more
frequently in female cases (58%) than male cases (42%).
In the same study by Strle et al. (2013), women who displayed the EM rash were
15 years younger than those who did not display the rash. The results from the current
study may or may not support the results presented by Strle et al. (2013). As shown in
Table 35, presence of the EM rash in women was present primarily in cases over the age
of 35, with the largest number of female cases with EM rash falling in the 50-54 year age
category. This result closely matched the data reported by Strle et al. (2013).
Unfortunately, other cutaneous symptoms were not measured in the current study so
additional comparison to Strle et al. (2013) cannot be made.
In a study conducted by Dandache and Nadelman (2008), the EM rash presence
shows a bimodal distribution. Caucasian males in age ranges 514 years and 45-54 years
reported the most cases of EM rash (Dandache & Nadelman, 2008). In addition,
Dandache and Nadelman (2008) were the first to discuss race in data reporting. The
current study did not support the reported sex and bimodal age distribution reported by
Dandache and Nadelman (2008). In the current study, females were more likely to have
the EM rash. Of the males who had the EM rash in the current study, most were above
age 55 years. In addition, the current study did not collect data on race or on participants
under 18 years of age.
Musculoskeletal symptoms. Musculoskeletal symptoms tested in the current
study include: painful joints, stiff neck, back pain, stiff joints, and sore muscles.
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Musculoskeletal symptoms are more common during the late stages of B. burgdorferi
infection, especially in the United States and with the species of Borrelia endemic to this
area of the world (Feder et al., 2006). In the current study, musculoskeletal symptoms
occurred more frequently and with greater severity in females over males; in cases more
often than controls; and between the ages of 30 and 75 years than in other age groups
below 30 years and over 75 years. Unfortunately, few other studies have been conducted
examining the variables of age and sex with regard to symptom frequency and severity.
In a European study conducted by Strle et al. (2013), sex differences were present
for arthritis symptoms. Within the patient sample (n = 60) diagnosed with Lyme arthritis,
three quarters of the patients were male (Strle et al., 2013). This significant difference
was supported even when the possibility of misdiagnosis was controlled for (Strle et al.,
2013). In a study conducted in Germany, male participants made up 52% of the subjects
positive for Lyme arthritis (Wilking & Stark, 2014). These findings have not been
supported by other published research in the United States or Europe to date and have not
been supported by the current study either.
In the current study, 46% of female cases experienced musculoskeletal symptoms
every day, while only 18% of males experienced musculoskeletal symptoms every day.
In a study conducted in Slovakia, 56% of women with Lyme disease had musculoskeletal
symptoms (Bochnickova, Szilagyiova, & Celec, 2014). In addition, 30% of female cases
from the current study classified the musculoskeletal symptoms as being completely
disabling, as opposed to only 12% of the male cases ranking the musculoskeletal
symptoms with the same severity. These results are directly contradictory to most of the
European studies conducted to date, but this difference may be directly related to the
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species of bacteria causing the infection. In the United States, Borrelia burgdorferi is the
primary causative agent of Lyme disease and typically presents with musculoskeletal
symptoms (O’Connell, 2014). In Europe, Borrelia garinii and Borrelia afzelii tend to
present with neurological symptoms (O’Connell, 2014).
Neurological symptoms. Neurological symptoms included in the current study
included: facial paralysis (Bell’s palsy), blurred vision, eye pain, ear ringing, jaw pain,
testicular/pelvic pain, and tingling/burning/numbness. Neurological symptoms occur
during the early disseminated stage of Lyme disease (Binder et al., 2012; Donta, 2012).
Neurological presentation of Lyme disease is often described as neuroborreliosis
(Koedel, Fingerie, & Pfister, 2015).
Strle et al. (2013) found that males diagnosed with Lyme neuroborreliosis made
up 60% of the study population. Unfortunately, Strle et al. only provided the age range of
participants (15-79 years) but did not provide specific data on age distribution by sex for
neuroborreliosis cases. Bochnickova, Szilagyiova, and Celec (2014) found that males
with Lyme neuroborreliosis made up 44% of the study population and morbidity occurred
between the ages 35-54 years. This morbidity was not differentiated based on sex, so
direct correlation to the current study cannot be completed. In addition, Wilking and
Stark (2014) discovered that 57% of the Lyme neuroborreliosis cases were male and
showed a bimodal distribution. The first mode occurred in males between ages 5-9 years;
the second mode occurred in males between ages 50-69 years. The current study did not
support these results.
While the current study found a significant difference in neurological symptom
frequency and severity between cases and controls and based on the age of the
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participant, there was no significant difference between neurological symptoms
experienced by the males and females in the study. The age range for cases experiencing
neurological symptoms from the current study were primarily in the 35-65 years age
range, which is consistent with previously published findings (Bochnickova, Szilagyiova,
& Celec, 2014; Bremell & Hagberg, 2011; Strle et al. 2013; Wilking & Stark, 2014).
Unfortunately, the neurological symptom results of the current study do not
support the reported results from these four European studies. All studies reported male
cases experiencing neurological symptoms more frequently than female cases
(Bochnickova, Szilagyiova, & Celec, 2014; Bremell & Hagberg, 2011; Strle et al. 2013;
Wilking & Stark, 2014). The current study shows male and female cases experiencing
neurological symptoms equally across the range of frequency and severity scores.
This discrepancy may be related to the fact that all four studies were conducted in
Europe where the causative agent for Lyme disease is different than the causative agent
present in the United States. There is strong evidence that the different species of
Borrelia produce distinctly different symptoms (O’Connell, 2014; Rizzoli et al., 2011).
Borrelia burgdorferi sensu stricto causes musculoskeletal symptoms; Borrelia afzeli
causes cutaneous symptoms; and Borrelia garinii causes neurological symptoms
(Bochnickova, Szilagyiova, & Celec, 2014). The current study did not identify the
bacterial species that caused Lyme disease in the cases. Because B. afzeli and B. garinii
are found only in Europe, the assumption was made that all cases were caused by
Borrelia burgdorferi, the causative agent for Lyme disease in the United States.
Cognitive Symptoms. Cognitive symptoms included in this category were:
disturbed sleep, poor concentration, memory loss, irritability, crying, and
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sadness/depression. Aucott et al. (2013) conducted a study that examined Post-treatment
Lyme disease syndrome (PTLDS) and the functional disability related to long term Lyme
disease symptoms. This study by Aucott et al. was the only study that examined cognitive
symptoms as outlined above. While the Aucott et al. study provided demographic
information on the study participants, the study did not make comparisons based on age
or sex. The study had 63 participants (35 males/28 females) whose ages ranged from 2075 years (Aucott et al., 2013). In addition, 43 out of the 63 study participants were
college graduates, which is similar to the education level found within the current study
case population. Lastly, Aucott et al. found that one-third of the study participants
experienced cognitive symptoms at the end of the study.
In the current study, cognitive symptoms were found more frequently and with
greater severity in cases over controls and upon comparison between age groups. No
significant difference was found based on sex. Cognitive symptoms associated with
Lyme disease have not been studied extensively, partially due to the controversy over
whether PTLDS and chronic Lyme disease exist. Cognitive symptoms are not typically
found in the early stages of infection, but do show up in the later stages (Aucott, Seifter,
& Rebman, 2012). In the current study, comparisons were not made based on length of
time from diagnosis, so participants may have been in the later stages of infection where
cognitive symptoms would occur.
General symptoms. Analysis of general symptom frequency and severity results
are complicated. All of the symptoms are not cause specific and can occur in relation to
many different infections. General symptoms included in the current study were fatigue,
fever, chills, headaches, sore throat, persistent swollen glands, dizziness, lightheadedness,
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nausea, diarrhea, and night sweats. For example, fever and chills are generated in
response to a bacterial or viral infection, so the presence of these two symptoms in both
the case and control groups was not surprising (Mayo Clinic, 2015). Dizziness,
lightheadedness and headache also have a wide variety of causes including infection,
inner ear problems, eye problems, and blood pressure issues (Mayo Clinic, 2015).
Each symptom could have multiple causes. Cases and controls were only selected
based on Lyme disease status. No one was excluded based on the presence of another
illness, so the presence of the general category symptoms in both groups was expected.
Comparisons of frequency and severity scores between cases and controls and males and
females based on the whole group of symptoms did reach the level of statistical
significance. Because many of the symptoms found in the general symptom category are
also present during the early localized stage of Lyme disease, further exploration of this
group of symptoms in diagnosis is warranted.
Age differences. The immune system undergoes extensive changes as a person
ages (Giefing-Kroll et al., 2015). Innate immune cells, like macrophages and dendritic
cells, lose the ability to effectively present foreign antigens to T-lymphocytes for
activation (Giefing-Kroll et al., 2015). In addition, thymus function declines with age so
T-lymphocyte maturation is reduced leading to fewer T-lymphocytes available to fight
infection (Giefing-Kroll et al., 2015). Lastly, effective antibody production also declines
with age (Giefing-Kroll et al., 2015). Sex-differences of the immune system level off
with declining production of estrogen by the ovaries as a woman ages (Giefing-Kroll et
al., 2015).
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Lyme cases displayed a significant difference from controls with regards to both
symptom frequency and severity. Symptom frequency and severity scores for cases
increased progressively as the case ages increased, with the highest frequency and
severity scores falling in the 35-60 age range. Females made up 2/3 of both the case and
control populations and most were under 60 years of age. Sixty-four percent of female
cases and 69% of female controls had not completed menopause yet. Estrogen effects
were equal between both groups, so differences in symptom frequency and severity
related to age were based on Lyme disease differences.
In a study conducted by Nelson et al. (2015), Lyme disease incidence supported
the CDC bimodal distribution of cases based on age. Males aged 5-9 years and
males/females aged 60-64 had the highest incidence rate of Lyme disease (Nelson et al.,
2015). In addition, physician diagnosed Lyme disease showed an increased incidence in
females aged 15-44 years (Nelson et al., 2015). The study by Nelson et al. did not
examine specific symptoms associated with Lyme disease, but the study does support the
increased incidence of Lyme disease found in the current study population.
Unfortunately, few studies have been conducted on symptom frequency and severity of
Lyme disease symptoms based on age and sex. Reported differences in specific symptom
presentation have been discussed previously in this chapter.
Seasonality of infection. In the current study, no differences in symptom
presentation based on sex and age were found related to month of tick exposure or month
of diagnosis. Lyme disease transmission to a susceptible host is dependent on the tick life
cycle and availability of host-tick interactions (Moore et al., 2014). Cases in the current
study were exposed to the Ixodes tick during either late spring or early fall, which is
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typical for tick questing and feeding behaviors (Moore et al., 2014). Month of diagnosis
varied among cases dependent mainly on whether the EM rash was present or the tick
was discovered. Based on the current study data, the largest number of cases occurred in
May (n = 34) and June (n = 29).
In addition, a large number of cases were diagnosed in January (n = 21). This
winter diagnosis may be because the EM rash was not present and/or no tick was
discovered. According to Moore et al. (2014), temperature and moisture levels can affect
the length of time tick questing and feeding behaviors continue. With a warm or moist
fall, ticks are able to seek blood meals later in the season leading to later cases of Lyme
disease (Moore et al., 2014). In addition, warmer weather in fall or spring encourages
humans to spend more time outdoors, allowing for the opportunity for the human-tick
interaction to occur (Moore et al., 2014). No matter what month tick exposure or
diagnosis occurred, there was no significant difference in the way symptoms presented in
cases.
Theoretical Framework
The CDC outbreak investigation model was used as a basis for the current study.
Ultimately, this model is designed to determine the causative agent involved in a disease
outbreak and prevent the continued spread of the disease. Lyme disease surveillance has
been limited, resulting in the under-reporting of Lyme disease cases (Hinkley et al.,
2014). According to Hinkley et al (2014), the number of actual cases of Lyme disease in
the United States in 2008 was between 288,000 and 440,000 people based on clinical
laboratory tests performed. The number of cases reported to the CDC was only 38,000.
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Results from the current study can be used to reduce the number of under-reported (and
untreated) cases of Lyme disease in the United States.
Lyme disease symptoms frequency and severity are associated with both sex and
age as supported by the statistically significant differences found between cases and
controls, males and females (for certain symptoms categories), and various age groups.
The differences in symptom frequency and severity can be used to aid in the early
diagnosis of Lyme disease. In addition, the Lyme disease symptom frequency and
severity symptom index score can be used as a diagnostic tool. Odds ratio calculations
were performed based on the symptom index score. The musculoskeletal (OR = 11),
neurological (OR = 12), cognitive (OR = 10) and cutaneous (OR = 144) symptoms all
displayed significant variation between cases and controls. Clinical symptom observation
would fall under the “physician-based surveillance” method (Ertel, Nelson, & Carter,
2012, pg. 246).
Ertel, Nelson, and Carter (2012) examined the importance of physician-based
surveillance methods compared to laboratory-based surveillance methods alone or in
combination with physician-based surveillance. A combination method of laboratory
diagnosis with physician surveillance provided the most complete and accurate
surveillance information for case reporting in the earliest stages of infection (Ertel,
Nelson, & Carter, 2012). The calculated odds ratios and the observed differences between
Lyme disease cases and controls in symptom frequency and severity found in the current
study support physician-based surveillance in the diagnosis and reporting of Lyme
disease cases.
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Limitations of the Study
One of the main limitations for this study was sampling bias. Cases needed to be
Lyme disease positive. This fact reduces the ability to have a true random sample
population. The sampling bias was addressed in several ways. At the primary care site,
cases were selected at random based on the daily appointment schedule. During the study
period, cases who came in for an appointment (whether the appointment was Lyme
disease related or not) were enrolled in the study. In addition, controls were selected
based on the daily appointment schedule (for non-Lyme disease patients) or because the
control was at the primary care site with a patient. At the secondary site, ROSS scales
were distributed at a variety of meetings on campus to anyone who was in attendance at
the meeting. This method for selection of meetings and campus groups allowed for some
random sampling of the population.
Matching was also utilized to reduce sampling bias (Mann, 2003; Zondervan,
Cardon, & Kennedy, 2002). First, matching was performed based on state of residence
for participants. All participants came from one of the 14 Lyme endemic states for
inclusion in the study. The endemic states include Pennsylvania, New York, New Jersey,
Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire,
Rhode Island, Vermont, Virginia, and Wisconsin (CDC, 2015). The Lyme endemic states
correspond to the habitat of the Ixodes tick, the vector for Lyme disease in the United
States. States of residence for both cases and controls included Connecticut,
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, and Vermont.
State of residence matching required at least one case and one control from a state in
order for the study participant to remain in the study.
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In addition, no cases or controls were enrolled in the study from Wisconsin or
Minnesota. During data collection, a new species of bacteria was linked to Lyme disease
– Borrelia mayonii. Currently, this species of Borrelia has only been identified in
Wisconsin and Minnesota. At the time of the bacteria’s discovery, there were no cases or
controls that resided in either Wisconsin or Minnesota, so complications associated with
the new species of Borrelia were not introduced into the current study.
The second type of matching performed was frequency matching. Frequency
matching based on sex was performed so that the sample population did not contain a
single sex in cases or controls (Schlesselman, 1982). Females made up 64% of the case
population and 69% of the control population. Males made up 36% of the case population
and 31% of the control population. In addition, a case (n = 203) to control (n = 388) ratio
of approximately 1:2 was used to reduce sampling bias.
Matching on education level was performed. While educational level was not a
variable under study, the secondary site was a college campus. Matching on educational
level became an important consideration as advanced educational level can change
socioeconomic status and effect, specifically, access to health care. Because all but five
of the cases came from the primary care site, a matching of cases between collection sites
based on educational level was not necessary. Matching between controls based on
educational level was explored. While the population was not matched person for person,
participants with at least a college degree were matched by percentage of the total
population at both sites. In addition, all cases and controls had at least a high school
education. With all three types of matching performed to minimize sampling bias,
generalizability of study results beyond the sampled population was insured.
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An additional limitation of this study was recall bias. Recall bias occurs when
cases recall exposures more frequently than controls (Hassan, 2005; Pannucci et al.,
2010; Schulz & Courtright, 2002). This differential recall between cases and controls can
be intentional or unintentional (Hassan, 2005). This recall difference often occurs
because the cases spend more time trying to determine what exposure may have led to
their disease state (Pannucci et al., 2010; Schulz & Courtright, 2002). In addition, the
amount of time between an occurrence and the remembrance of an occurrence can
contribute to the problem (Hassan, 2005; Pannucci et al., 2010). The longer the time
frame, the more likely recalled data may be distorted (Hassan, 2005).
To reduce recall bias, all participants were asked to fill out a ROSS scale. The
ROSS scale collects symptoms for the week prior to the date the form is filled out, so the
amount of time between symptom occurrence and recall is minimized. The ROSS scale is
completed at each visit to the primary care clinic, so symptoms in cases were verified by
comparison to the previous visit’s ROSS scale.
An additional way to address recall bias is to use an instrument with a high degree
of validity (Hassan, 2005). Data for this study was collected using a modified Burrascano
Symptom Checklist that is based on the Wahler Physical Symptoms Inventory (PSI),
which has demonstrated previously to have a high level of internal consistency on testretest scores over several different subgroups (Wahler, 1968). The PSI collects data on
the frequency of general symptoms associated with most any illness, but does not
specifically address severity of symptoms. A modified version of the PSI was created by
Burrascano (2008) to address the specific symptoms associated with Lyme disease and
the severity of those symptoms. A modified version of the Burrascano Symptoms
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Checklist (ROSS scale) was created by my clinical partner to address the needs of his
practice. The only modification in both the Burrascano Symptom Checklist and the PSI
was to reduce the number of symptoms surveyed. Symptoms surveyed were specific to
Lyme disease; all other symptoms were removed.
One additional limitation of note was the fact that most cases (n = 198) came from
a single clinical practice. The clinical practice treats a large number of Lyme disease
patients each year, some of whom are in the later stages of infection. Because this clinical
practice specializes in Lyme disease and treats patients in the later stages of infection,
reported symptom frequency and severity may reflect long term infection. All cases were
not necessarily in the same stage of infection.
The use of the EM rash as a diagnostic tool for identifying cases is also a
limitation. Based on the CDC criteria for reporting cases to the NNDSS, presence of the
EM rash is a positive indicator of Lyme disease and no further testing is required (CDC,
2015). In addition, both the IDSA and ILADS accept the presence of the EM rash as a
positive indicator of Lyme disease and don’t require further testing to confirm the
diagnosis (Cameron, Johnson, & Maloney, 2014; Wormer et al., 2006). The current study
only identified the EM rash in 28% of cases and other studies found the EM rash didn’t
follow the classic bull’s eye pattern (Aucott et al., 2012; Bennet et al., 2007; Stonehouse,
Studdiford, & Henry, 2012; Strle et al., 2013). If the presence of the EM rash is
considered a gold standard for diagnosis and not all cases of Lyme disease experience the
EM rash, other avenues to early diagnosis must be explored.
The final study limitation also leads into areas for further research. All data
collected was self-reported. While case data could be confirmed via patient medical
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records, control data could not be independently verified. Unfortunately, the study
required participant self-reporting of symptoms and severity. All cases and controls
received the same forms, were allowed take as much time as needed to fill the forms out,
and were assured of the completely anonymous nature of the form as no personal
identifiers were included on the form.
Future Research
Symptoms, by definition, are subjective since they are experienced only by the
person describing them. The severity of a symptom is also subjective; what one person
experiences as debilitating pain may be considered minor by another. This difference in
symptom reporting and severity may be related to sex. In a review of the literature
conducted by Barsky, Peekna, and Borus (2001), women consistently reported “more
intense, more numerous, and more frequent bodily symptoms than men” (pg. 266).
Kroenke and Spitzer (1998) found that symptom reporting was significantly higher in
women than in men, regardless of the symptom type surveyed.
Some of the symptoms in the current study were included in the Barsky, Peekna,
and Borus (2001) and the Kroenke and Spitzer (1998) studies. These symptoms included
headache, nausea, fatigue, palpitations, joint pain, and back pain (Barsky, Peekna, &
Borus, 2001; Kroenke & Spitzer, 1998). Joint and back pain was assessed as part of the
musculoskeletal category of symptoms when analyzing study data and displayed a
significant difference between males and females in the current study. Headache, nausea,
and fatigue were included in the general category of symptoms and were only included in
the total symptom index score. Palpitations were included in the cardiac category of
symptoms and was only included in the total symptom index score.
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In cases where a specific disease was experienced, these sex differences in
symptom reporting disappeared (Barsky, Peekna, & Borus, 2001; Davis, 1981; Eskelinen,
Ikonen, & Lipponen, 1994; Katz & Criswell, 1996; Macintyre, 1993; Marshall & Funch,
1986). Katz and Criswell (1996) studied rheumatoid arthritis, an autoimmune disease.
Eskelinen, Ikonen, and Lipponen (1994) studied acute appendicitis, caused by a bacterial
infection, and Macintyre (1993) studied the common cold, caused by a virus. Lastly,
Marshall and Funch (1986) studied colorectal cancer. Since the current study was based
on a specific disease (Lyme disease), the sex differences in reporting may also be
minimal.
Many of the research studies cited are older studies; the current focus of sex
differences in symptom reporting has shifted to specific diseases and variations in
reporting based on age group. Macintyre, Hunt, and Sweeting (1996) suggested that
gender differences in symptom reporting vary over the course of a person’s lifetime. Both
sex and age based differences in Lyme disease symptom reporting across a period of time
would make an interesting area to explore next.
An additional area for future research focuses on the biological differences related
to the immune system response to an infection. Pennell et al. (2012) discussed the
differences in immune system responses based on genes contained on the X-chromosome
and the presence of miRNA. While genetic influences were not a part of the current
study, sex based differences in symptom presentation, frequency and severity could be
related to the physical differences in how the immune system reacts to the Borrelia
bacteria. The X-chromosome contains miRNA; the Y-chromosome does not (Pennell et
al., 2012). miRNAs are thought to regulate transcription of certain genes, some of which
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regulate the immune system response (Pennell et al., 2012). Genetic mapping of miRNAs
from case X-chromosomes may present some insight into the symptom presentation
differences found in the current study.
Positive Social Change Implications
The suggested implications of this research for positive social change include
increased knowledge of the sex differences found in Lyme disease; prevention of delays
in diagnosis and treatment for patients with Lyme disease; decreased expenses associated
with late Lyme disease due to increased diagnosis in the early stage of infection; and
early access to needed health care services.
Based on the results of the current study, presence of the EM rash and the
musculoskeletal symptoms examined in this study displayed a significant difference
based on both sex and age variables. The EM rash did not occur as frequently overall as
reported in previous studies; the EM rash only appeared in 28% of cases in the current
study (Binder et al., 2012; Donta, 2012; Franz & Krause, 2003; Girschick et al., 2009;
Miraflor et al., 2016; Wormser et al., 2006). Of the 28% of cases that reported the EM
rash, 56% were women over the age of 35 years. Musculoskeletal symptoms were present
with greater frequency and severity in female cases over male cases.
In addition, this significant difference extended to case/control differences.
Significant differences between cases and controls were also found for the overall
symptom index scores, as well as the specific symptoms in the neurological and cognitive
categories. Because all of the symptoms of Lyme disease can be associated with another
disease or condition, information regarding the occurrence of these groups of symptoms
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in Lyme disease cases will help with the earlier diagnosis of the disease (Henry et al.,
2012).
Based on a recent online survey conducted by Lymedisease.org, only 7% of the
6,000 study participants were diagnosed within the first month after the initiation of
symptoms (Lymedisease.org, 2015). Most research suggests that earlier treatment
provides the patient’s best chance for a full recovery (Cameron, 2007; Donta, 2012;
Johnson & Stricker, 2004). Once treatment is initiated, 80-90% of patients significantly
improve (CDC, 2015). Delaying treatment can be costly, both in patient health costs and
in reduced quality of life (Johnson et al., 2011). Zhang et al. (2006) determined that the
annual health care costs associated with late Lyme disease treatment ($16,199 per person)
can be 12 times higher than those costs associated with early Lyme disease treatment
($1,310 per person).
During the early stage of infection, treatment with beta-lactam antibiotics is
highly successful at killing the bacteria and stopping the progression of the infection
(Binder et al., 2012; Cameron, 2007; Donta, 2012; Franz & Krause, 2003; Girschick et
al., 2009; Johnson & Stricker, 2004; Muellegger, 2004; Wormser et al., 2006). Late phase
infections may require longer term or intravenous treatments with antibiotics (Binder et
al., 2012; Cameron, 2007; Donta, 2012; Franz & Krause, 2003; Girschick et al., 2009;
Johnson & Stricker, 2004; Muellegger, 2004; Wormser et al., 2006). Unfortunately,
antibiotic treatment for late phase infections does not always result in a complete
recovery with no symptoms (Johnson et al., 2011). It is in these instances that posttreatment Lyme disease syndrome and/or chronic Lyme disease may be the diagnosis.
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Because late phase manifestations can be incapacitating, adults could be burdened
with “functional impacts” of Lyme disease (Aucott et al., 2013, p 2). Functional impacts
occur when a patient experiences symptoms, and/or increased severity of symptoms, that
prevent them from completing daily activities (Aucott et al., 2013). These functional
impacts may include loss of job, loss of productivity, lapse of insurance coverage, and
disability (Johnson et al., 2011). In fact, loss of productivity makes up more than half the
costs of late Lyme disease infection (Johnson et al., 2011). Early, accurate diagnosis of
Lyme disease can prevent all of these impacts by stopping the spread of the infection
before the serious complications of late Lyme disease occur.
Early, accurate diagnosis of Lyme disease is so important to recovery that the
federal government is working on legislation to improve the possibility for early
detection. In the House of Representatives, HR 4701 – “Vector-Borne Disease Research
Accountability and Transparency Act of 2014” passed in September 2014. This act
establishes an advisory committee to examine all aspects of Lyme disease including
research, diagnosis and treatment and includes all stages of Lyme disease, including the
heavily disputed chronic Lyme disease stage (Lyme Disease Association, 2016). In the
U.S. Senate, The Lyme and Tick-Borne Disease Prevention, Education, and Research Act
of 2015 was proposed in July 2015. This act provides more federal government action in
the development of education and prevention programs, along with enhanced research
support for diagnosis and treatment options for Lyme disease patients (Lyme Disease
Association, 2016). Vital to creation of federal legislation are research findings to provide
insights into the highly complex disease that is Lyme disease. The current study may be
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used to provide additional insights into sex and age differences in symptom presentation
of Lyme disease.
In addition, 18 states have proposals under consideration to become laws (Lyme
Disease Association, 2016). Currently, eleven of those states have some type of law in
place to allow extended treatments for Lyme disease patients and to protect physicians
from medical hearing and licensing issues related to extended Lyme disease treatments.
Proposals that require insurance companies to pay for extended treatments are also being
considered. Each of these instances provide Lyme disease patients the opportunity for
access to the necessary treatments for complete recovery once the infection has moved
beyond the early stages of infection.
Methodological Implications
The current study followed a quantitative quasi-experimental methodology. A
case/control prospective study was conducted to determine whether frequency and
severity of Lyme disease symptoms were different in males and females or based on the
age of the individual. In addition, the current study sought to determine if Lyme disease
symptom frequency and severity could be used as a diagnostic tool through calculation of
a symptom index score.
This method was well suited for data collection and analysis to answer the
research questions posed. A few changes to the study design would improve the outcome
slightly. Additional locations for control enrollment would help boost the sample size of
the population. Surprisingly, case enrollment was easy. The minimum number of cases
required to reach statistical significance was quickly reached. Unfortunately, control
enrollment was more difficult. A secondary site was required to locate and enroll enough
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controls to reach the 1:2 case to control ratio needed to reduce the sampling bias present
in the study.
The ROSS scale has been used by the primary care clinic physician for many
years and is a modification of a validated instrument. Despite this fact, the ROSS scale
has not been validated on its own. Comparing reported results within the study population
(N = 591), participant answers displayed consistent reporting across the entire study
population, which provides some support for the validity of the instrument. In addition,
evidence of consistency from patient medical records is present. Patients at the primary
care clinic fill out the ROSS scale at each visit, so consistency is present from form to
form.
Lastly, race/ethnicity information was not collected in the current study, but a
recently published study conducted by Nelson et al. (2016) suggested that Lyme disease
among the Hispanic population in Lyme endemic states is increasing. Lyme disease
displayed the same bimodal age distribution in the Hispanic population that is reported
overall for Lyme disease (Nelson et al., 2016). This bimodal distribution was slightly
skewed to older age groups (Nelson et al., 2016). In addition, Hispanic males were
reported to have Lyme disease more frequently than Hispanic females (Nelson et al.,
2016). One interesting finding from the Nelson et al. study was that Hispanic males and
females are often diagnosed at a later stage of infection than their Caucasian counterparts.
Lack of access to health care was the proposed cause.
In an earlier study conducted in Connecticut, Caucasians made up 82% of the
reported cases of Lyme disease and Hispanics made up only 1% of the sample population
(Ertel, Nelson, & Carter, 2012). Surveillance data from the CDC list Lyme disease as a
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primarily Caucasian disease with 94% of all reported cases for 1992-2006, with Blacks,
Asians/Pacific Islanders, and American Natives/Alaskan Natives making up the other 6%
(CDC, 2008). In the case of African Americans, inability to recognize the EM rash may
lead to misdiagnosis in the early stage of infection (Borchers et al., 2015). No ethnicity
data was available at all and data for the time period 2006-2015 was not available. More
studies on race/ethnicity variations in Lyme disease are required.
Recommendations
Diagnosis of Lyme disease continues to be a controversial topic. The efficacy of
the two-tiered testing method recommended by the CDC is consistently called into
question (Donta, 2012; Moore, 2015; Stricker & Johnson, 2011). Typically, the issue is
related to when the two-tiered testing is performed. The first step in the two-tiered testing
process is an enzyme immunoassay (EIA), which looks for IgM and IgG antibodies to
Borrelia (Borchers et al., 2015). The second test is the Western Blot (Moore, 2015).
Unfortunately, antibody production takes some time after exposure to an antigen – IgM
antibodies develop first but can take up to two weeks to be found in measureable
quantities (Borchers et al., 2015). IgG antibodies develop later in the infection and are not
found in measureable quantities until 4-6 weeks after the initial infection (Borchers et al.,
2015). In addition to this delay in production, the EIA and Western Blot tests cannot
distinguish between old and new infections (Borchers et al., 2015). Lastly, the cost of the
two-tiered testing method has increased in recent years. According to Hinkley et al
(2014), the cost of two-tiered testing for Lyme disease in 2008 was $492 million. As the
cost of laboratory testing increases, a viable option for diagnosis must be found.
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In addition to the problems associated with the two-tiered testing methods, a
second imperfect diagnostic method is the presence of the EM rash (Binder et al., 2012;
CDC, 2015; Donta, 2012; Franz & Krause, 2003; Girschick et al., 2009; Miraflor et al.,
2016; Wormser et al., 2006). The current study, as well as other studies, showed that the
EM rash does not occur in all cases of Lyme disease (Aucott et al., 2012; Bennet et al.,
2007; Miraflor et al., 2016; Stonehouse, Studdiford & Henry, 2010; Strle et al., 2013). If
the EM rash is present, it may have a non-typical appearance (Aucott et al., 2012).
Lastly, PCR and bacterial culturing from infected tissues are alternative testing
methods that can be used to confirm diagnosis (Borchers et al., 2015). Both methods are
expensive, time-consuming, and not always successful (Borchers et al., 2015). Waiting
for results from both PCR and bacterial culturing would delay treatment as well
(Borchers et al., 2015).
With these issues in mind, finding alternative methods for diagnosis is important.
The symptom index scoring (SIS) system is based on symptom frequency and severity as
experienced by the patient. The SIS system can be used at the initial visit independent of
when the tick exposure happened or whether enough time has elapsed for antibodies to be
produced. The SIS system’s only requirement is computer access and the computational
Excel spreadsheet developed as part of the current research study. While the SIS system
is not a standalone diagnostic tool, it can be used during any stage of infection and will
help to identify possible Lyme disease cases.
Conclusions
Lyme disease is a vector-borne disease that is caused by the bacteria Borrelia
burgdorferi and transmitted to susceptible hosts via the Ixodes scapularis and Ixodes
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pacificus ticks in the United States. Lyme disease is endemic to 14 states, primarily
located in the northeastern section of the United States. As the habitat for the tick vector
expands, the incidence of Lyme disease will increase in new states along the border for
the current endemic region.
Based on the results of the current research study, Lyme disease symptom
frequency and severity display significant differences based on biological sex and age. In
addition, odds ratio variations support these differences. The likelihood of an individual
experiencing musculoskeletal symptoms with Lyme disease is 11 (95% CI: 6.34, 18.49)
times higher than experiencing those symptoms in the absence of Lyme disease. The
likelihood of an individual experiencing neurological symptoms with Lyme disease is 12
(95% CI: 7.90, 19.48) times more likely than experiencing neurological symptoms in the
absence of Lyme disease. The likelihood of an individual experiencing cognitive
symptoms with Lyme disease is 10 (95% CI: 5.24, 17.30) times more likely than
experiencing cognitive symptoms in the absence of Lyme disease. The likelihood of an
individual experiencing cutaneous symptoms with Lyme disease is 144 (95% CI: 19.72,
1048.73) times more likely than experiencing cutaneous symptoms in the absence of
Lyme disease. Each of these symptoms can then be used to help diagnose Lyme disease
at an early stage of infection, where treatment will be the most successful.
The symptom index scoring (SIS) system can provide assistance in the diagnosis
of Lyme disease at any stage of infection. A minimal calculated score of 3.7 or higher in
the SIS system is suggestive of Lyme disease infection. The SIS system has 82%
sensitivity and 78% specificity using the 3.7 point score. While not a perfect test, it can
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be another weapon in the arsenal for early Lyme disease diagnosis. The earlier the
diagnosis, the more likely the disease outcome will be positive.

184

References
Alao, O. R. & Decker, C. F. (2012). Lyme disease. Disease-a-Month, 58, 335-345.
American Heart Association. (2013). Heart attack symptoms in women. Retrieved June
15, 2013, from
http://www.heart.org/HEARTORG/Conditions/HeartAttack/WarningSignsofaHea
rtAttack/Heart-Attack-Symptoms-in-Women_UCM_436448_Article.jsp.
Arsnoe, I. M., Hickling, G. J., Ginsberg, H. S., McElreath, R., & Tsao, J. I. (2015).
Different populations of blacklegged tick nymphs exhibit differences in questing
behavior that have implications for human Lyme disease risk. PLOS ONE, 10(5),
1-21.
Arthritis Foundation. (2014). Understanding arthritis. Retrieved January 8, 2014, from
http://www.arthritis.org/conditions-treatments/understanding-arthritis/.
Aucott, J. N., Crowder, L. A., & Kortte, K. B. (2013). Development of a foundation for a
case definition of post-treatment Lyme disease. International Journal of
Infectious Diseases, 17(6), e443-449.
Aucott, J. N., Crowder, L. A., Yedlin, V., & Kortte, K. B. (2012a). Bull’s eye and nontarget skin lesions of Lyme disease: An internet survey of identification of
erythema migrans. Dermatology Research and Practice, 2012, Article ID 451727,
1-6. doi:10.155/2012/451727
Aucott, J. N., Morrison, C., Munoz, B., Rowe, P. C., Schwarzwalder, A., & West, S. K.
(2009). Diagnostic challenges of early Lyme disease: Lessons from a community
case series. BMC Infectious Diseases, 9, 79-86. doi:10.1186/1471-2334-9-79

185
Aucott, J. N., Rebman, A.W., Crowder, L. A., & Kortte, K. B. (2012b) Post-treatment
Lyme disease syndrome symptomatology and the impact on life functioning: Is
there something there? Quality of Life Research, 22(1), 75-84.
doi:10.1007/s11136-012-0126-6.
Aucott, J. N. & Seifter, A. (2011).Misdiagnosis of early Lyme disease as the summer flu.
Orthopedic Reviews, 3(e14), 65-68.
Bacon, R. M., Kugeler, K. J., & Mead, P. S. (2008). Surveillance for Lyme disease –
United States, 1992-2006. Morbidity and Mortality Weekly Report, 57(SS-10), 112.
Baker, L., Meldrum, K. K., Wang, M., Sankula, R., Vanam, R., Raiesdana, A., . . .
Meldrum, D. R. (2003). The role of estrogen in cardiovascular disease. Journal of
Surgical Research, 115, 325-344.
Barsky, A. J., Peekna, H. M., & Borus, J. F. (2001). Somatic symptom reporting in
women and men. Journal of General Internal Medicine, 16, 266-275.
Belongia, E. A., Reed, K. D., Mitchell, P. D., Chyou, P. H., Mueller-Rizner, N., Finkel,
M. F., & Schriefer, M. E. (1999). Clinical and epidemiological features of early
Lyme disease and human granulocytic Ehrlichiosis in Wisconsin. Clinical
Infectious Diseases, 29, 1472-1477.
Bennet, L., Stjernberg, L., & Berglund, J. (2007). Effect of sex on clinical and
epidemiologic features of Lyme borreliosis. Vector-Borne and Zoonotic Diseases,
7(1), 34-41.

186
Binder, S. C., Telschow, A., & Meyer-Hermann, M. (2012). Population dynamics of
Borrelia burgdorferi in Lyme disease. Frontiers in Microbiology, 3(Article 104),
1-11. doi:10.3389/fmicb.2012.00104
Bochnickova, M., Szilagyiova, M., & Celec, P. (2014). Lyme disease in northern
Slovakia (1989-2010): Clinical and epidemiological characteristics.
Epidemiology: Open Access, 4(2), 1-8.
Borchers, A. T., Keen, C. L., Huntley, A. C., & Gershwin, M. E. (2015). Lyme disease: A
rigorous review of diagnostic criteria and treatment. Journal of Autoimmunity, 57,
82-115.
Bremell, D. & Hagberg, L. (2011). Clinical characteristics and cerebrospinal fluid
parameters in patients with peripheral facial palsy caused by Lyme
neuroborreliosis compared with facial palsy of unknown origin (Bell’s palsy).
BioMed Central Infectious Diseases, 11, 215-221.
Brett, M. E., Hinckley, A. F., Zielinski-Gutierrez, E. C., & Mead, P. S. (2014). U.S.
healthcare providers’ experience with Lyme and other tick-borne diseases. Ticks
and Tick-borne Diseases, 5, 404-408.
Brisson, D., Drecktrah, D., Eggers, C. H., & Samuels, D. S. (2012). Genetics of Borrelia
burgdorferi. Annual Review of Genetics, 46, 1-29.
Brosschot, J. F. & Aarsse, H. R. (2001). Restricted emotional processing and somatic
attribution in fibromyalgia. International Journal of Psychiatry in Medicine,
31(2), 127-146.
Bullard, M. K., Bir, N., Kwan, R., Cureton, E., Knudson, P., & Harken, A. (2010).
Women rule. Surgery, 147, 134-137.

187
Bundoc, V. G. & Barbour, A. G. (1989). Clonal polymorphisms of outer membrane
proteinOspB of Borrelia burgdorferi. Infection and Immunity, 57(9), 2733-2741.
Burrascano Jr., J. J. (2008). Advanced topics in Lyme disease: Diagnostic hints and
treatment guidelines for Lyme and other tick borne illnesses (16thed.). Retrieved
from http://www.lymenet.org/BurrGuide200810.pdf.
Caimano, M. J., Hu, L. T., Radolf, J. D., & Stevenson, B. (2012). Of ticks, mice, and
men: Understanding the dual-host lifestyle of Lyme disease spirochaetes. Nature
Reviews Microbiology, 10(2), 87-99.
Cairns, V. & Godwin, J. (2005). Post-Lyme borreliosis syndrome: A meta-analysis of
reported symptoms. International Journal of Epidemiology, 34, 1340-1345.
Caliendo, M. V., Kushon, D. J., & Helz, J. W. (1995). Delirium and Lyme disease.
Psychosomatics, 36(1), 69-74.
Cameron, D. J. (2007). Consequences of treatment delay in Lyme disease. Journal of
Evaluation in Clinical Practice, 13, 470-472.
Cameron, D. J. (2010). Proof that chronic Lyme disease exists. Interdisciplinary
Perspectives on Infectious Diseases, 2010, Article ID 876450, 1-4.
doi:10.1155/2010/876450.
Cameron, D. J., Johnson, L. B., & Maloney, E. L. (2014). Evidence assessments and
guideline recommendations in Lyme disease: the clinical management of known
tick bites, erythema migrans rashes and persistent disease. Expert Review of Antiinfective Therapy, 12(9), 1103-1135.

188
Cameron, D., Gaito, A., Harris, N., Bach, G., Bellovin, S., Bock, K., . . . Stricker, R.
(2004). The International Lyme and Associated Diseases Society: Evidence based
guidelines for the management of Lyme disease. Expert Reviews: Anti-Infective
Therapy, 2(1), S1-S13. Retrieved June 1, 2013, from
http://www.ilads.org/files/ILADS_Guidelines.pdf.
Caracta, C. F. (2003). Sex differences in pulmonary disease. The Mount Sinai Journal of
Medicine, 70(4), 215-224.
Carrasco, S. E., Troxell, B., Yang, Y., Brandt, S. L., Li, H., Sandusky, G.E., Condon, K.
W., Serezani, C. H., & Yang, X. F. (2015). Outer surface protein OspC is an
antiphagocytic factor that protects Borrelia burgdorferi from phagocytosis by
macrophages. Infection and Immunology, 83, 4848-4860.
Casimir, G. J. A., Mulier, S., Hanssens, L., Knoop, C., Ferster, A., Hofman, B., &
Duchateau, J. (2010). Chronic inflammatory diseases in children are more severe
in girls. Shock, 34(1), 23-26.
Castle, S. C. (2000). Clinical relevance of age-related immune dysfunction. Clinical
Infectious Diseases, 31, 578-585.
Centers for Disease Control and Prevention (2007). Lyme disease --- United States, 20032005. Morbidity and Mortality Weekly Report, 56(23), 573-576. Retrieved
January 4, 2014, from
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5623a1.htm.
Centers for Disease Control and Prevention (2008). National Notifiable diseases
surveillance system (NNDSS): Lyme disease (Borrelia burgdorferi). Retrieved
October 15, 2012, from http://NNDSSWeb@cdc.gov.

189
Centers for Disease Control and Prevention (CDC). (2015). Lyme disease. Retrieved
August, 15, 2015, from http://www.cdc.gov/lyme/.
Chandra, A. M., Keilp, J. G., & Fallon, B. A. (2013). Correlates of perceived healthrelated quality of life in post-treatment Lyme encephalopathy. Psychosomatics,
54(6), 552-559.
Cohen, J. (1992). A power primer. Psychological Bulletin, 112(1), 155-159.
Currie, L. J., Harrison, M. B., Trugman, J. M., Bennett, J. P., & Wooten, G. F. (2004).
Postmenopausal estrogen use affects risk for Parkinson disease. Archives of
Neurology, 61(6), 886-888.
Dai, J., Narasimhan, S., Zhang, L., Liu, L., Wang, P., & Fikrig, E. (2010). Tick histamine
release factor is critical for Ixodes scapularis engorgement and transmission of
the Lyme disease agent. PLoS Pathology, 6(11), e1001205.
Dandache, P. & Nadelman, R. B. (2008). Erythema migrans. Infectious Disease Clinics,
22(2), 235-260.
Davis, M. A. (1981). Sex differences in reporting osteoarthritic symptoms: A
sociomedical approach. Journal of Health and Social Behavior, 22(3), 298-310.
Dean, A. G., Sullivan, K. M., & Soe, M.M. (2015). OpenEpi: Open source epidemiologic
statistics for public health. (Version 3.03a). Retrieved May 8, 2016 from
http://www.openepi.com/Menu/OE_Menu.htm.
Dehnert, M., Fingerle, V., Klier, C., Talaska, T., Schlaud, M., Krause, G., . . . Poggensee,
G. (2012). Seropositivity of Lyme borreliosis and associated risk factors: A
population based study in children and adolescents in Germany. PLoS One, 7(8),
1-7.

190
Deluca, J., Eisendle, K., & Zelger, B. (2013).Cutaneous and systemic Lyme disease.
Expert Review of Dermatology, 8(1), 65-82 doi:10.1586/edm.12.71
de Silva, A. M., Fish, D., Burkot, T. R., Zhang, Y., & Fikrig, E. (1997). OspA antibodies
inhibit the acquisition of Borrelia burgdorferi by Ixodes ticks. Infection and
Immunity, 65(8), 3146-3150.
de Silva, A. M., Telford III, S. R., Brunet, L.R., Barthold, S. W., & Fikrig, E. (1996).
Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme
disease vaccine. Journal of Experimental Medicine, 183, 271-275.
DeVon, H. A., Ryan, C. J., Ochs, A. L., & Shapiro, M. (2008). Symptoms across the
continuum of acute coronary syndromes: Differences between women and men.
American Journal of Critical Care, 17(1), 14-25.
DeVon, H. A. & Zerwic, J. J. (2002). Symptoms of acute coronary syndromes: Are there
sex differences? A review of the literature. Heart & Lung, 31(4), 235-245.
Dey, S. Flather, M. D., Devlin, G., Brieger, D., Gurfinkel, E. P., Steg, P. G.,. . .Eagle,
K.A. (2009). Sex-related differences in the presentation, treatment and outcomes
among patients with acute coronary syndromes: the Global Registry of Acute
Coronary Events. Heart, 95, 20-26.
Donta, S. T. (2012). Issues in the diagnosis and treatment of Lyme disease. The Open
Neurology Journal, 6(S1-M8), 140-145.
Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine.
Science, 196(4286), 129-196.

191
Ertel, S. H., Nelson, R. S., & Cartter, M. L. (2012). Effect of surveillance method on
reported characteristics of Lyme disease, Connecticut, 1996-2007. Emerging
Infectious Diseases, 18(2), 242-247.
Eskelinen, M., Ikonen, J., & Lipponen, P. (1994). Contributions of history-taking,
physical examination, and computer assistance to diagnosis of acute small-bowel
obstruction. A prospective study of 1333 patients with acute abdominal pain.
Scandinavian Journal of Gastroenterology, 29(8), 715-721.
Esposito, S., Bosis, S., Sabatini, C., Tagliaferri, L., & Principi, N. (2013). Borrelia
burgdorferi infection and Lyme disease in children. International Journal of
Infectious Diseases, 17, e153-e158.
Fairweather, D. L., Petri, M.A., Coronado, M. J., & Cooper Jr., L. T. (2012).
Autoimmune heart disease: Role of sex hormones and autoantibodies in disease
pathogenesis. Experts Review Clinical Immunology, 8(3), 269-284.
Feder, Jr., H. M., Abeles, M., Bernstein, M., Whitaker-Worth, D., & Grant-Kels, J. M.
(2006). Diagnosis, treatment, and prognosis of erythema migrans and Lyme
arthritis. Clinics in Dermatology, 24, 509-520.
Finch, C., Al-Damluji, S., Krause, P. J., Niccolai, L., Steeves, T., O’Keefe, C. F., &
Diuk-Wasser, M. A. (2014). Integrated assessment of behavioral and
environmental risk factors for Lyme disease infection on Block Island, Rhode
Island. PLOS ONE, 9(1), 1-8.
Franz, J. K. & Krause, A. (2003).Lyme disease (Lyme borreliosis). Best Practice &
Research Clinical Rheumatology, 17(2), 241-264. doi:10.16/S15216942(02)00129-8

192
Free Dictionary. (2013). Age. Retrieved December 20, 2013, from
http://www.thefreedictionary.com/age.
Free Dictionary. (2013). Presenting symptom. Retrieved December 20, 2013, from
http://medical-dictionary.thefreedictionary.com/Presenting+symptom.
Free Dictionary. (2013). Symptom severity. Retrieved December 20, 2013, from
http://medical-dictionary.thefreedictionary.com/symptom+severity.
Fu, L., Bundy, C., & Sadiq, S. A. (2011). Psychological distress in people with
disfigurement with facial palsy. Eye, 25, 1322-1326.
Gerstenblith, T. A. & Stern, T. A. (2014). Lyme disease: A review of its epidemiology,
evaluation, and treatment. Psychosomatics, 55, 421-429.
Giefing-Kroll, C., Berger, P., Lepperdinger, G., & Grubeck-Loebenstein, B. (2015). How
sex and age affect immune responses, susceptibility to infections, and response to
vaccination. Aging Cell, 14, 309-321.
Girschick, H. J., Morbach, H., & Tappe, D. (2009).Treatment of Lyme borreliosis.
Arthritis Research & Therapy, 11(6), 258-268. doi:10.1186/ar2853
Gisjbers van Wijk, C. M. & Kolk, A. M. (1997). Sex differences in physical symptoms:
The contribution of symptom perception theory. Social Science & Medicine,
45(2), 231-246.
Glass, G. E., Schwartz, B. S., Morgan III, J. M., Johnson, D. T., Noy, P. M., & Israel, E.
(1995). Environmental risk factors for Lyme disease identified with geographic
information systems. American Journal of Public Health, 85(7), 944-948.

193
Glickstein, L., Moore, B., Bledsoe, T., Damle, N., Sikand, V., & Steere, A. C. (2003).
Inflammatory cytokine production predominates in early Lyme disease in patients
with erythema migrans. Infection and Immunity, 71(10), 6051-6053.
Grimm, D., Tilly, K., Byram, R., Stewart, P. E., Krum, J. G., Bueschel, D. M., . . . Rosa,
P. A. (2004). Outer-surface protein C of the Lyme disease spirochete: A protein
induced in ticks for infection in mammals. Proceedings of the National Academy
of Science, 101(9), 3142-3147.
Haaxma, C. A., Bloem, B. R., Barm, G. F., Oyen, W. J. G., Leenders, K. L. Eshuis, S. .
..Horstink, M. W. I. M. (2006).Sex differences in Parkinson’s disease. Journal of
Neurology, Neurosurgery, and Psychiatry, 78, 819-824.
Hartiala, P., Hytonen, J., Suhonen, J., Lepparanta, O., Tuominen-Gustafsson, H., &
Viljanen, M. K. (2008). Borrelia burgdorferi inhibits human neutrophil function.
Microbes and Infection, 10, 60-68.
Hassan, E. (2005). Recall bias can be a threat to retrospective and prospective research
designs. The Internet Journal of Epidemiology, 3(2), 1-7.
Hassan, S., Gordon, A., & Einstein, G. (2016). Sex differences in overlapping chronic
non-cancer pain conditions in a tertiary pain clinic. Pain Management in
Medicine, 2(1), 1-5.
Heck, K. E. & Parker, J. D. (2002). Family structure, socioeconomic status, and access to
health care for children. Health Services Research, 37(1), 171-184.
Henry, B., Crabtree, A., Roth, D., Blackman, D., & Morshed, M. (2012). Lyme disease:
Knowledge, beliefs, and practices of physicians in a low-endemic area. Canadian
Family Physician, 58, e289-295.

194
Henry, B., Roth, D., Reilly, R., MacDougal, L., Mak, S., Li, M., & Muhamad, M. (2011).
How big is the Lyme problem? Using novel methods to estimate the true number
of Lyme disease cases in British Columbia residents from 1997to 2008. VectorBorne and Zoonotic Diseases, 11, 863-868. doi:10.1089/vbz.2010.0142
Hickie, I., Davenport, T., Wakefield, D., Vollmer-Conna, U., Cameron, B., Vernon, S.
D…Lloyd, A. (2006). Post-infective and chronic fatigue syndromes precipitated
by viral and non-viral pathogens: Prospective cohort study. British Medical
Journal, 333(7568), 575. doi:10.1136/bmj.38933.585764.AE.
Hinckley, A. F., Connally, N. P., Meek, J. I., Johnson, B. J., Kemperman, M. M.,
Feldman, K. A., White, J. L., & Mead, P. S. (2014). Lyme disease testing by large
commercial laboratories in the United States. Clinical Infectious Diseases, 59(5),
676-681.
Hirsch, L., Jette, N., Frolkis, A., Steeves, T., & Pringsheim, T. (2016). The incidence of
Parkinson’s disease: A systematic review and meta-analysis. Neuro-epidemiology,
46(4),
Hofhuis, A., Herremans, T., Notermans, D.W., Sprong, H., Fonville, M., van der Giessen,
J. W. B., & van Pelt, W. (2013). A prospective study among patients presenting at
the general practitioner with a tick bite or erythema migrans in the Netherlands.
PLOS One, 8(5), e63461.
Horak, E., Grassl, G., Skladal, D., & Ulmer, H. (2003). Lung function and symptom
perception in children with asthma and their parents. Pediatric Pulmonology,
35(1), 23-28.

195
Hynote, E. D., Mervine, P. C., & Stricker, R. B. (2012). Clinical evidence for rapid
transmission of Lyme disease following a tickbite. Diagnostic Microbiology and
Infectious Disease, 72, 188-192.
International Lyme and Associated Diseases Society.(2009). About ILADS. Retrieved
June 10, 2013, from http://www.ilads.org/about_ILADS/about_us.html.
International Labor Organization. (2012). International standard classification of
occupations 2008. Retrieved March 7, 2014, from
http://www.ilo.org/global/publications/ilo-bookstore/orderonline/books/WCMS_172572/lang--en/index.htm.
Iverson, G. L., Brooks, B. L., Langenecker, S. A., & Young, A. H. (2011). Identifying a
cognitive impairment subgroup in adults with mood disorders. Journal of
Affective Disorders, 132, 360-367.
Janz, N. K., & Becker, M. H. (1984). The health belief model: A decade later. Health
Education Quarterly, 11(1), 1-47.
Johnson, L., Aylward, A., & Stricker, R. B. (2011). Healthcare access and burden of care
for patients with Lyme disease: A large United States survey. Health Policy, 102,
64-71.
Johnson, L., & Stricker, R. B. (2004). Treatment of Lyme disease: A medicolegal
assessment. Expert Reviews Anti-Infective Therapy, 2(4), 533-557.
Johnson, M. & Feder, Jr., H. M. (2010). Chronic Lyme disease: A survey of Connecticut
primary care physicians. The Journal of Pediatrics, 157, 1025-1029.
doi:10.1016/j.jpeds.2010.06.031

196
Johnson, R. C., Schmid, G. P., Hyde, F. W., Steigerwalt, A. G., & Brenner, D. J. (1984).
Borrelia burgdorferi sp. nov.: Etiologic agent of Lyme disease. International
Journal of Systematic Bacteriology, 34(4), 496-497.
Kalish, R. (2013).Lyme disease. American College of Rheumatology. Retrieved
December 2, 2013, from http://www.rheumatology.org.
Katz, M. H. (2006). Multivariable analysis: A practical guide for clinicians. (2nd ed.).
Cambridge University Press: New York.
Katz, P. & Criswell, L. (1996). Differences in symptom reports between men and women
with rheumatoid arthritis. Arthritis and Rheumatism, 9(6), 441-448.
Kenedy, M. R., Lenhart, T. R., & Akins, D. R. (2012). The role of Borrelia burgdorferi
outer surface proteins. Immunology and Medical Microbiology, 66, 1-19.
Ki, V. & Rotstein, C. (2008). Bacterial skin and soft tissue infections in adults: A review
of their epidemiology, pathogenesis, diagnosis, treatment and site of care.
Canadian Journal of Infectious Disease and Medical Microbiology, 19(2), 173184.
Klein, J. D., Eppes, S. C., & Hunt, P. (1996). Environmental and life-style risk factors for
Lyme disease in children. Clinical Pediatrics, 35(7), 359-363.
Koedel, U., Fingerle, V., & Pfister, H. W. (2015). Lyme neuroborreliosis – epidemiology,
diagnosis and management. Nature Reviews Neurology, 11(8), 446-456.
Kolk, A. M., Hanewald, G. J. F. P., Schagen, S., & Gijsbers van Wijk, C. M. T. (2003). A
symptom perception approach to common physical symptoms. Social Science &
Medicine, 57, 2343-2354.

197
Kroenke, K. & Spitzer, R. L. (1998). Gender differences in the reporting of physical and
somatoform symptoms. Psychosomatic Medicine, 60, 150-155.
Kumar, R. & Indrayan, A. (2011). Receiver operating characteristic (ROC) curve for
medical researchers. Indian Pediatrics, 48, 277-287.
Kure, C. E., Chan, Y. K., Ski, C. F., Thompson, D. R., Carrington, M. J., & Stewart, S.
(2016). Gender-specific secondary prevention? Differential psychosocial risk
factors for major cardiovascular events. Open Heart, 3, 1-8.
Lane, R. S., Manweiler, S. A., Stubbs, H. A., Lennette, E. T., Madigan, J. E., & Lavoie,
P. E. (1992). Risk factors for Lyme disease in a small rural community in
northern California. American Journal of Epidemiology, 136(11), 1358-1368.
Lantos, P. M. (2011). Chronic Lyme disease: The controversies and the science. Expert
Reviews Anti-Infective Therapy, 9(7), 787-797.
Lewallen, S. & Courtright, P. (1998). Epidemiology in practice: Case-control studies.
Community Eye Health, 11(28), 57-58.
Ley, C., Olshen, E. M., &Reingold, A. L. (1995). Case-control study of risk factors for
incident Lyme disease in California. American Journal of Epidemiology, 142(9),
S39-S47.
Liang, F. T., Yan, J., Mbow, M. L., Sviat, S. L., Gilmore, R. D., Mamula, M., & Fikrig,
E. (2004). Borrelia burgdorferi changes its surface antigenic expression in
response to host immune responses. Infection and Immunity, 72(10), 5759-5767.

198
Lipsker, D., Lieber-Mbomeyo, A., & Hedelin, G. (2004). How accurate is a clinical
diagnosis of erythema chronicum migrans? Prospective study comparing the
diagnostic accuracy of general practitioners and dermatologists in an area where
Lyme borreliosis is endemic. Archives of Dermatology, 140(5), 620-621.
Liu, R., Guo, X. Park, Y., Huang, X., Sinha, R., Freedman, N.D., . . . Chen, H. (2012).
Caffeine intake, smoking, and risk of Parkinson disease in men and women.
American Journal of Epidemiology, 175(11), 1200-1207.
Lyme Disease Association, Inc. (2016). Government activities. Retrieved April 26, 2016
from http://www.lymediseaseassociation.org/index.php/govt.
Lyme Disease.org (2015). My Lyme data. Retrieved on April 26, 2016 from
https://www.lymedisease.org/mylymedata/.
Lyons, K. E., Hubble, J. P., Troster, A. I., Pahwa, R., & Koller, W. C. (1998).Sex
differences in Parkinson’s disease. Clinical Neuropharmacology, 21(2), 118-121.
MacIntyre, S., Hunt, K., & Sweeting, H. (1996). Gender differences in health: Are things
really as simple as they seem? Social Science Medicine, 42(4), 617-624.
Mann, C. J. (2003). Observational research methods. Research design II: Cohort, cross
sectional, and case-control studies. Emergency Medicine Journal, 20, 54-60.
Marshall, J. R. & Funch, D. P. (1986). Gender and illness behavior among colorectal
cancer patients. Women & Health, 11(3-4), 67-82.

199
Maselli, A., Conti, F., Alessandri, C., Colasanti, T., Barbati, C., Vomero, M., . . .
Pierdominici, M. (2016). Low expression of estrogen receptor β in T-lymphocytes
and high serum levels of anti-estrogen receptor α antibodies impact disease
activity in female patients with systemic lupus erythematosus. Biology of Sex
Differeneces, 7(3), 1-10.
Masuzawa, T., Wilske, B., Komikado, T., Suzuki, H., Kawabata, H., Sato, N., . . .
Yanagihara, Y. (1996). Comparison of OspA serotypes for Borrelia burgdorferi
sensu lato from Japan, Europe, and North America. Microbiology & Immunology,
40(8), 539-546.
Mayo Clinic. (2014). Fever causes. Retrieved May 7, 2016 from
http://www.mayoclinic.org/diseases-conditions/fever/basics/causes/con20019229.
Mayo Clinic. (2015). Dizziness causes. Retrieved May 7, 2016 from
http://www.mayoclinic.org/diseases-conditions/dizziness/basics/causes/con20023004.
McDermott, R. (2011). Internal and external validity. Cambridge Handbook of
Experimental Political Science, Cambridge University Press: Cambridge, MA.
McKenna, D., Faustini, Y., Nowakowski, J. & Wormser, C. P. (2004). Factors
influencing the utilization of Lyme disease prevention behaviors in a high risk
population. Journal of the American Academy of Nurse Practitioners, 16(1), 2531.
Mead, P. S. (2015). Epidemiology of Lyme disease. Infectious Disease Clinics of North
America, 29, 187-210.

200
Mehnert, W. H. & Krause, G. (2005). Surveillance of Lyme borreliosis in Germany 2002
and 2003. European Surveillance, 10, 83-85.
Miraflor, A. P., Seidel, G. D., Perry, A. E., Castanedo-Tarden, M. P., Guill, M. A., &
Yan, S. (2016). The many masks of cutaneous Lyme disease. Journal of
Cutaneous Pathology, 43, 32-40.
Mittal, V., Khanna, P., Panjabi, C., & Shah, A. (2006). Subjective symptom perceptual
accuracy in asthmatic children and their parents in India. Annals of Allergy,
Asthma, and Immunology, 97(4), 484-489.
Moore, K. S. (2015). Lyme disease: Diagnosis, treatment, guidelines, and controversy.
The Journal for Nurse Practitioners, 11(1), 64-69.
Moore, S. M., Eisen, R. J., Monaghan, A., & Mead, P. (2014). Meteorological influences
on the seasonality of Lyme disease in the United States. American Journal of
Tropical Medicine and Hygiene, 90(3), 486-496.
Muellegger, R. R. (2004). Dermatological manifestations of Lyme borreliosis. European
Journal of Dermatology, 14(5), 296-309.
Munro, B. H. (2005). Statistical methods for health care research. (5thed.). Lippincott,
Williams, & Wilkins: Philadelphia.
Murphy, E. (2011). Estrogen signaling and cardiovascular disease. Circulation Research,
109, 687-696.
Murphy, E., Lagranha, C., Deschamps, A., Kohr, M., Nguyen, T., Wong, R., . . .
Steenbergen, C. (2011). Mechanism of cardioprotection: What can we learn from
females? Pediatric Cardiology, 32(3), 354-359.

201
Neelakanta, G., Li, X., Pal, U., Liu, X., Beck, D. S., DePonte, K., . . . Fikrig, E. (2007).
Outer surface protein B is critical for Borrelia burgdorferi adherence and survival
within Ixodes ticks. PLoS Pathogens, 3(3), 1-11.
Nelson, C. A., Saha, S., Kugeler, K. J., Delorey, M. J., Shankar, M. B., Hinckley, A. F.,
& Mead, P. S. (2015). Incidence of clinician-diagnosed Lyme disease, United
States, 2005-2010. Emerging Infectious Diseases, 21(9), 1625-1631.
Nichols, C. & Windemuth, B. (2013). Lyme disease: From early localized disease to
post-Lyme disease syndrome. The Journal for Nurse Practitioners, 9(6), 362-367.
Ngo, S. T., Steyn, F. J., & McCombe, P. A. (2014). Gender differences in autoimmune
disease. Frontiers in Neuroendocrinology, 35, 347-369.
Norris, C., Dasgupta, K., & Kirkland, S. (2007). Differences in cardiovascular
presentation in women and men. Canadian Medical Association Journal, 176(6),
S22-S23.
O’Connell, S. (2014). Lyme borreliosis. Medicine, 42(1), 14-17.
Oertelt-Prigione, S. (2012). The influence of sex and gender on the immune response.
Autoimmunity Reviews, 11, A479-A485.
Onder, O., Humphrey, P. T., McOmber, B., Korobova, F., Francella, N., Greenbaum, D.
C., & Brisson, D. (2012). OspC is a potent plasminogen receptor on surface of
Borrelia burgdorferi. The Journal of Biological Chemistry, 287(20), 1686016868.

202
Orloski, K. A., Campbell, G. L., Genese, C. A., Beckley, J. W., Schriefer, M. E.,
Spitalny, K. C., & Dennis, D. T. (1998). Emergence of Lyme disease in
Hunterdon County, New Jersey, 1993: A case-control study of risk factors and
evaluation of reporting patterns. American Journal of Epidemiology, 147(4), 391397.
Owen, J., Punt, J., & Stranford, S. (2013). Kuby immunology. (7th ed). Elsevier
Publishing.
Pal, U., de Silva, A.M., Montgomery, R. R., Fish, D., Anguita, J., Anderson, J. F., . . .
Fikrig, E. (2000). Attachment of Borrelia burgdorferi within Ixodes scapularis
mediated by outer surface protein A. The Journal of Clinical Investigation,
106(4), 561-569. Pannucci, C.J. & Wilkins, E.G. (2010). Identifying and avoiding
bias in research. Plastic and Reconstructive Surgery, 126(2), 619-625.
Pal, U., Li, X., Wang, T., Montgomery, R. R., Ramamoorthi, N., de Silva, A. M., . . .
Fikrig, E. (2004a). TROPSA, an Ixodes scapularis receptor for Borrelia
burgdorferi. Cell, 119, 457-468.
Pal, U., Yang, X., Chen, M., Bockenstedt, L. K., Anderson, J. F., . . . Fikrig, E. (2004b).
Osp C facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary
glands. The Journal of Clinical Investigation, 113(2), 220-230.
Patel, H., Rosengren, A., & Ekman, I. (2004). Symptoms in acute coronary syndromes:
Does sex make a difference? American Heart Journal, 148, 27-33.
Peacock, B. N., Gherezghiher, T. B., & Hilario, J. D. (2015). New insights on Lyme
disease. Redox Biology, 5, 66-70.

203
Pennell, L. M., Galligan, C. L., & Fish, E. N. (2012). Sex affects immunity. Journal of
Autoimmunity, 38, J282-J291.
Piacentino, J. D. & Schwartz, B. S. (2002). Occupational risk of Lyme disease: An
epidemiological review. International Journal of Occupational and
Environmental Medicine, 59, 75-84.
Polk, D. M., & Naqvi, T. Z. (2005). Cardiovascular disease in women: Sex differences in
presentation, risk factors, and evaluation. Current Cardiology Reports, 7, 166172.
Pritt, B. S., Mead, P. S., Hoang-Johnson, D. K., Neitzel, D. F., Respicio-Kingry, L. B.,
Davis, J. P., . . . Petersen, J. M. (2016). Identification of a novel pathogenic
Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia:
A descriptive study. The Lancet Infectious Disease, 16(5), 556-564.
doi:10.1016/S1473-3099(15)00483-1.
Quintero, O. L., Amador-Patarroyo, M. J., Montoya-Ortiz, G., Rojas-Villarraga, A., &
Anaya, J. M. (2012). Autoimmune disease and gender: Plausible mechanisms for
the female predominance of autoimmunity. Journal of Autoimmunity, 38, J109J119.
Radolf, J. D., Caimano, M. J., Stevenson, B., & Hu, L. T. (2012). Of ticks, mice and men:
Understanding the dual-host lifestyle of Lyme disease spirochaetes. Nature
Reviews Microbiology, 10(2), 87-99.
Regitz-Zagrosek, V., Lehmkuhl, E., & Weickert, M. O. (2006). Sex differences in the
metabolic syndrome and their role for cardiovascular disease. Clinical Research
in Cardiology, 95, 136-147.

204
Reingold, A. L. (1998). Outbreak investigations – A perspective. Emerging Infectious
Diseases, 4(1), 21-27.
Rietveld, S. & Brosschot, J. F. (1999). Current perspectives on symptom perception in
asthma: A biomedical and psychological review. International Journal of
Behavioral Medicine, 6(2), 120-134.
Rizzoli, A., Hauffe, H. C., Carpi, G., Vourc’h, G. I., Neteler, M., & Rosa, R. (2011).
Lyme borreliosis in Europe. European Surveillance, 16(27), 1-8.
Roher, J. E. (2013). Using an outbreak investigations model for quality improvement
studies. Journal of Primary Care & Community Health, 4(3), 158-159.
Romagnani, S. (2000). T-cell subsets (Th1 versus Th2). Annals of Allergy, Asthma, and
Immunology, 85(1), 9-18.
Rosa, P. A., Tilly, K., & Stewart, P. E. (2005). The burgeoning molecular genetics of the
Lyme disease spirochaete. Nature Reviews Microbiology, 3, 129-143.
Samuels, D. S. (2011). Gene regulation in Borrelia burgdorferi. Annual Review of
Microbiology, 65, 479-499.
Sandesara, C. M. & Olshansky, B. (2014). Atrioventricular block. Retrieved April 2016
from http://emedicine.medscape.com/article/151597-overview#a5.
Savely, V. (2010). Lyme disease: A diagnostic dilemma. The Nurse Practitioner, 35(7),
44-50.
Saydah, S. H., Imperatore, G., & Beckles, G. L. (2013). Socioeconomic status and
mortality: Contribution of health care access and psychological distress among
U.S. adults with diagnosed diabetes. Diabetes Care, 36(1), 49-55.

205
Schlesselman, J. J. (1982). Case-control studies: Design, conduct, analysis. (1sted.).
Oxford University Press: New York, NY.
Schuijt, T. J., Hovius, J. W. R., van Burgel, N. D., Ramamoorthi, N., Fikrig, E., & van
Dam, A. P. (2008). The tick salivary protein Salp15 inhibits the killing of serumsensitive Borrelia burgdorferi sensu lato isolates. Infection and Immunity, 76(7),
2888-2894.
Schulz, K. F. & Grimes, D. A. (2002). Case-control studies: Research in reverse. The
Lancet, 359, 431-434.
Schutzer, S. E., Fraser-Liggett, C. M., Casjens, S. R., Qiu, W. G., Dunn, J. J., . . .Luft, B.
J. (2011). Whole genome sequences of thirteen isolates of Borrelia burgdorferi.
Journal of Bacteriology, 193(4), 1018-1020.
Schwan, T. G., Piesman, J., Golde, W. T., Dolan, M. C., & Rosa, P. A. (1995). Induction
of an outer surface protein on Borrelia burgdorferi during tick feeding.
Proceedings of the National Academy of Science, USA, 92, 2909-2913.
Schwartz, B. S. & Goldstein, M. D. (1990). Lyme disease in outdoor workers: Risk
factors, prevention measures, and tick removal methods. American Journal of
Epidemiology, 131(5), 877-885.
Schwarzwalder, A., Schneider, M. F., Lydecker, A., & Aucott, J. N. (2010). Sex
differences in the clinical and serological presentation of early Lyme disease:
Results from a retrospective review. Sex Medicine, 7(4), 320-329.
Sehgal, V. N. & Khurana, A. (2015). Lyme disease/borreliosis as a systemic disease.
Clinics in Dermatology, 33(5), 542-550. doi:10.1016/j.clindermatol.2015.05.006.

206
Shin, O. S., Isberg, R. R., Akira, S., Uematsu, S., Behera, A. K., Hu, L. T. (2008).
Distinct roles for My88 and toll-like receptors 2, 5, and 9 in phagocytosis of
Borrelia burgdorferi and cytokine induction. Infection and Immunity, 76(6),
2341-2351.
Sieck, G. C. (2015). Physiology in perspective: Why do we continue to ignore sex
differences? Physiology, 30, 406-407.
Skogman, B. H., Glimaker, K., Nordwall, M., Vrethem, M., Odkvist, L., & Forsberg, P.
(2012). Long-term clinical outcome after Lyme neuroborreliosis in childhood.
Pediatrics, 130, 262-269.
Smith, G., Wileyto, E. P., Hopkins, R. B., Cherry, B. R., & Maher, J. P. (2001). Risk
factors for Lyme disease in Chester County, Pennsylvania. Public Health Reports,
116, 146-156.
Smith, P. F., Benach, J. L., White, D. J., Stroup, D. F., & Morse, D. L. (1988).
Occupational risk of Lyme disease in endemic areas of New York State. Annals of
the New York Academy of Sciences, 539, 289-301.
Song, J. W. & Chung, K. C. (2010). Observational studies: Cohort and case-control
studies. Plastic Reconstruction Surgery, 126(6), 2234-2242.
Stanek, G., Flamm, H., Groh, V., Hirschl, A., Kristoferitsch, W., Neumann, R., . . .
Wewalka, G. (1987). Epidemiology of Borrelia infections in Austria. Zentralblatt
fur Bakteriologie, Mikrobiologie, and Hygiene, Series A, 263(3), 442-449.
Sternbach, G. & Dibble, C. L. (1996). Willy Burgdorfer: Lyme disease. The Journal of
Emergency Medicine, 14(5), 631-634.

207
Stewart, P. E., Wang, W., Bueschel, D. W., Clifton, D. R., Grimm, D., Tilly, K., . . .
Rosa, P. A. (2006).Delineating the requirement for the Borrelia burgdorferi
virulence factor OspC in the mammalian host. Infection and Immunity, 74(6),
3547-3553.
Stonehouse, A., Studdiford, J. S., & Henry, C. A. (2010). An update on the diagnosis and
treatment of early Lyme disease: “Focusing on the bull’s eye, you may miss the
mark.” The Journal of Emergency Medicine, 39(5), e147-e151.
Stricker, R. B., DeLong, A. K., Green, C. L., Savely, V. R., Chamallas, S. N., & Johnson,
L. (2011). Benefit of intravenous antibiotic therapy in patients referred for
treatment of neurologic Lyme disease. International Journal of General
Medicine, 4, 639-646.
Stricker, R. B. & Johnson, L. (2007). Lyme disease: A turning point. Expert Review of
Anti-Infective Therapy, 5(5), 759-762. doi:10.1586/147210.5.5.759.
Strijks, E., Kremer, J. A., & Horstink, M. W. (1999). Effects of female sex steroids on
Parkinson’s disease in postmenopausal women. Clinical Neuropharmacology,
22(2), 93-97.
Strle, F., Wormser, G. P., Mead, P., Dhaduvai, K., Longo, M. V., Adenikinju, O., . .
.Stupica, D. (2013). Gender disparity between cutaneous and non-cutaneous
manifestations of Lyme borreliosis. PLOS ONE, 8(5), 1-5.
http://dx.doi.org/10.1371/journal.pone.0064110
Subak, S. (2003). Effects of climate on variability in Lyme disease incidence in the
northeastern United States. American Journal of Epidemiology, 157(6), 531-538.

208
Suss, J., Klaus, C., Gerstengarbe, F. W., & Werner, P. C. (2008). What makes ticks tick?
Climate change, ticks, and tick-borne diseases. Journal of Travel Medicine, 15(1),
39-45.
Tager, F. A., Fallon, B. A., Keilp, J., Rissenberg, M., Jones, C. J., &Liebowitz, M. R.
(2001). A controlled study of cognitive deficits in children with chronic Lyme
disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 13(4), 500507.
Tibbles, C. & Edlow, J. A. (2007). Does this patient have erythema migrans? The Journal
of the American Medical Association, 297(23), 2617-2627.
Tiemstra, J. D. & Khatkhate, N. (2007). Bell’s palsy: Diagnosis and management.
American Family Physician, 76, 997-1002.
Tilly, K., Krum, J. G., Bestor, A., Jewett, M. W., Grimm, D., Bueschel, D., . . .Rosa, P.
(2006). Borrelia burgdorferi OspC protein required exclusively in a crucial early
stage of mammalian infection. Infection and Immunity, 74(6), 3554-3564.
United States Census Bureau. (2001). Population change and distribution 1990 to 2000:
Census 2000 brief. Retrieved August 1, 2013, from
http://www.census.gov/prod/2001pubs/c2kbr01-2.pdf.
United States Census Bureau. (2014). USA state and county quick facts. Retrieved March
4, 2014, from http://quickfacts.census.gov/qfd/states/00000.html.
United States Department of Health and Human Services. (n.d.). Calculating sample size.
Retrieved August 28, 2013, from
http://bphc.hrsa.gov/policiesregulations/performancemeasures/patientsurvey/calcu
lating.html.

209
Vazquez, M., Muehlenbein, C., Cartter, M., Hayes, E. B., Ertel, S., & Shapiro, E. D.
(2008). Effectiveness of personal protective measures to prevent Lyme disease.
Emerging Infectious Diseases, 14(2), 210-216.
Wahler, H. J. (1968). The physical symptoms inventory: Measuring levels of somatic
complaining behavior. Journal of Clinical Psychology, 24(2), 207-211.
Whitacre, C. C. (2001). Sex differences in autoimmune disease. Nature Immunology,
2(9), 777-780.
Widhe, M., Grusell, M., Ekerfelt, C., Vrethem, M., Forsberg, P., & Ernerudh, J. (2002).
Cytokines in Lyme borreliosis: Lack of early tumour necrosis factor – α and
transforming growth factor – β1 responses are associated with chronic
neuroborreliosis. Immunology, 107, 46-55.
Wilking, H. & Stark, K. (2014). Trends in surveillance data of human Lyme borreliosis
from six federal states in eastern Germany, 2009-2012. Ticks and Tick-borne
Diseases, 5, 219-224.
Wizeman, T. M. & Pardue, M. (Eds.). (2001). Exploring the biological contributions to
human health: Does sex matter?.Washington, DC: National Academy Press.
Wolfe, F., Clauw, D. J., Fitzcharles, M., Goldenberg, D. L., Hauser, W., Katz, R. S.
…Winfield, J. B. (2011). Fibromyalgia criteria and severity scales for clinical and
epidemiological studies: A modification of the ACR preliminary diagnostic
criteria for fibromyalgia. Journal of Rheumatology, 38, 1113-1122.
World Health Organization. (2007). Addressing sex and sex in epidemic prone infectious
diseases. Retrieved June 23, 2013, from
http://www.who.int/csr/resources/publications/SexSexInfectDis.pdf.

210
Wormser, G. P., Dattwyler, R. J., Shapiro, E. D., Halperin, J. J., Steere, A. C., Klempner,
M. S., . . . Nadelman, R. B. (2006). The clinical assessment, treatment, and
prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis:
Clinical practice guidelines by the Infectious Disease Society of America.
Clinical Infectious Diseases, 43, 1089-1134.
Wormser, G. P., Nadelman, R. B., & Schwartz, I. (2012). The amber theory of Lyme
arthritis: Initial description and clinical implications. Clinical Rheumatology,
31(6), 989-994. doi:10.1007/s10067-012-1964-x.
Wormser, G. P. & Shapiro, E. D. (2009). Implications of gender in chronic Lyme disease.
Journal of Women’s Health, 18(6), 831-834.
Yanagawa, T. (1979). Designing case-control studies. Environmental Health
Perspectives, 32, 143-156.
Yoos, H. L., Kitzman, H., McMullen, A., &Sidora, K. (2003). Symptom perception in
childhood asthma: How accurate are children and their parents? Journal of
Asthma, 40(1), 27-39.
Yoos, H. L., & McMullen, A. (1999). Symptom perception and evaluation in childhood
asthma. Nursing Research, 48(1), 2-8.
Yunus, M. B. (2001). The role of sex in fibromyalgia syndrome. Current Rheumatology
Reports, 3, 128-134.
Zhang, X., Meltzer, M. I., Pena, C. A., Hopkins, A. B., Wroth, L., & Fix, A. D. (2006).
Economic impact of Lyme disease. Emerging Infectious Diseases, 12, 653-660.

211
Zondervan, K. T., Cardon, L. R., & Kennedy, S. H. (2002). What makes a good casecontrol study? Design issues for complex traits such as endometriosis. Human
Reproduction, 17(6), 1415-1423.

212
Appendix A: ROSS Scale
Sex:

Date of Birth:

State of Residence:

Male
Female
Menopause:
Completed
Experiencing symptoms now
Have not experienced symptoms yet
Not applicable
Marital Status:
Married
Single
Divorced
Widowed

Occupation:

Education Level:
Number of Children Under 18:
High School Graduate
0
College Graduate
1-2
Graduate School
3-4
Technical School
5+

ANSWER THE NEXT QUESTIONS IF YOU ARE A LYME AND ASSOCIATED DISEASES PATIENT
History of Tick Bite:
Present:
Yes
No

Date of Tick Bite (Month/Year)

Lyme Test Positive:
Yes
No

Which Test (if Applicable):
ELISA
Western Blot
Other:

Date of Initial Diagnosis (MM/YY):

Diagnosis Based on:
Clinical Symptoms
EM Rash
ELISA and Western Blot
Other:

Date of Initial Symptoms(MM/YY):

Bull’s Eye Rash
Yes
No
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Please put an X in the box that BEST describes the frequency of each symptom as you
experienced it – DURING THE PAST WEEK.
Symptom
Fatigue/Tiredness
Fever
Chills
Facial Numbness
Disturbed Sleep
Poor Concentration
Memory Loss
Irritability
Crying
Sadness/Depression
Headaches
Blurred Vision
Eye Pain
Ear Ringing/Buzzing
Jaw Pain
Sore Throat
Swollen Glands
Dizziness
Lightheadedness
Stiff Neck
Back Pain
Chest Pain
Palpitations
Nausea
Diarrhea
Testicular/Pelvic Pain
Tingling/Numbness/Burning
Painful Joints
Stiff Joints
Sore Muscles
Night Sweats
Other
Other

Never 1-2 days 3-4 days 5-6 days Everyday
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Please put an X in the box that BEST describes the severity of each symptom as you
experienced it – DURING THE PAST WEEK. Scale: 0 – Not affected; 1 – slightly noticeable; 2 –
Minor problem but noticeable; 3 – Moderate problem that interferes with some daily
activities; 4 – Major problem that interferes with most daily activities; 5 – Disabling
Symptom
Fatigue/Tiredness
Fever
Chills
Facial Numbness
Disturbed Sleep
Poor Concentration
Memory Loss
Irritability
Crying
Sadness/Depression
Headaches
Blurred Vision
Eye Pain
Ear Ringing/Buzzing
Jaw Pain
Sore Throat
Swollen Glands
Dizziness
Lightheadedness
Stiff Neck
Back Pain
Chest Pain
Palpitations
Nausea
Diarrhea
Testicular/Pelvic Pain
Tingling/Numbness/Burning
Painful Joints
Stiff Joints
Sore Muscles
Night Sweats
Other
Other

0

1

2

3

4

5
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Appendix B: Permissions
Permission to modify the Burrascano Symptom Checklist to align with the ROSS
Scale
Hi Dr. Burrascano,
My name is Vicki Stanavitch and I am an Assistant Professor at Keystone College, but I am
writing to you today in my other role as a PhD Candidate at Walden University. I am working
with Dr. Daniel Cameron as my clinical supervisor and he gave me this email address.
I am proposing a Lyme disease study to look at whether there are differences in symptom
presentation and severity based on sex or age. I would like to use your Symptom Checklist with a
slight modification as the measurement instrument. I am looking for either your permission or
your confirmation that the checklist is in the public domain. I need this for my IRB application.
You will be given full credit in all publications or presentations for the instrument whether it is in
the public domain or not.
The modification that will be made will be two-fold.
1. A few of the symptoms listed have been eliminated to allow for data collection and analysis to
be simplified.
2. The severity and frequency scale will be quantified in the following way:
a. frequency will be measured as never, 1-2 days, 3-4 days, 5-6 days, and/or everyday
b. severity will be measured as not affected, slight/barely noticeable, minor problem but
noticeable, moderate problem that interferes with some daily activities, or major problem that
interferes with most daily activities.
Both of these changes will help in the quantitative analysis of the data collected.
I hope that you will either give me permission to use your checklist or confirm that it is part of
the public domain.
Thank you for your consideration.
Vicki
Vicki A. Stanavitch
Assistant Professor of Biology, Chemistry and Public Health
Faculty Coordinator for Undergraduate Research
Keystone College
One College Green
La Plume, PA 18440
570-945-8410 (office)
570-499-1997 (cell)
vicki.stanavitch@keystone.edu
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*******************************************************************************************************
*********
Joe! [burraj51@bigplanet.com]
Actions
To:
M
Vicki A. Stanavitch

Inbox
Tuesday, September 09, 2014 9:49 AM

You forwarded this message on 9/24/2014 8:33 PM.

Good morning
Thank you for your e-mail. Your work sounds exciting! I would be happy to allow your
use of my checklists as you outlined. All I ask is that you send to me a copy of the revised
checklists. I would also love to get a copy of the results of your eventual studies- would
make me happy to see my work being expanded upon.
Best wishes and congratulations on your Doctorate.
Dr. B
Joseph J. Burrascano Jr. M.D.
Water Mill, NY, USA
Sent from my LapTop
Permission to use the ROSS Scale as the data collection instrument for the study
INFO [info@danielcameronmd.com]
Actions
To:
M
Vicki A. Stanavitch

Inbox
Tuesday, April 28, 2015 10:10 AM

You forwarded this message on 4/28/2015 10:27 AM.

Good news. You can use the ROSS with our name on the scale.
Dr. Cameron
On 4/28/15 9:59 AM, Vicki A. Stanavitch wrote:
Hi Dr. Cameron,
Hope all is well!
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I am working on the IRB approval for data collection here at Keystone College so that I
can increase the control population for my study.
I need your permission to use the ROSS Scale to collect control data here at the College.
The IRB requires your written permission for use. I know you had given me verbal
permission at the clinic, but I have to provide that permission in writing. I can remove
your name from the scale if you prefer.
An email stating that it is fine to use the scale is all I need…nothing more formal is
required. Let me know as soon as you can.
Thanks for your help so far with this project! I hope to be finished this summer.
Vicki
Vicki A. Stanavitch
Assistant Professor of Biology, Chemistry, and Public Health
Faculty Coordinator of Undergraduate Research
Keystone College
One College Green
Capwell Hall
La Plume, PA 18440
570-945-8410 (office)
570-499-1997 (cell)
vicki.stanavitch@keystone.edu

Permission to publish the ROSS Scale as part of my dissertation

ROSS Scale Permission
Daniel Cameron [info@danielcameronmd.com]

Actions
To:
M
Vicki A. Stanavitch
Attachments:
(2)Download all attachments
Chapter4FinalResults.docx(1003KB)[Open as Web Page]; ModifiedROSSScale.pdf(262KB)[Open as Web Page]
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Thursday, August 18, 2016 8:58 PM

Vicki Stanavitch
You have my permission to include the modified ROSS scale in your
final dissertation. I would appreciate being a contributor to your
outstanding research.
Dr. Cameron

